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SUMMARY 
 
HISTORICAL PERSPECTIVE 
Stem cell therapy was commenced after using rabbits as research models. Once this process was successful, 
the first human transplant was done in 1974. 
 
Certain prerequisites were necessary and these were achieved - a protected environment, an apheresis unit, 
protocols and accreditation with International Registries. 
 
Initially, unmanipulated bone marrow and peripheral blood stem cells were used together with 
immunosuppressive drugs followed by the use of Cyclosporin A then the addition of ex vivo Campath®. 
 
AUDIT OF ACUTE ASSOCIATIONS (468 subjects in initial cohort)  
NEPHROLOGY 
Creatinine was used as an indication of renal function. Of the 76 available for analysis, 47% had acute kidney 
injury. Dialysis had a poor outcome as reported in the literature.  Renal complications occurred frequently 
mostly due to infection. 
 
CARDIOLOGY 
A total of 119 individuals were available for analysis. Echocardiograms and electrocardiograms were part of 
pre-transplant assessment.  Left ventricular systolic dysfunction predicted for increasing post transplant 
problems. Cardiac complications occurred at a lower frequency than other post-transplants side-effects 
consistent with the published data. 
 
DERMATOLOGY 
Cases were evaluated on a daily basis and referred to a dermatologist when necessary. 
 
To confirm Graft-Versus-Host Disease (GVHD), a skin biopsy was done to differentiate it from drug 
hypersensitivity or viral infections.   
 
The exposure to ex vivo Campath® significantly improved outcome by reducing the incidence and severity of 
GVHD. Quality of life was enhanced with substantial cost saving. 
 
GASTROENTEROLOGY 
Foregut symptoms occurred in 90% of patients. Nutritional problems were encountered. Altered liver 
functions were relatively common attributable to drugs, sepsis and conditioning regimens.  Liver biopsies were 
not performed in this series and endoscopy performed only when necessary. 
 
A STUDY ON LATE COMPLICATIONS (55 subjects) 
RESPIRATORY 
Spirometry and diffusing capacity were done in this cohort. All the lung function studies were within the 
predicted normal range apart from some marginal reduction in diffusing capacity. In none of these patients 
did late consequences such as Bronchiolitis Obliterans Organising Pneumonia and Late Onset Non-Infectious 
Pulmonary complications occur. Cytomegalovirus reactivation was common but early intervention prevented 
serious complications. 
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IMMUNOLOGY 
An in vitro functional study was done. 
 
Both the innate and adaptive systems were evaluated. Taken into consideration were the type of transplant, 
age from transplant, diagnosis and conditioning. 
 
The granulocyte Burst-test was done for the innate profile. Reduced activity was shown in all the subgroups. It 
appears as if the innate response of the granulocytic cells never recovered due to reduced granulocytic function 
in vitro. 
 
The adaptive responses were evaluated in vitro and only the autografts showed better CD4+ and CD8+ 
cytokine production. No major differences were seen in other groups. 
 
Normal cytokine production by CD4+ and CD8+ T cells were present when these were activated in vitro to 
produce regulatory cytokines, implying that their lymphoid component was intact post-transplant.  
 
BONE DISEASE 
Here both the Dual energy X-ray Absorptiometry (DXA) and Quantitative Computed Tomography (QCT) were 
used to evaluate bone mineral density. There was a discrepancy present between the two modalities. DXA 
showed no osteoporosis but QCT 22%. Biomarkers were normal in all. There was no history of fracture and no 
objective evidence of vertebral fractures using vertebral fracture assessment. 
 
Although QCT was used for the study, DXA remains the gold standard in South Africa. 
 
CONCLUSION 
This doctoral provided information on the non-haematological consequences in South Africa with the use of 
Campath® ex vivo. 
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OPSOMMING 
 
HISTORIESE PERSPEKTIEF 
Stamsel terapie is voortgesit nadat konyne aanvanklik as navorsingsmodelle gebruik is. Na suksesvolle 
voltooiing van hierdie proses, is die eerste menslike oorplanting gedoen in 1974. 
 
Sekere voorvereistes was nodig en hierdie was bereik – ŉ beskermde omgewing, ŉ aferese eenheid, protokolle 
en akkreditasie by Internasionale Registers.  
 
Aanvanklik is ongemanipuleerde beenmurg- en perifere bloed stamselle gebruik, tesame met 
immuunonderdrukkende middels, gevolg deur die gebruik van Sikloporien A en daarna die toevoeging van ex 
vivo Campath®. 
 
OUDIT VAN AKUTE ASSOSIASIES (468 GEVALLE IN DIE OORSPRONKLIKE GROEP) 
NEFROLOGIE 
Kreatinien is gebruik as ŉ aanduiding van nierfunksie. Van die 76 gevalle beskikbaar vir ontleding, het 47% 
akute nierbeserings gehad. Dialise het ŉ swak uitkoms gehad soos gerapporteer in publikasies. Nier 
komplikasies het gereeld voorgekom, meestal as gevolg van infeksie. 
 
KARDIOLOGIE 
ŉ Totaal van 119 gevalle was beskikbaar vir ontleding. Eggokardiogramme en elektrokardiogramme was deel 
van die pre-oorplanting assessering. Linker ventrikulêre disfunksie was voorspelbaar van verhoogde post-
oorplanting probleme.  Kardiale komplikasies het konstant volgens publikasies minder geredelik voorgekom 
as ander post-oorplantings newe-effekte.  
 
DERMATOLOGIE 
Gevalle is op ŉ daaglikse basis geëvalueer en verwys na ŉ dermatoloog wanneer nodig. 
 
ŉ Velbiopsie is gedoen om “Graft-Versus-Host” siekte (GVHD) te bevestig en dit te onderskei van middel 
hipersensitiwiteit of virale infeksies. 
 
Die blootstelling aan ex vivo Campath® het uitkomste aansienlik verbeter deur die voorkoms en erns van 
GVHD te verminder. Kwaliteit van lewe is verhoog met aansienlike koste besparing. 
 
GASTROENTEROLOGIE 
Boonste gastro-intestinale simptome het voorgekom in 90% van die pasiënte. Wanvoeding het voorgekom..  
Abnormale lewerfunksies was relatief algemeen toeskryfbaar  aan middels, sepsis en kondisionerings 
protokolle. Lewer biopsies is nie in hierdie reeks uitgevoer nie en endoskopie slegs wanneer dit noodsaaklik 
was. 
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DIE STUDIE VAN LAAT KOMPLIKASIES (55 GEVALLE)  
RESPIRATORIES 
Spirometrie en diffusie kapasiteit is gedoen in hierdie groep. Al die longfunksie ondersoeke  was binne die 
voorspelde normale waardes behalwe ŉ paar marginale afnames in die diffusie kapasitiet. In geen van hierdie 
pasiënte het laat nagevolge soos Bronchoilitis Obliterans Organiserende Pneumonie en Laat Aanvangs Nie- 
infektiewe Long komplikasies voorgekom nie. Sitomegaal virus heraktivering was algemeen maar vroeë 
intervensie het ernstige komplikasies voorkom.  
 
IMMUNOLOGIE 
ŉ In vitro funksionele studie is gedoen. 
 
Beide die spesifieke en nie-spesifieke immuun stelsels is geëvalueer. Die tipe oorplanting, tyd vanaf 
oorplanting, diagnose en kondisionering is in ag geneem.  
 
Die “Granulocyte Burst” toets is gedoen vir die nie-spesifieke profiel. Verminderde aktiwiteite is bewys in al 
die subgroepe. Dit wil voorkom asof die nie-spesifieke respons van die granulosiete nooit herstel nie as gevolg 
van die verlaagde in vitro granulosiet funksie. 
 
Die spesifieke immuun respons is in vitro geëvalueer en slegs die outotransplantaat het beter CD4+ en CD8+ 
sitokiene produksie getoon. Geen groot verskille is gesien in ander groepe nie. 
 
By CD4+ en CD8+ T selle was normale sitokiene produksie teenwoordig toe dit in vitro geaktiveer is om 
regulatoriese sitokiene produksie te produseer, wat beteken dat hul limfoïede komponent na oorplanting 
ongeskonde was. 
 
BEEN SIEKTE 
Beide die Dubbele energie x-straal absorpsiemetrie (DXA) en Kwantitatiewe rekenaar tomografie (QCT) is hier 
gebruik om been mineraal digtheid te evalueer. Daar was ŉ teenstrydigheid teenwoordig tussen die twee 
modaliteite. DXA het geen osteoporose getoon nie maar QCT het 22% getoon. Biomerkers was normaal in 
albei. Daar was geen geskiedenis van frakture en geen objektiewe bewyse van vertebrale frakture met 
Vertebrale Fraktuur Assessering nie. 
 
Alhoewel QCT gebruik is vir die studie bly DXA die goue standaard in Suid-Afrika. 
 
GEVOLGTREKKING   
Hierdie doktoraal verskaf inligting oor die nie-hematologiese gevolge in Suid-Afrika met die gebruik van 
Campath® ex vivo. 
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CXR Chest X-ray 
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DOB Date of birth 
DOT Date of transplant 
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E Coli Escherichia coli 
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EBV Epstein Barr virus 
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ESR Erythrocyte sedimentation rate 
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FBC Full blood count 
FDA Food and Drug Administration 
FEF25-75 Forced expiry flow rate at 25 – 75% of forced vital capacity 
FEV1  Forced expiratory volume in the first second 
FEV1/FVC Forced expiratory ratio 
FISH Fluorescent in situ hybridisation 
FLAG Fludarabine, Cytosine Arabinoside, G-CSF 
Fmlp Formyl-Methionyl-Leucyl-Phenylalanine 
FVC Forced vital capacity 
G Gram 
G-CSF Granulocyte colony-stimulating factor 
GEC Gastroenterology consultation 
Geog Geographical 
GGT Gamma-glutamyl transpeptidase 
GI Gastrointestinal 
GIT Gastrointestinal Tract 
GM-CFUc Granulocyte macrophage colony-forming unit 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GVHD Graft-versus-host disease 
HCL Hairy cell leukaemia 
HES Hydroxyethyl Starch 
H Pylori Helicobacter Pylori 
“Haem Team” Haematology Team 
HIV Human immunodeficiency virus 
HL Hodgkin's lymphoma 
HLA Human Leucocyte Antigen 
HYDREA® Hydroxyurea 
IBM International Business Machines 
IBS Irritable Bowel Syndrome 
ICE Ifosfamide, Carboplatin, Etoposide 
IFN Interferon 
IL4 Interleukin 4 
INF Infections 
IFN-y Interferon gamma 
INR International Normalised Ratio 
IQR Interquantile range 
ISCH International Society for Clinical Densitometry 
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ISCT International Society for Cell Therapy 
IVI Intravenous infusion 
J Lines Jacobson lines 
JACIE Joint Accredited Committee of ISCT 
Kg  Kilogram 
L Litre 
LBBB Left bundle branch block 
LD Lymphocyte depleted 
LDH Lactic Dehydrogenase 
LFT Liver function test 
LL Lymphocytic lymphoma 
LONIP Late onset non-infectious pulmonary complications 
LP Lumbar puncture 
LTFU Lost to follow up 
LVEF Left ventricular ejection fraction 
m² Meter squared 
MDS Myelodysplastic syndrome 
MESNA 2-Mercaptoethanesulfonate 
MFC Mitomycin 5-Fluorouracil 
Mg  Milligram 
MINI-ICE Idarubicin, Cytosine Arabinoside, Etoposide 
Ml Milliliter 
MM Multiple myeloma 
MS Mixed-cellularity 
MUD Matched unrelated donor 
MYELOPROLIF Myeloproliferative syndrome 
N Number 
Ng Nanogram 
NHANES 111 Third National Health and Nutrition Examination Survey 
NHL Non-Hodgkin's lymphoma 
NK cells Natural killer cells 
NMDP National Marrow Donor Program 
NS Nodular sclerosing 
N & V Nausea and vomiting 
OBS Observations 
PA Posterior Anterior 
PBSC Peripheral blood stem cells 
PCR Polymerase chain reaction 
PEFR Peak Expiratory Flow Rate 
PET Positron emission tomography 
PKC Protein Kinase C-activator 
PMA Phorbol-myristate acetate 
PPI Proton pump inhibitor 
PR Partial remission 
PRA Pure Red Cell Anaemia 
Pro-BNP Brain natriuretic peptide 
p-value Probability value 
P Vera Polycythemia Vera 
Q1 1st Quantile 
Q3 3rd Quantile 
QCT Quantitative computed tomography 
RA Refractory Anaemia 
RAI Staging developed by Dr Kanti Rai 
RAEB Refractory Anaemia with excess blasts 
RARS Refractory Anaemia with ringed sideroblasts 
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RBBB Right bundle branch block 
REAL Revised European American Lymphomas 
RFC Rituximab, Fludarabine, Cyclophosphamide 
RV Residual volume 
SABMR South African Bone Marrow Registry 
SCID Severe combined immunodeficiency 
SCT Stem cell transplant 
SD Standard deviation 
SS Sickle cell anaemia 
T Transfusion 
TC Transplant Centre 
T cell T-Lymphocyte 
TH1 "T" helper cell 
TH2  "T" helper cell 
THAL Thalassaemia 
TLC Total lung capacity 
TLCO Carbon monoxide transfer factor 
TNC Total nucleated cells 
TPA  Tissue plasminogen activator 
TPN Total Parenteral Nutrition 
TTP Thrombotic Thrombocytopenic Purpura 
USA United States of America 
VECD Vincristine,Epirubicin, Cyclophosphamide,Dexamethasone 
VFA Vertebral fracture assessment 
VOD Veno-occlusive disease 
Vol Excl Voluntary exclusion 
WHO World Health Organisation 
μg Microgram 
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CHAPTER 1 
 
 
THE PROJECT IN OVERVIEW 
 
 
 
FOCUS 
 
Stem cell transplantation is an increasingly used life-saving procedure. Laboratory and 
clinical advances continue to broaden the indications and improve outcome whilst 
simultaneously exposing a greater number of recipients, and donors, to complications 
which may be relatively common early associations or only emerge as late effects. 
Awareness of haematopoietic, and non-haematopoietic, sequelae underlie the concept of 
survivorship which can be viewed as cure with care. These correlations, which are the 
core of this long running clinical and laboratory research project, were acknowledged 
by a systematic audit, to define the complete data set. More than three decades of 
paediatric and adult experience with allogeneic and autologous grafting carried out by 
a single internationally accredited team have been recorded. Initially, the donor source 
was bone marrow but subsequently it was extended to the use of peripheral and 
umbilical cord blood. These modifications facilitated clear delineation of the physiologic 
pattern by which immunohaematopoietic recovery took place. It was in this cohort that 
the two distinct groups of tissue injury were defined outside the process of blood 
formation. In the first three months after transplant almost uniform and typically 
reversible acute abnormalities of kidney and cardiovascular system function were 
analysed together with a range of short lived reactions in the skin. Gastroenterological 
problems, including the challenge of maintaining nutrition, were also seen. With longer 
survival, typically beyond one year, a quite different spectrum of late effects emerged in 
the lung, skeleton and in the process of immunologic reconstitution. Accordingly, in a 
group of surviving transplant volunteers a selected panel of tests was performed. This 
study was the main theme of this PhD thesis. 
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1.1 INTRODUCTION  
By way of orientation and justification a brief note is needed for better appreciation of the reason behind the 
introduction of new haematologic high technology into South Africa. This process took place at a time when 
transplantation had recently emerged in first world academic centres. It had tentatively been accepted as a 
realistic therapy which had clinical applicability.  
 
The reason and decision can be traced back to two events.  
 
The entire field was given enormous impetus at the University of Cape Town Medical School by the success of 
the first human heart allograft carried out in the Groote Schuur Hospital by Professor Christiaan Neethling 
Barnard.  
 
In this environment, pulsating with advances in immunology and tissue typing required to support expansion 
of cardiac and other solid organ exchanges, came the University Council decision to formally and fully 
integrate every aspect of clinical and laboratory haematology. This innovative restructuring was made possible 
by the establishment of an entirely new and autonomous department for the comprehensive study of blood 
and bone marrow.  It was modelled on the facility at University of Washington in Seattle led by Professor E 
Donnall Thomas and his rapidly growing multidisciplinary team. The motivation was based in scientific, 
academic and intellectual linking of numerous already strong disciplines in the school. Equally relevant and 
important, was the potential of major benefit for all patients in South Africa, where this new technology was 
destined to find a specialised niche. 
 
Looking back on the foregoing circumstances, those who shared the vision and supported the imperative will 
be gratified with the current position enjoyed by the South African immunohaematopoietic stem cell 
transplantation programmes in both local and international settings.  
 
The author was involved in these endeavours and seized the opportunity to systematically and serially 
document her early experience.  
 
The process represents a practical means of highlighting possibilities for further research into phenomena that 
have received less attention than initially thought to be appropriate. Patient survivals increased and the short 
and longer term adverse impacts on a number of systems outside the blood and bone marrow increasingly 
became evident. There was already a worldwide appreciation of how previously unsuspected injury, ranging 
from occult to severe, produced increasing morbidity and mortality. These variables constitute a poorly 
defined group but nevertheless are an important arena which presents ethical, scientific and clinical questions 
which need to be addressed. 
 
Historically two consecutive phases can be described.  
 
The entire intact database, from the time that the first human stem cell transplant was carried out in 1974, 
records a detailed description of all technical, nursing and medical aspects as they evolved over the last 37 
years.  
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From this exercise was synthesised a consolidated model that could be applied, clinically and in a structured 
post-transplant follow-up protocol, to precisely document those pathological differences that were already 
taking place. At the time these were largely unappreciated, yet, had a potential impact on the conventional 
endpoints of outcome.  
 
Building on this foundation, a carefully organised and systematic analysis was undertaken in a series of 
patients to delineate these underemphasised risk factors for both quality and duration of life. This endeavour 
occupied a period of 15 years during which time the observations were focused on the concept of survivorship. 
Stated differently, these phenomena which encapsulated wide ranging changes in the internal environment 
affecting a number of primarily non-haematopoietic organ systems, gathered sufficient momentum to justify a 
formal research application.  
 
This imperative shifted focus from the traditional retrospective preoccupation with events that have already 
resulted in recognisable symptoms and signs defined as side-effects or complications, to an approach seeking 
to recognise potential risk factors. These influenced quality of life and, being amenable to intervention, 
dictated a more innovative restructuring in the years following stem cell grafting. 
 
The rationale for these clinicopathological studies that were cross-disciplinary by intention and design, was to 
examine the impact of profound alterations in physical and mental status which are an integral part of the 
subtly altered lifestyle that follows these procedures. These have only recently started to find acceptance but 
appear to be potentially avoidable consequences with steadily improving benefits.  This is being made possible 
by increasing sophistication and understanding in diagnosis followed by proactive management. The whole 
area is of immense and ever escalating importance where, for example, the source of immunohaematopoietic 
stem cell has moved from marrow to blood, now to umbilical cord and, likely in the future, to amniotic fluid.   
 
Patient preparation continues to oscillate between myeloablative and reduced intensity or essentially only 
immunosuppressive regimens.  The concept of autografting as a form of gene therapy and the challenge of 
embryonic stem cells opens up a whole new landscape, both conceptually and functionally, that offers 
movement from replacement to regenerative medicine.  Central to this aspect of biology are the recipients. 
While fully supportive of the rapidly growing and wider frontiers, there is the obligation to give careful 
attention to the frequently, overlooked changes in persons who survive these costly and hazardous 
interventions.  Into this equation must now be factored potential risk to donors over long periods of follow up.  
 
For these reasons, the scope of this 37-year research imperative focused firstly on establishing the facility, then 
refining the protocols and confirming conventional outcomes in children and adults. Once achieved, early 
associations that were typically reversible were identified. Focus then shifted priority to quantitating these 
problems as more long survivors were added to the follow-up clinic. It was at this point that the stimulus arose 
to study selected extra haematopoietic organ systems following stem cell transplantation. 
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1.2 REFERENCE COHORT (1972-1994) 
The 22-year observational data set, which comprised consecutive individuals registered from the start of the 
experimental programme, which was translated into clinical practice in 1974.  Every person, from that date 
until 2010, was reported to the International and Autologous Bone Marrow Transplant Registries which 
merged to form the the Centre for International Blood and Marrow Transplant Research. This practice 
continues to the present date. 
 
The same outcomes were concurrently recorded in the European Group for Blood and Bone Marrow 
Transplant registry. When donors were sourced from the National Marrow Donor Program, these transplants 
were additionally reported to the latter registry.  
 
This audit of technical details was used to recognise changes within each of the selected organ systems which 
occurred with sufficient frequency as to pose a future risk. It was the motivation for the exploration of lesions 
outside the usual end points of transplantation.  Although all patients were reported to the registries, none of 
the data was obtained from them. 
 
There followed a 15 year segment (1995-2010) generated by all patients detailed in the comprehensive record 
(Annexure 1). These were registered in the Department of Haematology and Bone Marrow Transplant Unit 
incorporating The Searll Research Laboratory for Cellular and Molecular Biology in the Constantiaberg Medi-
Clinic. This became a designated satellite of the Division of Clinical Haematology - Department of Internal 
Medicine at Stellenbosch University and Tygerberg Academic Hospital.   
 
 
1.3 AUDIT OF ACUTE ASSOCIATIONS 
The audit contained data extracted from the patients’ records. Four organ systems were chosen as they were 
affected most frequently and sufficient data was available to analyse these.  This damage typically occurred in 
the neutropenic period after which, almost universally, resolution took place in the majority of cases. 
 
1.3.1 NEPHROLOGY 
Biochemical disturbances were a frequent occurrence which were not only exacerbated by fluid and electrolyte 
imbalance, but also by a wide range of infections where nephrotoxic antibiotics compounded abnormalities in 
biochemical tests. Whether any of these drugs as well as immunosuppressive regimens, particularly 
cyclosporin A, affected these special approaches additionally to routine treatment were evaluated.  This 
calcineurin inhibitor was largely reserved for the matched unrelated allografts in the present study and not 
routinely employed. 
 
 
1.3.2 CARDIOLOGY  
The heart can precipitously malfunction and was specifically monitored during the first three months after 
transplantation. This was undertaken by constant clinical review supported by a selected series of tests 
including 12 lead electrocardiogram and echocardiogram.  Thereafter, serial studies were continued in order to 
characterise any emerging adverse effects. 
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1.3.3 DERMATOLOGY  
The skin has a large surface and disturbances arose in two distinct ways. Frequent rashes reflected a range of 
allergies and viral infections most of which were readily recognisable, transient and had little lasting 
importance. A notable problem was the engraftment syndrome typically in persons undergoing autologous 
transplantation and not initially recognised.  
 
Particularly challenging manifestations were found after allogeneic grafting in the form of graft-versus-host 
disease (GVHD). Here a uniquely different regimen has been standardised following introduction and 
continuous use of ex vivo T cell depletion using the Campath® series of monoclonal antibodies. This approach 
was named the in-the-bag technique.1 The innovation created a distinct model when compared to 
unmanipulated marrow used in many other centres. The latter required a range of immunosuppressive agents 
after the procedure, notably corticosteroids and cyclosporin A, among others.2 
 
The only variation in the present programme was a subset created by introduction of matched unrelated 
volunteer donors with varying degrees of histoincompatibility. In this setting, immunologic phenomena, 
exemplified by graft-versus-host disease, were anticipated and a tapering dose of cyclosporin A was used to 
blunt the expression of an unusual variant or forme frust of the acute syndrome. This distinctive cutaneous 
lesion was different in duration and severity from the more traditional acute and chronic manifestations of the 
immunologically mediated change arising with infusion of unmanipulated grafts.1 Contrastingly, cyclosporin A 
given to donors and recipients produced a superficially similar benefit but did not abrogate either acute or 
chronic variant3 – these were a feature only of the Campath® in-the-bag technique. 
 
1.3.4 GASTROENTEROLOGY  
Specific focus was given to the incidence and management of mucositis with pain control and hygiene 
extending to the foregut and small bowel that overshadowed colonic dysfunction. Typically, both were self-
limited and reversed promptly with engraftment. The aetiology was often viral ranging from herpes simplex to 
cytomegalovirus and concurrently disturbed liver enzymes, particularly cannalicular enzymes such as alanine 
aminotransferase (ALT) which corrected as the marrow recovered. 
 
Liver biopsy was unnecessary in almost all cases as dysfunction and injury were meticulously surveyed and 
their normalization documented. A particular aspect was a long-term experience of enteral nutrition analysed 
in terms of practical endpoints that included weight stability and serum albumin estimation. Over this entire 
period, reversal to intravenous supplementation was seldom necessary. The point had practical relevance in 
safety and quality of life as well as cost containment. Specifically, the early placement of a fine-bore nasal 
feeding tube, into the jejunum rather than into stomach, was proven to be effective. This outcome is thought to 
represent a significant contribution from the study.4 This approach had virtually no concomitant bacterial or 
fungal infectious complications. Similarly there were no problems with thromboembolism which can 
complicate parenteral nutrition. Serious efforts to examine supplements, particularly the impact of glutamine, 
were not possible due to lack of funding. In selected cases, laboratory studies were supplemented by 
endoscopy with biopsy but these were few and insufficient for any significant conclusion. 
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1.4 STUDY POPULATION REQUIREMENTS 
The sustained reporting to registries which ensured international surveillance, transparency and 
accountability, has remained unchanged. Optimum communication culminated in fully informed consent for 
each of the management protocols.  
 
All these activities were notified to the Institutional Review Board, known as the Committee for Clinical 
Governance which resided in the Mediclinic Corporation. The cross-sectional research project on a group of 
post transplant volunteers was approved by Stellenbosch University Committees for Health, Research, Ethics 
and PhD evaluation.  It is important and relevant to note that no new drugs were tested nor were any 
randomised trials undertaken. 
 
1.5 CHARACTERISATION OF LATE EFFECTS 
The reason the following three organs were selected for the study was due to the availability of specialised 
assistance to do these tests with no cost to the patients.  Additionally, we had very little data available on 
pulmonology, immunology and bone disease due to financial constraints.  A group of surviving volunteers was 
recruited for this study (Annexure 2). 
 
1.5.1 PULMONOLOGY  
The majority of the cohort was clinically asymptomatic in terms of exercise tolerance and none had a proven 
diagnosis of lung pathology. Accordingly the starting point for the evaluation of any silent injury was 
consideration of potential damage from exposure to a range of chemotherapy programmes that had been given 
to obtain disease control prior to transplantation.  
 
The next stop was to reflect on the toxicity profile of agents, including radiotherapy, and high-dose multiple 
drug administration for immunosuppression during the preparatory phase. The airways and pulmonary 
parenchyma are targets for damage some of which may be subtle yet irreversible. Accordingly, a series of 
specific studies was selected for the ability to demonstrate impaired function with reference to bacterial as well 
as viral insult. 
 
The patients were at risk of reactivation of the cytomegalovirus. This possibility received extra attention 
including consideration of the relative importance of laboratory studies ranging from serology to the 
polymerase chain reaction. Such information was the basis for pre-emptive intervention. The approach 
included therapy with valganciclovir in an attempt to prevent progression to the potentially lethal 
complication of pneumonitis or other, less frequent, inflammatory changes in the gut and liver. 
 
A second more ominous lesion reflected acute and subsequently chronic graft-versus-host disease. These 
immunologic phenomena were shown to be of much less frequency and severity in patients conditioned with 
the monoclonal antibodies.1 This observation provided a strong impetus for the evaluation of subclinical 
changes in the respiratory system and comparison of findings to published data, particularly non-infectious 
sequelae.5 
 
Many of the carefully selected tests were limited for financial reasons in the early phases of transplantation. 
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For this reason, collaboration with the Division of Pulmonology at Stellenbosch University and Tygerberg 
Academic Hospital was undertaken to define lung function and correlate any changes with the type of 
procedure or, secondarily, the underlying disease where protocol management might have included potentially 
damaging interventions. 
 
1.5.2 IMMUNOLOGY 
Although opportunities were not initially available to critically characterise innate and adaptive competence, 
there was nevertheless appreciation that integrity in both aspects were generally known to be impaired. Risk 
factors included the type of procedure, conditioning and the use of post-transplant and extended 
immunosuppressive regimens.  
 
Again, an opportunity was created to contrast selected function tests between cohorts of patients prepared for 
transplantation with ex vivo CD 52 antibody. 
 
1.5.3 BONE DISEASE 
The fundamental comparison started with simultaneous dual energy x-ray absorptiometry (DXA) and 
quantitative computed tomography (QCT) imaging and extended as relevant results accumulated. These were 
supplemented with biochemical measurements of bone turnover. 
 
 
1.6 ORGANISATION AND TIMELINES  
These were compliant with the university rules and regulations for doctoral studies.  Specifically, each segment 
of work was interpreted statistically and the local results analysed. The entire thesis is supported by selective 
review of the literature.  In 2011 new ethics approval was needed and took approximately six months to 
finalize. Appoval was obtained from Tygerberg Hospital where the studies were done. Patient recruitment 
occupied from April-July 2012. The various tests started in August 2012 and completed February 2013. Audit 
data was collected January 2012 to January 2013. Statistical analysis was done from March 2013 to July 2013. 
Literature review and writing the thesis followed next. The preliminary analysis was completed during the 
course of 2013 and the completed project submitted for examination in 2014.  
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1.7 SUMMARISING COMMENT 
 
This project has occupied 37 years (1972-2010). In the initial two decades, the aim was to 
participate, as an international centre, in setting up the transplant programme in South 
Africa. During that period the clinical programmes were refined, ensuring that data was 
available on every case from inception. Once the necessary infrastructure was standardised, 
analysis was done on audited data to establish outcome on both children and adult patients. 
Concurrently, identification of non-haematologic consequences in selected major target 
organs was undertaken and these were then systematically defined. The comprehensive 
project led to a model for immunohaematopoietic stem cell transplantation that has specific 
relevance in South Africa.  
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CHAPTER 2 
 
TRANSPLANT PROCEDURES IN SOUTH AFRICA 
A SHORT HISTORICAL PERSPECTIVE 
 
 
 
 
FOCUS 
 
Physiologically, irreversible bone marrow failure is incompatible with life despite 
availability of short-term therapy with red cells and platelets.  Pathophysiologically, 
the aetiology may be congenital or acquired and benign versus malignant.  
Therapeutically, the challenge is to favour autologous reconstitution wherever possible. 
Alternatively, replacement of this entire organ system with one or other form of stem 
cell grafting may be undertaken.  Experimental haematology has demonstrated, by 
means of animal models and in vitro culture systems, the existence of cells with 
repopulating capacity that home to niches in the bone marrow microenvironment.  
Translational research established that clinical applicability and ongoing scientific 
endeavour improve outcome, broaden indication, refine technique and now 
increasingly focus attention on patient consequences in the concept of survivorship. 
Three circumstances predicated the decision in 1972 to commit the future direction for 
the newly established and autonomous Department of Haematology in the Faculty of 
Health Sciences at the University of Cape Town to immunohaematopoietic stem cell 
transplantation under the Headship of Peter Jacobs as Foundation Professor. There 
was already, in other parts of the world, a clear demonstration that these procedures 
were potentially life-saving when properly used. Protocol studies for haematologic 
malignancy were introduced locally and some of these would require transplantation to 
achieve outcomes comparable to international standards of care. No such treatment 
options existed on the African continent. It was relevant that a research environment, 
including tissue-typing, existed at the Groote Schuur Hospital to sustain the impetus 
created following the first human heart transplant by Professor Christiaan Barnard.1  
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2.1 INTRODUCTION 
Formal inclusion of this brief historical orientation in the thesis is based on three facts. The awareness of side 
effects only became possible with accumulating experience of bone marrow transplantation in South Africa. In 
the start-up period, many short term symptoms and signs were recognised as therapy-related and reversed 
with engraftment: these are interpreted as early associations. The focus of this study was damage outside the 
blood and bone marrow, which was sufficiently recognised to justify a research study designated as late effects. 
In recognition of this time frame, the Faculty Committees accepted the relevance of preceding development as 
integral to this whole PhD study. 
 
 
2.2 THE PHYSICAL FACILITY – GROOTE SCHUUR HOSPITAL 
Initially the Department of Haematology had no beds or clinic space. There was only a small laboratory for 
blood clotting tests in C8 and space on the F floor adjoining the Falconer Lecture Theatre for routine 
haematological service including morphology. Brief comment is given to this start-up allocation since the 
unusual esprit de corps which was engineered was sufficient to anchor all members of staff through the 
difficult period ahead as the “Haem Team”. Space for research and development did not exist: an office was 
provided on the fifth floor in the somewhat remote Anatomy block on the medical school campus. Thereafter, 
with a research building being developed under the chairmanship of Professor Eugene Dowdle, it was possible 
to obtain a dedicated area for the first time and concurrently to integrate the administrative components. This 
challenging mandate was important in the forging of a functional discipline that would permanently and 
inseparably fuse clinical and laboratory medicine in line with the accepted world standard.  
 
How did the bone marrow transplantation unit develop? 
 
As the momentum gradually increased, it was possible to create an outpatient clinic, group in-patients on the 
D floor and to consolidate the staff, including dedicated nurses and pharmacists. Representatives from the 
Departments of Physiotherapy, Logopedics and Social Work were significant additions. These innovations 
established the future hallmark of the Department of Haematology – a morning report followed by walking 
rounds in which the entire group discussed the referrals that always accommodated each patient and their 
families.  
 
It was now time to take the next step. 
 
The legacy in which benign or malignant disorders of the haematopoietic system were treated by the admitting 
medical firm resulted in a lack of any statistical base and random management. With willingness by the 
haematologists to accept responsibility for all these cases within the Teaching Hospitals Group, it became 
possible to change this entrenched practice. The development provided an opportunity to work very closely 
with other departments including Radiotherapy and Nuclear Medicine, as well as Pharmacology and the major 
disciplines. This resulted in the introduction of combined clinics for lymphoma, myeloma and leukaemia 
where protocols had a final common pathway to one or other form of transplantation. 
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Shortly there followed the opportunity to document and report outcomes to European and American 
Transplant Registries. Such a model remains evident today and has become part of other transplant facilities 
which are developing in South Africa. 
 
As results were published from major centres in Europe, Australasia and particularly the United States of 
America, the emerging role of bone marrow transplantation moved up the South African agenda. It was 
unlikely that these procedures could have been started without some special dispensation, and cardiac and 
renal groups came to the rescue by making space available in the newly built Heart Tower. At the same time a 
day ward was created as the link between the transplant unit and dedicated beds for chemotherapy. 
 
This was the status of the new haematological programme at a time when money was allocated to re-build 
Groote Schuur Hospital. The government of the day decreed that it was to match and be based largely on the 
recently completed gigantic Tygerberg Academic counterpart.  
 
Despite numerous petitions to use a completely different or radial design with central facilities and specialised 
service, this fell on deaf ears and the plans proceeded for the new monolith. Nevertheless haematology 
received a fair share of general bed allocation and input to planning design with the result that almost all of 
the previous limitations were overcome.2 
 
 
2.3 HAEMATOLOGY CONSOLIDATED – NEW GROOTE SCHUUR HOSPITAL 
Without exaggeration the many long hours, days, weeks and eventually years to commissioning the 
redeveloped facility launched the completely redesigned Department of Haematology finally into the modern 
era. This was achieved by integrating various activities by having all the staff, except the developmental 
positions, in a single geographical area. This new arrangement made possible the ability to deliver appropriate 
interaction between the reverse isolation unit, custom-built for administering high-intensity chemotherapy 
programmes, managing neutropenia and meeting international standards for bone marrow transplantation. 
 
Throughout this exercise there was the sharing of engineering knowledge on such things as filters and all the 
associated aspects of laminar down-flow units which were magnanimously made available by our American 
colleagues in Seattle. The net result was a highly efficient and state-of-the-art protected environment for safe 
bone marrow grafting with emphasis on reverse isolation that played an important role during periods of 
profound low white cell counts. 
 
 
2.4 CREATING AN INFRASTRUCTURE – APHERESIS TECHNOLOGY 
Advances in immunohaematology, accelerated by better understanding of transplantation biology, gave 
impetus to the provision of a sound blood transfusion practice. At this time packed red cells were delivered in 
glass bottles and platelets supplied as single units without any quality control either by the user or prescribed 
by the service provider! The regular visits to the MD Anderson Hospital and Tumour Institute in Houston 
brought contact with Professor Jeane Porter Hester. 
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She had been developing the physics and engineering facilities required for continuous blood flow separation 
in collaboration with International Business Machines (IBM). It was clear that, if the serious intention was to 
set up this new and innovative programme then, somehow, comparable advances needed to be available in the 
department. Fortunately, donations were obtained and the model 2990 apheresis system, with a disposable 
polycarbonate bowl, was delivered for introduction of this technology in Africa.3 Paradoxically, although these 
instruments are now commonplace in commercial blood banks the first use, and all the refinements, took 
place in Groote Schuur Hospital.4 This close association continues to the current day and the prototype South 
African apheresis unit was named in respect and honour of this extraordinarily capable lady colleague and 
scientist.   
 
To be fully compliant with prevailing transfusion regulations, both hospital and university administration 
obtained authorisation from the Department of Health for the establishment of a dedicated research 
programme in this area. There was a solitary proviso that the products, other than stem cells, would not be 
stored and it is a matter of record that volunteers flocked to donate essential granulocytes5 and platelets.6 It 
was now possible to add expertise that had been accumulated at the Royal Marsden Hospital in the United 
Kingdom via an exchange programme that brought nursing staff, with a particular interest in these 
procedures, to the unit. 
 
This was an important acknowledgement by the licensing authority because, although with restricted approval 
of the Western Province Blood Transfusion Service in the form of their medical director, it created a 
precedent. The arrangement was vested within the Teaching Hospitals Group – the Professor and the Nursing 
Coordinator with the latter given overall charge of this special area. At no time, from the first trial run to the 
establishment of a flawlessly operated system that was constantly updated and refined, was any serious 
adverse event encountered. Indeed this became the acknowledged training centre for South Africa and 
extended to new groups embarking on similar approaches. 
 
 
2.5 MULTIDISCIPLINARY MANAGEMENT TEAM 
Based on the constantly changing complex symptoms and signs arising during the course of transplantation, 
typically preceded by complicated treatment programmes dictated by the underlying disease, it was early 
acknowledged that the model so well developed in Seattle would be employed as reference point.7 A number of 
visitors from academic medical centres worldwide personally coordinated much of that development. The 
Haematology Staff (“Haem Team”) defined a holistic or cross-disciplinary approach that recognised and 
constructively responded to the crucial role played by the paramedicals. Impressively, one of the concessions 
made by hospital management to this somewhat unusual continuum was of a trained and experienced 
scientist constantly moving between clinics, dedicated ward and transplantation unit with very particular 
focus on rapid access through the outpatients. This was achieved by creating a Chief Professional Nurse level 
post designated Haematology Coordinator. This position had already been widely acknowledged and 
implemented by transplant units elsewhere in the world and shown to function most efficiently.  
 
Added to the growing team was the increasingly integrated contribution from Physiotherapy, Logopedics, 
Pharmacy, Dietetics and Social work.  
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Consultants from other specialities, notably from the Infectious Diseases service played an important role as 
did a psychiatrist. This step blurred the previous emphasis between physical and other emotional disturbances 
that required careful attention in maintaining quality of life of the patients. 
 
 
2.6 RELOCATION TO A PRIVATELY BASED ACADEMIC CENTRE 
Changing circumstances in health care delivery provided an opportunity to test the new concept that the 
established level of first world haematology could be duplicated in the private sector. To this end a University 
style department was successfully created by building a corresponding facility incorporating all the matching 
technology in the Wynberg Hospital. With steady growth, relocation became necessary to accommodate the 
need for space which at that time was only available at the Mediclinic Constantiaberg.  
 
The initial renovation of a paediatric ward to include an eight-bed reverse isolation unit founded on the 
experience of the prototype in Groote Schuur Hospital and refined in Wynberg proved efficient and functional. 
This self-sufficient unit had access control and comprised eight twin rooms – one of each pair for the patient 
with monitoring facilities including dialysis and linked to a central nursing station; the other for medication 
storage and preparation for procedures. (Figure 1) A complement of dedicated and trained professional 
nursing staff operated the unit as part of the holistic team: in-house special transplantation training was 
provided. This approach consolidated the holistic core of an integrated or cross-disciplinary team with strong 
management based in the daily report. 
 
A self-sufficient transplantation laboratory with all the necessary equipment and expertise for 
cryopreservation of grafts was included as well as space for consulting rooms and a conference centre. With 
additional pressure to centralise the increasing number of haematology referrals, a completely new wing was 
built and named the Sunflower Haematology Ward. This achievement facilitated continued reporting of every 
consecutive case to registries and unbroken accreditation as an internationally designated transplant, harvest 
and donor centre.  
 
The final step was the submission and approval of the recognition as a satellite within the recently established 
Division of Clinical Haematology in the Department of Internal Medicine of the Faculty of Health Sciences at 
Stellenbosch University. 
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FIGURE 1 
CHILD RECEIVING STEM CELLS IN A PROTECTED ENVIRONMENT 
 
 
 
Courtesy of child’s parents 
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2.7 SUMMARISING COMMENT 
 
 
 
This is the brief historical background to the introduction and development of 
immunohaematopoietic stem cell transplantation in South Africa. Careful attention to 
the clinical management, over time, shifted attention from primarily haematopoietic 
patterns of recovery to more subtle deviations outside blood and bone marrow. As such, 
evolution of the protected environment played a significant role in the comprehensive 
care of recipients. Control of external factors that impacted on injury to non-
haematopoietic tissues – some common, rapidly reversible and others of late onset. It is 
unrealistic to try and interpret the organ changes without an awareness of how 
stepwise improvements in the physical facility were modified to keep pace with 
demands generated by actual experience. Stated differently, the direct involvement in 
setting up and testing the prototype was part of arriving at the final model used in this 
country. Superimposed on this structure was the systematic generation of protocols, 
based on worldwide standards that were consolidated with experience. At all stages 
survival was matched to corresponding outcome published from reputable units in 
Europe and America. This model was used to promote dissemination elsewhere in South 
African Universities and ultimately spread to the private sector. 
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CHAPTER 3  
 
ACCOUNTABILITY AND ACCREDITATION 
 
 
 
 
FOCUS 
 
Continued acceptance of case referrals by registries that generated the research audit, 
was of such importance that it has been assigned separate presentation. Three crucial 
confirmatory statements apply to the study and thesis, each in their entirety. All the 
experimental and first two decades of clinical work had prior approval and ongoing 
authorisation by the local University of Cape Town Ethics and Research Committees. 
Consecutive reporting of details for each and every patient documented to time of death 
or remaining on study, under constant review by these groups, guaranteed compliance 
with conduct in keeping activities aligned to international codes. The participation in 
each, as a designated investigator, ensured observation of rules governing patient care 
as standard of practice and clinical research. Concurrently, on the basis of completed 
demographic capture sheets that have been subject to critical analysis, there has been 
accreditation remaining unbroken over three decades. These collaborative experiences, 
that include both joint reporting and incorporation of data into international 
publications, span the entire research project of some 37 years and continue actively to 
the present. This status reflects independent review of all aspects that included 
inspection by committees from the Centre for International Blood and Marrow 
Transplant Research and from the National Marrow Donor Program. 
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3.1 INTRODUCTION 
Although the importance of data verification was appreciated and implemented when transplantation was 
started, the major impact of this exercise on the evolving research project could not have been anticipated at 
the time when marrow grafting was first undertaken. Commitment to transparency and external review 
subsequently added authenticity to the entire listing of patients, in the reference cohort, and of post-transplant 
volunteers participating in the thesis protocol. For this reason, the approval from the different registries 
remained an important criterion. Accreditation was done on a yearly basis depending on compliance to certain 
requirements. Reporting now only involves the Center for International Blood and Marrow Transplant 
Research (CIBMTR), the European Group for Blood and Bone Marrow Transplant (EBMT) and the National 
Marrow Donor Progam (NMDP) if donors were recruited from the latter registry 
 
3.2 INTERNATIONAL BONE MARROW TRANSPLANT REGISTRY 
This registry was the only peer review group available when allografting was introduced in South Africa. Once 
application was approved, including review of curriculum vitae of the investigators, a probationary period was 
followed by membership with our data incorporated into the registry’s reports.1    This registry became part of 
the CIBMTR and was discontinued. 
 
3.3 AUTOLOGOUS BONE MARROW TRANSPLANT REGISTRY 
As technology became better established and dual reporting fully compliant, our designated team was assigned 
a centre number and each individual case was registered.2   We initially reported to them but this registry was 
subsequently incorporated into CIBMTR. 
 
3.4 CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH – 
(TRANSPLANT CENTRE – TC – 348) - CIBMTR 
With the explosion of hospitals all over the world undertaking stem cell grafting, a profusion in the number of 
registries has resulted in this parent body being established. Reporting continues in full compliance with the 
updated rules and regulations.3 
 
3.5 EUROPEAN GROUP FOR BLOOD AND BONE MARROW TRANSPLANT – EBMT 
From the time that our team was established, with both investigators officially designated as members, it 
continued to operate as an audited and accredited transplant, donor and harvest centre. (Centre identification 
code – CIC-772).4 Reporting was done simultaneously with CIBMTR. 
 
3.6 JOINT ACCREDITATION COMMITTEE OF ISCT – EBMT – JACIE 
Close participation in as many of the activities of the above organisation has continued. As we are not a 
member of the European Community, we are excluded due to being geographically based in South Africa. 
Nevertheless, we have maintained standards designed to fully comply with those set out in the guidelines for 
demonstrating excellence in stem cell transplantation. Although some aspects, notably enrolment in clinical 
trials, remain desirable it is still not possible in terms of prevailing European Commission Directives. Efforts 
to formally register with JACIE were precluded due to financial reasons but nevertheless standard operating 
procedures were followed according to publication guidelines.5 
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3.7 THE SOUTH AFRICAN BONE MARROW REGISTRY - SABMR 
Continuous expansion of the program activity created a problem with finding suitable histocompatible donors. 
This led to the establishing of the Bone Marrow Transplant Registry.6 The initiative was undertaken by 
Professor Peter Jacobs jointly with Professor Ernette du Toit, Director of Tissue Immunology and Dr Arthur 
Bird, Director of Blood Transfusion Services. This registry has grown steadily and it is currently housed in the 
Provincial Laboratory for Tissue Immunology where all tissue typing is performed. This laboratory has 
international endorsement for immunogenic competence and interacts widely particularly with the World 
Marrow Donor Association. All donors coming into our service did so via the local laboratory with which we 
held regular scheduled meetings.  
 
 
3.8 THE NATIONAL MARROW DONOR PROGRAM – TC 475 - NMDP 
Difficulties were encountered with access to this large group of volunteers in the United States. After 
application and processing of curriculum vitae and a lengthy evaluation, we were designated as the initial and 
probably still the only centre in South Africa enjoying transplantation privileges, particularly harvest and 
donor, accreditation.7  Our representation on their Council has ensured continued close interaction and, as an 
outgrowth, our status and links with the South African Bone Marrow Registry have made it possible to 
increasingly include members of their staff in this international collaborative venture.  We reported patients 
only if a donor was recruited from them. 
 
 
3.9 AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION 
Active membership is maintained with this group where interaction and concurrent availability of data is 
being explored through a combined process that will notably be included in the Centre for International Blood 
and Bone Marrow Transplant Research. 
 
 
3.10 ALTERNATIVE SOURCES OF STEM CELLS 
It has been a privilege to enjoy access to Eurocord8 and international Netcord foundation largely through 
searches conducted worldwide on our behalf by the South African Bone Marrow Registry.  
 
Throughout this period, there has been an increasing awareness of the apparently unlimited potential of 
alternative donor sources – not only from blood and bone marrow but also umbilical cord and now amniotic 
fluid. Here again accountability will be a challenge for years to come and this can be based on the precedent 
set by this prototype unit. 
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3.11 SUMMARISING COMMENT 
 
 
 
It is currently not clear how future development will extend to umbilical cord blood and 
amniotic fluid or how these donor sources will interface with the shift in use of 
immunohaematopoietic stem cells. This brings into sharp focus the ethical and moral 
issues that surround the use of these human biological reagents in adult as opposed to 
embryonic stem cells. Such differences need to continue being researched but with 
responsible regulation. The future landscape will accommodate naturally the place of 
restorative, in contrast to regenerative, medicine. Against this reality is confidence in 
the proactive way that all aspects of these technologies were documented from 
inception. This research design has anchored use of this precious human resource in 
South African clinical practice. It also provides a framework on which to develop the 
responsible use of these procedures, particularly as their deployment escalates, even in 
this under-resourced area of the globe. The overarching impact of this wide ranging 
registry participation is two-fold. In the first instance, that quality of programme 
continues to match highest possible international standards. Secondly, there is long 
term uniformity of outcome to the relevant extent that the cohort selected for more 
advanced testing of specific organ system, extrapolates back to both the reference 
sample and to other centres that participate in registry reporting. 
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CHAPTER 4 
TECHNICAL DETAILS OF THE STEM CELL TRANSPLANT PROCESS. 
 
 
 
 
FOCUS 
 
This section sets out the minutae that had been standardised via constant refinement to 
include ongoing review by international colleagues from the time the programme was 
introduced. It defined the methodology used throughout all aspects of the transplant 
process. To that specific end a consolidated perspective, or audit, is provided from 
personal observations that focused attention on the outcome of these various types of 
immunohaematopoietic stem and progenitor cell transplantation. Procedures have 
remained largely uniform from inception and were updated only as needed. Then, 
based on observations,  changes in non-haematopoietic tissues and organ systems that 
had been identified as potentially at risk were additionally exploredd. There emerged 
two patterns. Early associations that were almost universal, transient and corrected 
with myeloid recovery proactively managed as integral to this routine protocol. Late 
effects were quite different, separate and needed additional methods to define 
functional and structural alterations previously not reported locally. 
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4.1 INTRODUCTION 
This section of the thesis provides a description of the transplant process.  Protocols were established for each 
step contributing to the successful outcome of this procedure. 
 
 
4.2 PROTECTED ENVIRONMENT - THE PHYSICAL PLANT 
Advice from the Fred Hutchinson Cancer Center in Seattle, resulted in building a dedicated prototype unit 
with a safe air exchange facility which incorporated the capacity to exhaust room volume and to do so safely.1 
 
Each two-room suite was made up of a patient bed with necessary monitoring equipment interlinked to a 
constantly staffed medical and nursing workstation. Individual temperature and humidity stabilisation was 
instituted. Microbiological studies and maintenance of the filters were a regular routine. Initially 16 beds were 
commissioned in the new Groote Schuur Hospital but subsequently downsized to eight in the privately based 
Mediclinic Constantiaberg.  
 
Access and exit were controlled by the Unit Manager. Linen changes were part of staff and visitor regulation in 
which appropriate gowning required change into surgical scrubs. The numbers of visitors were restricted and 
determined by the condition of the patients with particular concerns about risk of post-transplant infections.2 
 
 
4.3 PSYCHOSOCIAL SUPPORT  
In adults as well as children one of the earliest deficiencies was that of good, explicit and simple but reliable 
communication with patients and their families.3 This step, when viewed superficially, might be regarded as 
non-medical and perhaps only remotely related to the underlying haematologic disorder. However, 
chemotherapy or radiotherapy and the frightening use of the words such as leukaemia and bone marrow 
transplantation were found to be a major cause for distress. This problem presents an ever-increasing focal 
point in the provision of comprehensive treatment.  
 
This supportive process was started on the basis of experience in Europe and USA and wisdom was brought to 
bear by the first liaison psychiatrist with whom we were able to work regularly. He patiently cultivated very 
wide ranging interaction with the patients and all immediate relatives. 
 
Emphasis was placed upon the involvement of paramedical professional members of the transplant team and 
included paediatricians. This holistic view was subsequently consolidated by encouraging participation of 
psychologists and, of special benefit, a bereavement counsellor.4 Reciprocally, support was available in the 
reverse direction whereby access to these members of the team was not only ongoing but could be activated, 
directly by patients of all ages or their families at any time.  
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4.4 TRANSPLANT DECISIONS  
Departmental staff conferences were routinely convened to ensure that all medical and haematologic criteria 
had been carefully checked and ratified prior to proceeding with this procedure. Simultaneously, information 
was provided for the patient and the family5 and this procedure included discussion with interested and 
involved parties, specifically the psychosocial counsellor, psychologists and psychiatrists. All necessary 
consent forms were completed including living wills or advance directives as part of the clinical record.6 
Separate agreements were signed for material collection as required as part of international studies. Where 
appropriate, clinical trials were formally registered with attention to ethics and research approval.7 
 
Participation within the European Group for Blood and Bone Marrow Transplant (EBMT) and subsequently 
by the Centre for International Blood and Marrow Transplant Research (CIBMTR) and links to the National 
Donor Program (NMDP) required the assignment of a unique haematology departmental accession and 
registry reporting number to ensure autonomy of all patients who were registered. 
 
In addition to these administrative requirements, important transplant related data were checked, these 
included histocompatibility and blood groups. HLA typing in year 2000 used serology testing for class I  and 
class II by molecular high resolution. In 2002 high resolution was introduced for class I and in both donor and 
recipient, five loci were tested (HLA–A,B,C, DRBI and DQBI). Planning for plasma exchange was necessary to 
remove isoagglutinins before a procedure where there was ABO incompatibility or remove antibody where 
platelet refractoriness was present. In the latter situation these complications could be reversed with apheresis 
and infusing gammaglobulin8  followed by platelet infusion and laparoscopic splenectomy.9 
 
These decisions were consolidated into a personalised patient calendar with the addition of consultation for 
cardiac assessment, chest radiology, simulation and consultation with radiation oncologists, placement of 
central venous lines10 and provision for later use of an antibiotic lock. 11 Dates were finalised for autologous 
harvest with cryopreservation in patients undergoing matched-unrelated volunteer donor procedures and also 
for autologous transplants. The timetable also included the conditioning regimen to be used. 
 
Fully informed consent documents were signed by both recipient and donor for the chemotherapy, harvesting 
and the transplant itself.  
 
 
4.5 RECIPIENT PREPARATION 
General requirements were physical examination including chest radiology, cardiac assessment 
(echocardiogram and electrocardiogram); height and weight were calculated to body surface area using the 
ideal body mass index.  
 
The following laboratory studies needed to be performed to ensure that the patient was in a suitable condition 
for the transplant: full blood count with manual differential and reticulocyte production index, appropriate 
biomarkers, biochemical profile defined as creatinine and electrolytes together with glucose estimation. 
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Liver function and enzyme tests were performed and confirmation that viral screens for cytomegalovirus, 
hepatitis, HIV I and II, as well as Epstein Barr virus serology, remained negative. If not already in position, 
central venous lines were placed by the Hickman technique which, if inactive, the line was locked with saline 
containing 5000 units/L of heparin, 10,000 mg/L of vancomycin, 10,000 mg/L of ceftazidime or alternatively 
20,000 mg/L of tazobactam or 5000 mg/L of gentamycin (Heparin – antibiotic lock), constituted in 100 ml, 
using a tenth of the dose. Our pharmacist used 50 ml and adjusted the dose accordingly and then provided 5 
ml of this solution in a syringe to insert 2.5 ml into each lumen. If required, bone marrow aspiration and 
trephine biopsy and lumbar puncture were also undertaken. Psychosocial counselling included quality of life 
assessment and assurance that all information about the procedure had been provided. At this time, we also 
ensured that storage of sperm and ova had been carried out and if the patient was entered in study protocols, 
that these be continued. Where indicated, a visit to the dentist and referral to maxillofacial surgical colleagues 
were also included. Repeat family discussions or conferences were held as needed.  
 
 
4.6 DONOR PREPARATION 
The following investigations and blood tests needed to be done to ensure that the donor qualified for the 
procedure. Physical examination with chest radiology and cardiology clearance and the collection of blood 
specimens for full blood count with manual differential, biochemical profile, viral screens for cytomegalovirus, 
hepatitis, Epstein Barr and immunodeficiency virus together with creatinine estimation.12 Five days before 
apheresis collection, we commenced granulocyte colony-stimulating factor (G-CSF) 300 µg (Roche) 
subcutaneously daily advising the donor that some side effects were possible. Large volume apheresis 
collection required that a minimum of 2 x 106/kg CD34 positive stem cells and 6.5 x 108/kg mononuclears are 
recovered with these being characterised by flow cytometry and in vitro clonogenic assay using the GM-CFUc 
to get a minimum of 5 x 104/kg body weight.13 
 
 
4.7 PLACING AND MANAGEMENT OF CENTRAL VENOUS OR J LINES 
In a distressed and already anxious patient, one of the most unpleasant events is the spectre of regular 
intravenous therapy. Based on a pilot and then a feasibility study, long stay intravenous access was pioneered 
by placing, under local anaesthetic, a paediatric nasogastric feeding tube into the right subclavian or 
preferably superior vena cava.14 (Figure 2) 
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FIGURE 2 
PROTOTYPE INTRAVENOUS ACCESS 14 
 
 
 
This approach was subsequently replaced by the Hickman procedure which is safe, reliable and has virtually 
no side-effects.15 The line was tunnelled to leave the teflon cuff about 1 cm above the placement incision. It 
was important to loop and secure the line to the anterior chest wall to avoid accidental dislocation or loss. 
(Figure 3) Colonisation, although always a matter for concern, proved to be a relatively minor problem in 
that only a few catheters had ever been removed on this suspicion.15  
 
 
FIGURE 3 
J LINE IN OPERATION – THE HICKMAN TECHNIQUE15 
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It was relevant, in each instance where cultures were negative, that removal did not result in resolution of the 
fever; an alternative site for the infection was subsequently identified. This observation in no way detracted 
from maintaining a very high index of sterility but, in contrast to many of the published recommendations that 
in this situation the lines should automatically be removed, the Haematology Team has recorded a 
substantially different, and less intrusive, outcome. Use of a heparin-antibiotic lock may explain this finding.11 
Low-level anticoagulation with 2.5 mg of warfarin on alternative days without prolongation of the INR 
contributed to reducing deposition of fibrin around the lines.  
 
When deposition did occur, radiological studies typically demonstrated a fibrin sheath.  Figure 4a shows a 
normal linogram while Figure 4b shows occlusion due to fibrin sheath around the tip of the catheter in the 
vena cava.  This could be readily lysed by installation of recombinant human tissue plasminogen activator into 
both channels by leaving it in situ for 24 hours and then aspirating the intraluminal material.16 In periods 
when not actively used, heparinised saline containing antibiotics was instilled into the lumens and may have 
contributed to an unusually low sepsis rate. Removal of the line was a simple outpatient procedure provided 
the teflon cuff had been correctly placed within a centimetre of the insertion site.  
 
 
FIGURE 4 
LINOGRAM TO IDENTIFY OBSTRUCTION – FIBRIN SHEATH 
 
 
(a)                                 (b) 
Courtesy Dr Derek Solomon – Tuft and Partners 
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4.8 CONDITIONING 
Although more trials are needed to recommend the routine use of CD52 antibody, it has been shown that it 
reduces GVHD without increasing graft rejection.  There was however an increase in relapse rate, especially in 
AML but not affecting overall survival.  There is ongoing debate about the use of Campath® in-the-bag and 
although it is not the norm, it is increasingly being used in other transplant centres. 
 
In this transplant centre, graft-versus-host disease ceased to be a dominant problem when Campath® 1G, and 
subsequently 1H, was added to bone marrow in-the-bag.17  This GVHD differed from the fully developed entity 
with only erythroderma being found in approximately 10 - 20% of peripheral blood stem cell grafts when 
exposed to Campath® 1H – but not 1G – ex vivo.  
 
Conditioning programmes were another area that attracted early interest because, as with the prior drug 
therapy, these different approaches brought with them alternative forms of morbidity and mortality. Since the 
graft-versus-host disease may have been related to conditioning, a question remained as to whether our 
established regimen combining cyclophosphamide with total body and total nodal irradiation had an impact 
on this complication.  
 
This method was different from the alternative standard approach using only busulphan and 
cyclophosphamide: the Bu-Cy218 or Bu-Cy4 regimens. Considerable literature exists but opinions are 
divergent and the two methods are variably reported to be beneficial – or disadvantageous – in one or other 
disease category. There is no consensus favouring either approach. Pragmatically, patients were allocated by 
disease category, after reading and signing an informed consent.  
 
On rare occasions individuals were precluded from the drugs because of specific sensitivities directed at lung 
or bladder: here the standard became etoposide combined with melphalan. Other options included 
mitoxantrone,19 BEAM, 20 CBV,21 and ICE22 or even more complex regimens23 particularly when only haplo-
identical family donors were used.24 In an extensive analysis of published data, there were  no significant 
differences in relapse rates and graft-versus-host disease or probabilities in survival for the period from 1995–
2002.25,26 
 
A comprehensive review from Sweden supported the observations but emphasized a higher risk of veno-
occlusive disease and haemorrhagic cystitis with the busulphan regimens: there also has to be a minimum of 
24 hours separating the busulphan and the cyclophosphamide to avoid drug interaction.27 Furthermore, in a 
study from Johns Hopkins Hospital (Santos, personal communication) 16 mg/kg of busulphan was given over 
four days followed by a rest period of 24 hours and two days of cyclophosphamide at a dose of 60 mg/kg per 
day. Therefore this replaced the earlier regimen in which cyclophosphamide was given at 50 mg/kg of ideal 
body weight to a total of 200 mg/kg: (the Bu-Cy4 protocol). This approach applied to both adults and children 
irrespective of disease category.18 
 
The interval between the two drugs and the slightly reduced dose of cyclophosphamide diminished most of the 
problems. Preferably intravenous busulphan was given as 3.2 mg/kg daily as a single infusion in place of the 
oral route. All individuals were and should be premedicated with standard anti-convulsant regimen to prevent 
Stellenbosch University  https://scholar.sun.ac.za
 53 
seizures; this was commenced one day before the busulphan. In unusual circumstances etoposide can be given 
at a dose of 60mg/kg continuously over 18 hours between the busulphan and the cyclophosphamide: this is 
not our current practice but noted for information.  
 
A crucial point is that the patients received MESNA and if any haematuria persisted, the dose of uromitexan 
was extended in 24-hour blocks until no further bleeding was evident. Urine output must have exceeded 75 ml 
per hour and furosemide was given as needed.  Platelets were maintained above 50 x 10 9/L.  
 
In Fanconi Anaemia recent data favoured non-radiotherapy conditioning regimens in the form of fludarabine, 
antilymphocyte globulin and cyclophosphamide.28,29  
 
In all age groups, benign disorders, notably haemoglobinopathies and thalassaemia as well as bone marrow 
failure, the same approach was used. In collaborative amyloid studies, preparation did not include 
radiotherapy. Only melphalan was used based on the data from Dr Phillip Hawkins and also the group in 
Boston: at a dose of 220mg/m2 (personal communication). It was found that two divided doses, or over two 
days (100mg/m2) had better patient acceptability and this became the subsequent standard. An alternative is 
to employ melphalan 140 mg/m2 over 15 minutes and etoposide 2.5 g/m2 as a one hour infusion. The 
etoposide was used because of better solubility and bioequivalence between the two formulations.30 
 
Radiotherapy was retained as a myeloablative option for malignant conditions. 
 
Where blood group differences exist between donor and recipient plasma exchange may be needed. In these 
circumstances survival is unaffected but haematopoietic regeneration is often delayed.31 Thereafter only AB 
plasma and platelets were given with red cells limited to group O. Selective decontamination of the gut was 
standard practice and antibiotic regimens varied as a result of constant review. The use of ofloxacin or 
ciprofloxacin over co-trimoxazole was favoured and the current choice is levofloxacin at 500 mg orally daily.32 
 
4.9 SEQUENTIAL EVOLUTION OF SEVEN DEVELOPMENTAL PHASES 
These involved the main areas which had an influence on our program. 
 
4.9.1 UNFRACTIONED BONE MARROW AS THE GRAFT SOURCE 
This was, from inception and for many years thereafter, the worldwide standard. The stem cell harvesting was 
a dramatic process which required a general anaesthetic. Two teams working in parallel aspirated from 
sternum and both iliac crests, between 10 and 15 ml of marrow rich blood for every kilogram recipient lean 
body mass, in appropriate anticoagulant.33 (Figure 5) Recipients were immunosuppressed, marrow infused 
intravenously and an engraftment period monitored in reverse isolation or a protected environment. 
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FIGURE 5 
THE FIRST HUMAN ALLOGRAFT IN SOUTH AFRICA – HARVESTING OF STEM CELLS 
 
 
 
 
These efforts had widespread support throughout the Faculty. In reflecting on this defining aspect of the study 
there is recalled the same absolute dedication to scientifically approaching this challenge with a quiet and 
understated confidence that was so reminiscent of the leadership of Professor E Donnall Thomas (Figure 6) on 
which was modelled this first South African venture of transplant immunology, biology and haematology. These 
attributes are still shared and are a constant reminder of his continued influence through many graduates and 
fellows from the Fred Hutchinson Cancer Institute, Seattle USA, which remains a reference point for an 
exemplary standard of care. 
 
Much of our local achievement in Cape Town was anchored in the major and continuous guidance provided by 
this legendary father of bone marrow transplantation. To the present day his example and ready help are 
enjoyed by our group – the Seattle connection. 
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FIGURE 6 
DR E DONNALL THOMAS – NOBEL LAUREATE 
 
 
 
 (Courtesy: Meg E. Bender, Project Coordinator, Clinical Transplantation Support, Clinical Research 
Division – Fred Hutchinson Cancer Research Center). 
 
 4.9.2 REJECTION AND NONENGRAFTMENT 
These were significant impediments to survival but early recognition and repeat procedure with altered 
conditioning and enhanced post-transplant corticosteroid with methotrexate was standard of this era. 
 
4.9.3 GRAFT-VERSUS-HOST DISEASE 
 An acute syndrome (GVHD) occurred typically within the first 90 days.  A major immunologic phenomenon 
which caused enormous morbidity and significant mortality.34 
 
4.9.4 THE INFLUENCE OF CYCLOSPORIN A35 
This drug came when effective intervention was desperately needed. Access to the product was obtained 
through years of close association with pharmaceutical company Sandoz in Basel. This reflected collaboration 
with Swiss investigators and led to systematic studies with Dr Jean Borel which demonstrated a reduction in 
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the incidence and severity of acute graft-versus-host disease but not abrogation. This advance was based on a 
rabbit model and extended to clinical practice.36 
 
Wide and unpredictable variability existed in pharmacokinetics and dynamics when cyclosporin A was used in 
matched unrelated transplants. These transplants were started on 5 mg/kg as 2-hour infusion BD on day two 
and switched to an oral dose of 100 mg 12 hourly once the individual was able to swallow. 
 
The target was 1500 g/ml at 120 minutes using the C2 assay37 from giving the oral tablet or completing the 
intravenous administration. Individual differences in recipient drug handling were thought to explain 
unpredictable occurrences of skin rash in the allografts.38  
 
4.9.5 IMPACT OF CAMPATH® MONOCLONAL ANTIBODIES 
This was carried out in close collaborative studies with Professor Herman Waldman and Dr Geoff Hale first in 
Cambridge and then continuing subsequently in Oxford - actively ongoing to the present moment. These 
could, even in an understated way, be chronicled as momentous to the point of revolutionising interventional 
approaches to these lymphocyte-mediated inflammatory attacks on many body systems. 39 
 
4.9.5.1 HISTORY OF CAMPATH® 
In 1973 Herman Waldman started research on how the immune system could choose between immunity and 
tolerance. He then became aware in 1974 of monoclonal antibodies and in 1978 realised that such an antibody 
could be useful in bone marrow transplants, GVHD being a major complication caused by the contamination 
of bone marrow by “T lymphocytes”.  T cells can be depleted by using anti-CD 52 antibodies directed against 
the CD52 antigen found on T and B lymphocytes, monocytes and dendritic cells. Herman Waldman was joined 
by Geoff Hale at Cambridge University and subsequently they continued in Oxford.  They initially produced 
the monoclonal antibody Campath® I-M, a rat antibody that was capable of dissolving T cells by activating 
complement.  It was effective in preventing GVHD but caused graft rejection.  Then followed Campath® I-G  
developed for in vivo depletion of host cells to prevent rejection.  In 1988, this was humanised by genetic 
engineering to create Campath® 1-H. Herman Waldman constituted a Campath® Users’ Group of which 
Professor Peter Jacobs was a member. 
 
The “Haem Team” had the privilege and unique position of being assigned a particular responsibility by the 
Campath® Users’ Group of following up on their reported effect of adding the first of these, which was a mouse 
lytic immunoglobulin, to the graft in-the-bag – the ex vivo approach. This process has been refined by 
gradually improving the choice of reagents and currently the standard is the humanised opsonic protein that 
has the interesting capacity of binding to the CD52 receptor making these cells suitable for selective removal 
upon infusion by the reticuloendothelial system.39 
  
Campath® 1H was first approved by the Food and Drug Administration (FDA) in 2001 and in 2007, it was also 
approved as first-line therapy for CLL.  Commercialisation of the product then took place. 
 
The ex vivo use of this CD52 antibody was very successful in preventing GVHD. This approach was 
subsequently followed in our department and use of unmanipulated marrow was discontinued. 
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4.9.6 MOBILISED PERIPHERAL BLOOD WITH APHERESIS HARVESTING 
This procedure was a natural addition to the rapidly advancing achievements for improved technology.40  
Here again the Haematology Team was ideally placed to participate actively in this transition because of the 
early involvement with continuous flow cell separators and laboratory studies that documented the nomadic 
nature of the immunohaematopoietic stem cell.41 A short period was dedicated to systematically testing and 
demonstrating that, for practical and clinical purposes, this source was interchangeable with marrow although 
some subtle differences exist. A composition of various graft sources are seen using a modified table from 
Gluckman in the hand book from the Bone Marrow Registry. (Table 1) Notably local concern was focused on 
immunologic effects in donors.42 This point in the research programme included evaluation of differing 
cryobiology techniques and scrupulous attention to characterisation and behaviour of the recovered material 
both in terms of cell numbers and using clonogenic assay of long-term colony initiating population, which 
were required for re-establishment of immunohaematopoietic function.43 In parallel, introduction of flow 
cytometry to document the numbers of CD34 expressing population.44 
 
 
TABLE 1 
COMPOSITION OF THE GRAFT SOURCE45 
 
 VOLUME 
COLLECTED 
MEDIAN CD34 
CONTENT 
MEDIAN CD3 
CONTENT 
TARGET CELL 
DOSE 
BONE MARROW 10-20 mL/kg 2-3 x 106/kg* 25 x 106/kg >2 x 108 TNC/kg 
PERIPHERAL BLOOD 150-400 mL 8 x 106/kg 250 x 106/kg 5-10 x 106 CD34+/kg 
UMBILICAL CORD BLOOD 8—160 mL 0.2 x 106/kg 2.5 x 106/kg >3 x 107 TNC/kg 
 
*Per kg recipient body weight 
 
4.9.7 CORD BLOOD 
This alternative source of stem cells became routinely available over the last five years for the use in this 
transplant facility. It is determined by patient size and availability and is largely interchangeable with 
conventional marrow and peripheral blood. In all these situations corresponding values are now 
internationally standardised.45  It was mostly considered in paediatric patients as the total nucleated cell 
(TNC) dose is small.  It was seldom used as first choice and usually a fully matched donor cannot be found.  It 
is very expensive, there is delayed engraftment and there is no possibility that more product can be obtained if 
needed. 
 
4.10 DETAILS OF THE GRAFT 
A study was done in our department to characterise the response to the stimulatory peptide with most 
allogeneic donors achieving a peak mononuclear (Figure 7a) and CD34 cell population by day four. (Figure 
7b) Recovery of circulating immunohaematopoietic stem and progenitor cells rests on standardised apheresis 
methodology40 that takes into account appropriate use of stimulatory peptide to mobilise the required CD 34+ 
population.46 Data analysis from the series of donors showed a correlation between total number of 
mononuclear cells and the CD34 positive numbers.13 
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Following mobilisation with G-CSF, the appearance of peripheral blood mononuclear cells paralleled the all-
important CD34 population considered to identify the earlier progenitor and stem cells. At this point the graft 
was harvested with greatest concentration of the desirable population for haematopoietic reconstitution.  
 
 
FIGURE 7 
DETAILS OF ALLOGENEIC DONATION   
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In the 10 donors harvested for allografts, the mononuclear cells were sufficient but the required CD34 levels 
were not always achieved. The GM-CFUc did not always establish viability (5 x 104/kg) although patients were 
still engrafted.13 (Table 2) 
 
TABLE 2 
ALLOGRAFT COLLECTION AND INFUSION DATA 
Number and Mononuclear CD3 CD 34+ GM-CFUc Days to peripheral blood response   
subject cells (x 108kg) (x 108/kg) (x 106/kg) (x 104/kg) Neutrophils  Platelet   
     (x 109/kg)  (x 109/kg)   
     0.5 1.0 >20 >50 >100 
1. LC 6.8 4.9 2.2 0.9  -  -  -  -  - 
2.AdB 7.6 4.4 4.4 5.5 15 15 27 27 34 
3. CS 9.1 5.8 4.2 3.5 11 11 29 38 49 
4. CB 12.5 7.5 9.9 4.7 8 8 8 8 13 
5. HdP 7.0 5.5 3.0 1.9 13 13 3 13 23 
6. AP 6.6 4.5 4.2 2.8 12 12 14 21 45 
7. VS 7.0 4.3 15.1 7.2 10 10 19 30 44 
8. PF 8.8 6.6 14.6 14.7 12 12 30 37 54 
9. HdW 8.1 6.7 3.6 2.3 11 11 21 37  -  
10. RA 6.7 4.4 10.2 1.9 11 11 13 13  - 
11. JM 8.2 5.6 5.8 1.9 12 12 10 10 10 
12. FK 7.7 4.7 3.6 3.6 13 13 13 13 18 
13. PO 7.5 5.4 4.6 2.8 12 12 12 15 15 
14. EG 6.6 4.8 3.9 1.0 12 14 21 21  - 
15. IvZ 7.1 5.2 4.6 4.2 12 12 14 14 24 
16. JF 7.3 5.6 0.8 5.1 12 12 14 14 35 
17. MM 9.4 5.8 1.3 12.8 11 11 20 20 78 
18. CvdW 9.8 7.2 4.1 9.6 12 12 14 14 14 
19. ZV 9.1 6.9 2.8 6.5 11 12 56 77 100 
20. SK 8.2 5.3 1.1 12.5 7 31 7 61 61 
21. GF 7.6 5.7 2.6 7.4 12 12 12 14 100 
22. CT 6.7 5.1 3.2 11.3 12 12 6 6 15 
23. DH 7.4 5.6 2.8 2.3 13 13 7 14 37 
24.KvD 8.9 6.9 3.1 8.6 12 12 14 14 21 
25. MG 7.9 2.1 8.7 31.1 12 12 62 62 100 
26. LL 8.3 6.3 6.1 13.2 9 22 54 54 100 
27. KL 9.8 5.4 1.4 4.7 12 12 14 14 21 
          
Median 6.6 476 3.9 1.0 12 12 17.5 17.5 62 
Range 6.6 - 12.5 206 - 750 2.7 - 11 1.0 - 31.1  7 - 15  8 - 31  3 - 62  6 - 77 10 - 100+ 
Mean 8.0 54.8 5.3 6.8 11.5 13.0 20 25.7 46 
Standard  
deviation 
1.3 112.7 1.7 6.34 1.6 4.4 15.39 18.87 32.9 
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The same pattern of response in peripheral blood was seen as when graft was harvested from the patient for 
subsequent reinfusion. In these cases the CD4+ autologous transplant cells were less uniformly predicted by 
the mononuclear cells which were recovered. The explanation of this bimodal distribution remained unclear.13 
(Figures 8a and b) Differences in autografts were thought to reflect previous chemotherapy and a second 
peak was noted on day seven which was unexplained. 
 
 In autografts no further manipulation was necessary whereas in allogeneic transplants the Campath® 
monoclonal antibodies IG or IH were added under standard conditions.17 
 
FIGURE 8 
DETAILS OF AUTOLOGOUS DONORS   
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In the autografts, mononuclear cell numbers were achieved but with CD34 cells this was not always the case.  
Viability of cells was achieved on most of those who were tested.13 (Table 3) 
 
TABLE 3 
AUTOGRAFT COLLECTION AND INFUSION DATA 
Number and Total in bag   Days to peripheral blood response  
subject    Neutrophils Platelet  
    (x109/kg)  (x 109/kg)  
 Mononuclear CD34+ GM:CFUc 0.5 1 >20 > 50 >100 
 cells (x108kg) (x 106/kg) (x 104/kg)      
1.  RL 7.7 1.08 5.8 12 12 34 41 72 
2. SC 8.7 0.89 10.6 12 12 33 47 100 
3. ST 9.6 2.58 1.5 13 13 19 19 39 
4. DC 6.7 6.7 5.1 14 14 100 100 100 
5. SF 6.0 22.6 a a a a a a 
6. GC  1.43 a a a a a a 
7. KB 7.0 3.0 a a a a a a 
8. MA 9.7 2.24 a a a a a a 
9. TS 6.3 1.4 a a a a a a 
10. FB a 8.6 1.2 9.9 12 12 15 19 21 
11. HR 
a 8.4 1.2 16 22 22 100 100 100 
12. CvM 6.0 1.18       
13. PB a 11.77 0.46 0 15 15 63 100 100 
14. JS 12.13 2.08       
15. DE a 6.6 1.39 3.0 12 14 100 100 100 
         
Mean 8.2 3.3 7.4 14 14 58 60.8 72 
SD 2.0 5.5 5.0 3.4 3.3 37.5 38 34.7 
Range 6.0 - 12.13 0.89 - 2.256 1.5 - 16  12-22 12 - 22 15 - 100+ 19 - 100+ 21 - 100+ 
Median 7.5 1.4 5.1 13 13 57.5 59.5 60.5 
         
a Patients have to date not received their stored graft. 
 
 
In those individuals where the source material was not to be immediately infused, the cells were 
cryopreserved.  The details of cryopreservation had been extensively studied and standardised using a 
combination of DMSO, an intracellular cryoprotectant and hydroxyethyl starch (HES), an extracellular 
cryoprotectent. This included storage with appropriate inventory control.47 The cells were then stored in a 
minus 800C freezer.  The allogeneic cells were infused following addition of Campath® into the bag.  Practical 
indications of graft recovery were increments in the monocytes followed in 24 to 36 hours by neutrophils then 
by reticulocytes. This process was expressed as the production index.48 
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4.11 INFUSION OF MARROW OR CIRCULATING STEM CELLS 
The patients were premedicated for Campath® containing grafts with 100 mg hydrocortisone and 12.5 mg 
phenergan® intravenously and 500 mg paracetamol orally one hour before infusion. The dose was adjusted for 
children. This premedication was also used in autografting because of the side effects of dimethyl sulphoxide 
(DMSO). 
 
Campath® 20 mg was added to each collection bag. No attempt was made to adjust the amount of antibody for 
contained cells since the rationale is that excess immunoglobulin may have an immunosuppressive effect on 
the recipient lymphoreticular system in vivo. Marrow or peripheral blood stem cells were given intravenously 
over 60 minutes but the rate needed to be slowed down if abdominal cramps, diarrhoea, rigors or vomiting 
occurred. In these circumstances, 10 to 20 mg of hyoscine hydrobromide was generally efficacious.  
 
Blood pressure and pulse rate as well as oxygen saturation were monitored throughout the infusion. 
Cryopreserved cells were thawed in a water bath immediately prior to administration. Transient rises in blood 
pressure could be avoided by giving 10mg furosemide intravenously with every alternate bag and a careful 
watch on fluid balance to prevent under or over hydration was maintained. It was important to warn the 
patients about the unpleasant smell of demethyl sulphoxide (DMSO). 
 
4.12 BLOOD TRANSFUSION AND RELATED PRODUCT PROTOCOLS 
 Following conditioning patients often developed side effects which led to diarrhoea and vomiting causing 
dehydration. The chemotherapy was myeloablative and red cells, white cells and platelets were reduced until 
regeneration occurred. 
 
4.12.1 FLUID AND ELECTROLYTE BALANCE 
This was crucial and was monitored on a continuous 24-hour basis. In practical terms requirements were 
calculated and charted during the daily morning report but measured more frequently if necessary. 
Correlation was with daily body weight together with specific gravity and osmolality of blood and urine as 
needed. Additions were made to 24 hour replacement using isotonic or physiologic saline with the flexibility of 
using potassium or magnesium riders to maintain physiologic blood levels. Particular attention was paid to 
static creatinine levels with appropriate revision when any potentially nephrotoxic antibiotics or other 
medication was given. Regular review with a nephrology consultant was undertaken in order to anticipate or 
correct changes in metabolic status which required correction by haemofiltration or haemodialysis. 
 
4.12.2 ANAEMIA  
Although anaemia could be caused by reasons other than myeloablative chemotherapy, it remained the most 
important. Complications such as vaginal and GIT bleeding, haemorrhagic cystitis, renal failure, severe 
infections, graft rejection and myelodysplasia could all contribute to anaemia. 
 
When symptomatic this was preferentially treated by erythropoietin where possible.49 In more acute 
situations, determined by patient symptoms or clinical signs rather than arbitrary laboratory values, 
leukodepleted units were used.50  No post-transfusion  levels were done. All products were irradiated to 
reduce the risk of transfusion related acute graft-versus-host disease. 51 
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4.12.3 PLATELETS  
Platelets were leucocyte reduced and irradiated single apheresis donations.52 A minimum number of 5 x 1011/L 
were infused over 15 minutes and 15 minutes later a post-infusion value was established. From the post 
infusion result an increment in the platelet numbers and daily blood counts were used to follow platelet 
survival. All at risk thrombocytopenic patients, predicated by fever, uraemic platelet dysfunction and counts 
under 10 x 109/L, received the anti-fibrinolytic agent tranexamic acid or cyclokapron® orally or parenterally as 
a continuous intravenous infusion between 25 and 50mg per kilogram per 24 hours. 
 
4.12.4 NEUTROPENIA 
This was defined as an absolute neutrophil count below 0.5 x 1011/L. Treatment commenced with 300 µg of 
stimulatory peptide in the form of granulocyte (Roche) or granulocyte-monocyte colony-stimulating factor 
(Sanofi Aventis) intravenously to achieve confirmed white cell levels above 10 x 109/L and be apyrexial.  
 
It was recognised that this approach was controversial and needed to be implemented in the context of clinical 
status and the presence or absence of pyrexia.53 Furthermore, given the uncertainty about late effects 
occurring in donors, this intervention necessitated additional informed consent.54 
 
 
4.13 INTEGRATED FUNCTION OF THE CROSS-DISCIPLINARY MANAGEMENT TEAM   
Based on the combined ward rounds that characterise leading centres throughout the world, the cardinal 
commitment was concurrent information sharing at all levels of staff with inclusion of the patient and family 
members. In addition, to maintain teaching programmes, these activities were balanced with nursing in-
service requirements. To sustain such interaction the multidisciplinary or “Haem Team” started each day by 
reviewing overnight status, responded positively to decisions required and planned management covering the 
next 24-hour period. The participatory presence of infectious disease consultants and paramedical 
professionals including nurses, occupational and physiotherapists and an academic dietician55 was integral to 
these staff meetings.  
 
In this forum, that by design included dedicated pharmacists, treatment protocols were scrutinised and 
potential drug interactions were identified.  Similarly, nutritional status including management of mucositis 
and the placement of naso-jejunal, as opposed to naso-gastric, fine bore feeding tubes followed as part of 
standardised care. This approach virtually obviated recourse to total parenteral nutrition (TPN) in favour of 
the well tested and equally efficient enteral route. 56 
 
Cardinal to the whole exercise was the overarching organisational responsibility of a medical scientist to co-
ordinate movement between various departments and data recording. 
 
 
4.14 PROTOCOL FOR DISCHARGE AND FIRST THREE MONTHS 
On transfer to the outpatient post-transplant follow-up clinic, patients attended weekly. They were also seen at 
any time that symptoms developed and received locally manufactured stabilised human serum57 as a means of 
providing polyclonal immunoglobulins drawn from the community as an alternative to commercially available 
gammaglobulin. In this period, anti-viral therapy with valaciclovir58 and pneumocystis prophylaxis with oral 
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co-trimoxazole59 was given with awareness that side-effects, particularly vasculitis, can be encountered with 
the latter agent. Screening for reactivation of cytomegalovirus was routine with polymerase chain reaction to 
anticipate early treatment thereby preventing progression to organ involvement.60 
 
The discharge period was a high-risk time. Experiences with recipients being monitored, even by experienced 
doctors and nurses outside the multidisciplinary transplant group, were regarded sometimes as suboptimal, as 
complications did not always receive urgent intervention.  Specific problems were consistent and delayed 
presentation with typically neutropenic fever often necessitating urgent admission to high or even intensive 
care facilities with a concomitant and substantial increase in morbidity and mortality.61 
 
As experience accumulated, our team became aware of two slightly different sets of complications which were 
separated rationally on a temporal basis. The realisation led to the careful construction of rigidly structured 
protocols for scheduled monitoring.62 
 
The crucial post-graft follow-up very rapidly became a contentious area and was to some extent influenced by 
sophistication of the host transplantation referral. If this was back to care in a remote area, and irrespective of 
the perceived skills and competence of the attending medical and nursing consultants, a number of deaths 
occurred early on due to late diagnosis and fulminating sepsis.  
 
This was not a function of poor quality support but simply the treacherous nature of infections in patients 
whose immunologic competence was still compromised often years after they had their procedure. 
Accordingly it became obligatory practice to keep the patients in the immediate geographical area of Cape 
Town with weekly visits for a minimum of three months. (Table 4) Based on the reduction of adverse 
incidents such surveillance became entrenched practice. Currently a strict protocol exists for intensive follow 
up in the first twelve weeks and gradually decreasing over time.  The highest risk for sudden onset of 
complaints remained in the first 12 post-transplant weeks. Infection of central venous line, which was often a 
nidus leading to fulminating sepsis, reflected a slow return to viable immune status and dictated close 
supervision with meticulous data recording and review by the nurse co-ordinator. When indicated patients 
were promptly referred for special studies. 
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TABLE 4 
TYPE AND FREQUENCY OF SURVEILLANCE IN THE FIRST THREE MONTHS POST TRANSPLANT  
 
EXAMINATION FREQUENCY 
Full clinical examination  Weekly 
Central venous line hygiene Weekly 
Routine haematology (FBC, INR)  Weekly 
Renal biochemistry (BUN, creatinine) electrolytes. Weekly 
Liver function and enzymes (AST, ALT, bilirubin, LDH, albumin) Weekly 
CMV Weekly 
EBV; Hepatitis A, B and C When indicated 
Chimerism by short terminal repeat assay  Weekly 
Infusion of stabilised human serum  Weekly 
 
 
4.15 LOGISTICS FOR POST-TRANSPLANTATION SURVEILLANCE 
The value of such organisational detail cannot be over emphasised and remains of paramount importance as 
extension of the above outlined shorter-term obligation for care of these individuals. In the start-up days of 
the programme, the late effects of these profoundly new monitoring interventions were not clearly formulated 
yet their appreciation came to contribute significantly to the more recently emerging awareness of 
survivorship.  
 
This particular aspect of structured care has in the last four or five years attracted increasing investigation. 
With world interest in harmonising, for purposes of centre recognition a Joint Accreditation Committee of the 
originally Spanish-based group, an opportunity may now become available, although primarily focused on the 
European Economic Community, to seek registration for South Africa.63 
 
If successful, such attention to detail, aimed at technological standardisation, may help explain reported 
variations of graft content. The challenges brought about by the rapidly escalating acquired immunodeficiency 
disease syndrome arose with ominous overtones of new unusual infections and not the least of which is multi-
resistant tuberculosis.64  Of particular sub-Saharan impact, this situation understandably had widespread 
social and economic implications as budgets required readjustment to deal with this epidemic. Consequently, 
many of these immunohaematopoietic interventions suddenly required greater justification and, unlike the 
initial phase, patients were being denied ready access to life-saving treatment in state facilities because of 
limited funds. The situation in the private sector was similar as managed health care providers were reluctant 
to spend these amounts of money on individual members. 
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4.16 PROTOCOL FOR EXTENDED FOLLOW-UP  
Unpredictability of complications necessitated a careful surveillance structured system with comprehensive 
written case notes. It was from this matrix that some of the side effects were indirectly noted and could then 
subsequently be documented over time. (Table 5) 
 
TABLE 5 
LONG-TERM MONITORING RECOMMENDATIONS POST-TRANSPLANT 
 
CATEGORY EVALUATIONS 
History and physical exam Chronic GVHD-focused review of systems and examination 
Complete skin examination 
Range of motion testing, if indicated 
Weight, height, vital signs, medical photographs 
List of all medications and  supplements 
Laboratory testing Complete blood count with differential and reticulocyte count 
Comprehensive chemistry panel 
Fasting lipogram 
Virology screen (hepatitis, cytomegalovirus) 
Immunisation titers 
Endocrine evaluations (thyroid, sex hormones) 
Iron profile 
Immunosuppressive drug levels 
ABO typing (if ABO-mismatched) 
Chimerism testing 
Other studies Bone marrow aspirate and biopsy 
Skin biopsy 
Pulmonary function tests 
Schimer’s test – to determine moisture of eyes 
Dual energy X-ray absorptiometry – for bone density 
Chest X-ray (chest computed tomography scan if indicated) 
Secondary cancer screening Mammogram (if age >35 years) 
Pap smear in females (if age >21 years or sexually active) 
Prostate specific antigen in males (if age >45 years) 
Colonoscopy (if age >50 years) 
Stool for occult blood (if age >50 years) 
Subspecialist exams Ophthalmology 
Oral medicine (dentist) 
Gynaecology 
 
The follow-up programme required immediate referral should there be any clinical change. Routine monthly 
assessment needed to be done taking into account quality of life65 and psychosocial circumstances. This follow 
up protocol resembles that from groups elsewhere in the world notably the European Organization for 
Research and Treatment of Cancer (EORTC).66 
 
It was during this period of audit reporting to international registries that changes were first but consistently 
noted in this reference cohort. Collectively these drew attention to a wide range of complaints. These often 
only minimally and not infrequently occurring as solitary events, interfered with lifestyle but nevertheless gave 
emphasis to the important study concept of survivorship.67 
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4.17 PERSPECTIVES 
On this basis more than a quarter century of research and development necessary to import bone marrow 
transplantation to South Africa, a prototype reverse isolation unit and a thoroughly standardised protocol 
emerged. This set the standards for haematopoietic reconstitution following allograft or, more importantly, ex 
vivo T cell depletion using the Campath® series of monoclonal antibodies. 17,14 
 
It was this structured approach that provided the reference point for the management of patients in both 
academic and state services and subsequently in the private sector. Ongoing analysis was focused on the 
quality of life with psychiatric and psychosocial components and the subsequent evolution of the general 
support group extending to psychology specialists.  Systematic analysis of survival data much of which, 
focused in the early days simply on haematopoietic recovery, once secure and reproducible, drew attention to 
concurrent injury to non-haematopoietic tissue. These phenomena separated broadly, on a timescale, into two 
categories. 
 
There was an almost universal deterioration in renal function, potential chemotherapy related changes in 
cardiovascular status, an abundance of cutaneous manifestations and gastrointestinal tract symptoms 
including alterations in liver biochemistry. All of these complications were predictable, transient and, being 
anticipated, could be managed proactively. As a result of this experience, these problems were designated as 
the acute associations. This audited database was analysed and reported in this subsection on non-
haematopoietic sequelae. 
 
There were different findings in other organ systems that presented late, needed new laboratory methods and 
were therefore not researched in the initial audit but became the specific focus of the present investigation. In 
particular, this part of the overall project depended on specialised studies that were not at first available in 
respect of lung function, immunologic reconstitution and unusual findings in bone mineral density following 
transplantation.  
 
Immunosuppression was delivered by exclusive exposure to anti CD52 Campath® series of monoclonal 
antibodies given, not in vivo, but added to the incoming graft ex vivo or in-the-bag.  The exception was 
unrelated donors who received cyclosporin A briefly. This alternative preparatory regimen also focused 
attention on the possibility of immune recovery which followed a different pattern from conventional 
approaches and was therefore studied in both innate and adaptive pathways.   
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4.18 SUMMARISING COMMENT 
 
 
These details of the long established management programme in the Department of 
Haematology continued to undergo constant updating but have been relatively stable for 
at least five years preceding commencement of data collection for this research project. 
The next step was to confirm that this entirely reproducible regimen generated results 
comparable to published literature. 
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 CHAPTER 5 
COMPLICATIONS OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION 
 
 
 
 
FOCUS 
 
In this segment of the long-term study, it became clear that there was a wide range of 
outcomes following transplantation. There was, if carefully observed by following each 
case by the author, a disquieting pattern. For want of a sufficiently large number of 
individuals the initial step was descriptive with systematic and meticulous 
documentation of the symptoms and signs that could subsequently be correlated with 
adverse events. This, as more data accumulated over a prolonged follow-up and serial 
analysis, started to crystallise into a format that could be used objectively to define 
endpoints more sharply. Upon these could be structured a formal study of selected non-
haematopoietic complications which have been alternatively viewed as the frequent 
occurrence of acute associations and of less obvious late effects. Stated differently, 
survivorship or cure with care did not only concentrate on marrow recovery but also 
on complications in non-haematopoietic organs. 
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5.1 INTRODUCTION 
This section of the thesis includes acute and late complications. Only a few will be discussed in detail. An audit 
involved mainly the acute associations while a cohort of surviving volunteers was studied for late effects. The 
magnitude of the problem was constantly given reality by reporting to International Registries. This 
participation in regular outcome analysis, gauged from the audit and accrediting peer review, established a 
reliable reference point from which to start accumulating a local experience. The perspective of the 
professional nurse, working as an integral component of the multidisciplinary “Haem Team”, was of several 
dominant problems.  
 
5.2 BACKGROUND TO TRANSPLANTATION COMPLICATIONS 
Interest in these bone marrow transplantation related phenomena started slowly with the observation that 
some individuals experienced little by way of side effects while, apparently unpredictably in others, a range of 
newly encountered symptoms and signs occurred. This was at a time when these procedures were relatively 
novel worldwide and experience at the University of Cape Town in the newly established Department of 
Haematology was just awakening. While working in the wards directly with our patients, the initial excitement 
was simply the appearance of monocytes and neutrophils in the peripheral blood. In those days, bone marrow 
aspiration and particularly trephine biopsies were in vogue. The earliest morphologic evidence of engraftment 
could be demonstrated in bone marrow trephine biopsy.1   Here, the general intertrabecular hypoplasia is given 
relief by groups of normoblasts along the endosteal lining in specialised areas or haematopoietic 
microenvironment termed the niches. Gradually, these aggregations became more heterogenous by the 
appearance of myeloid lineage and megakaryocytes simultaneously by repopulation of the previously vacant 
areas when the marrow returned to normal. (Figure 9) 
 
It soon became apparent, again without any clear separation between individuals, that some patients would 
continue to regenerate and leave hospital to lead normal lives.  In contrast, others may lose even this 
rudimentary evidence of recommencing haematopoiesis and need to be treated alternatively or even re-
transplanted.  
 
FIGURE 9 
PHOTOMICROGRAPH: NUCLEATED RED CELLS OR NORMOBLASTS IN THEIR NICHES 
 
 
Courtesy Professor Barbara Bain 
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Table 6 shows the acute complications that may occur post-transplant.   
 
TABLE 6 
 ACUTE COMPLICATIONS OCCURRING DURING FIRST 100 DAYS POST-TRANSPLANT 
Complication Tests to be performed Time to complication 
CARDIAC   
Arrhythmias ECG Any time during first 100 days 
Cardiomyopathy ECG & ECHO Any time during first 100 days 
Failure ECG & ECHO, chest x-ray Any time during first 100 days 
   
RENAL   
AKI Renal function tests twice week Any time during first 100 days 
Haemorrhagic cystitis Monitor haematuria 72 hours or more than 2 weeks 
Obstructive uropathy Cystoscopy  
Hydronephrosis   
Acute renal failure   
   
GIT   
Mucositis Oral swabs Pre-transplant to 3-4 weeks 
Dysphagia   
Diarrhoea Stool culture  
Pain Keep pain ladder During mucositis 
Anorexia Weight  albumin Pre-transplant to 3-4 weeks 
Change in taste  Pre-transplant up to 100 days 
   
Hepatic   
Hepatitis Viral serology 2-3 weeks 
Liver failure Hepatic enzymes  
   
Endothelial   
VOD Hepatic enzymes LDH Ultrasound 30-60 days 
Capillary leak syndrome Weight  albumin 30-60days 
Engraftment syndrome Weight renal & liver function At engraftment 
Diffuse alveolar haemorage Chest x-ray, CT Chest BAL 19 Days (Auto);  12Days (Allo) 
Microangiopathy FBC, LDH. Liver biochemistry 60 Days 
 Viral screens Vital signs  
   
Idiopathic pneumonia syndrome Chest x-ray, CT chest, BAL 26 Days 
 Lung biopsy  
   
Various Infections   
Bacterial Blood cultures, tissue swabs Usually during neutropenia but 
may occur at any time. 
Fungal   
Viral Viral blood tests 1-4 weeks 
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5.2.1 REJECTION AND NON-ENGRAFTMENT 
Rejection is an immune response with both human and cellular components involved. It can be diagnosed by 
few peripheral cells in the circulation (not regenerating adequately) or loss of these occurring later. It can be 
associated with mixed chimerism within lymphocyte populations. Bone marrow biopsy will have infiltrating T 
cells perhaps accompanied by infiltrating eosinophils, plasma cells and neutrophils, occurring usually in 
allogeneic and matched unrelated donor transplants. 
 
These were significant impediments to survival but early recognition and repeat procedure with altered 
conditioning and enhanced post-transplant corticosteroids with methotrexate was the standard of this era.  
 
This was the first personal contact with the feared consequences previously described as either primary graft 
failure or secondary rejection, depending upon the time sequence. These have not been a problem since 
exposing haematopoietic stem and progenitor cells to the Campath® series of monoclonal antibodies in-the-
bag.2 Additional advantages might theoretically be derived from exposing haematopoietic stem and progenitor 
cells to the radiotherapy, both total nodal and total body, used as an anti-tumour agent in patients with 
haematologic malignancy.3 The short terminal repeat assay was established in order to anticipate any risk of 
graft loss and our results are consistent with published data on chimerism.4 
 
When rejection of the graft occurred the procedure could be repeated but conditioning changed to four days 
cyclophosphamide 50 mg/kg IVI over three hours and overlapped with ATG 30 mg/kg daily for three days – 
chemotherapy was given during the night and followed with protein during the day, as it could cause allergic 
reaction. 
 
 
5.2.2 GASTROENTEROLOGY 
These were relatively short lived normally returning to normal once regeneration occurred.  Painful mouth 
due to mucositis with sloughing of epithelial layers predicated a need for a high level of pain control. This step 
was best managed with patient education and personal attention to scrupulous hygiene. Rotating mouth wash 
with alternating hydrogen peroxide and warm sodium bicarbonate facilitated removal of dead tissue which 
was a nidus for infection. The pathogens were most often viral with ulcers and fungal superinfection extending 
down the oesophagus and contaminating of trachea with aspiration to the pulmonary parenchyma. (Figure 
10) 
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FIGURE 10 
EXAMPLE OF OROPHARYNGEAL MUCOSITIS WITH SUPERIMPOSED FUNGAL INFECTION 
 
 
 
 
Dry mouth could be a problem and was often helped by 30 mg pilocarpine hydrochloride orally each day5 with 
artificial saliva which is now routinely available. Patients were routinely commenced on maxalon 10mg daily, 
kytril® 1mg daily and phenobarbitone 10 mg three times daily one week before commencement of 
conditioning. Nausea and vomiting constituted a problem and adequate antiemetics needed to be provided. 
These were changed as necessary in order to give the individual adequate cover. A further ongoing challenge 
was that of diarrhoea and it was necessary to recognize that Clostridium Difficile infection could occur and 
that eradication regimens were uniform but not universally effective. Furthermore, there has been 
considerable interest in the use of anti-diarrhoea therapy in cancer patients where three principles apply: 
firstly, to reduce fluid loss by inhibiting intestinal secretion, then by promoting absorption and decreasing 
intestinal motility.   
 
The available therapeutic options are classified as bowel transit inhibitors (loperamide and codein) 
intraluminal agents (cholestyramine) and post-absorptive or antisecretory drugs (clonidine). These drugs were 
selected, singly or in combination, after consultation with the gastroenterologist on an individual basis.6,7 
 
As part of the bowel abnormalities, suboptimal nutrition emerged as a significant consequence which required 
moment–to-moment management of oesophageal pain due to mucositis, dysmotility and chemotherapy as 
well as radiation induced malabsorption. Following transplantation gluten intolerance was an unusual 
complication. This biopsy (Figure 11a and Figure 11b) demonstrate the features of gluten intolerance. 
There is a marked mucosal atrophy with flattening of the villi and an increase in the intraepithelial 
lymphocytes. The CD3 stain in (Figure 11c and Figure 11d) highlights a striking increase in intraepithelial 
T- lymphocytes. Similar symptoms may arise from viral infection such as cytomegaloviral injury on biopsy. 
(Figure 12) 
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FIGURE 11 
PHOTOMICROGRAPHS OF INTESTINAL BIPOSIES IN A CASE OF REFRACTORY MALABSORPTION  
  
 
 
 
(a)                    (b) 
 
  
(c)           (d) 
                   
 
Courtesy Dr Kathy Taylor – Pathcare 
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FIGURE 12 
PHOTOMICROGRAPHS OF AN ENDOSCOPIC BIOPSY DEMONTRATING CYTOMEGAROVIRUS 
INCLUSION BODIES 
 
 
 
 
 
 
 
 
 
 
 
 
CMV inclusions 
 
 
 
Courtesy Dr Kathy Taylor – Pathcare 
 
 
Gastroenterological injury resulted in more subtle changes that necessitated  individualised or targeted dietary 
regimens.8   This segment of the standard protocol incorporated the long experience of enteral nutrition using 
a fine bore nasojejunal feeding tube that showed that the need for total parenteral alternatives were largely 
unnecessary.9 Early on the greater patient acceptance of these tubes placed in the duodenum rather than the 
stomach was confirmed - careful explanation was provided. This technique was highly cost-effective and 
represents possibly the largest single unit experience of enteral long term nutritional supplementation. 
(Figure 13) 
 
The use of this route was effective in correcting coeliac changes over a three month period. 
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FIGURE 13  
PLACEMENT OF FINE BORE FEEDING NASO JEJUNAL TUBE (FLUOROSCOPIC IMAGE) 
 
 
Courtesy Dr Derek Solomon – Tuft and Partners 
 
 
5.2.3 GRAFT-VERSUS-HOST DISEASE 
The classical graft-versus-host syndrome, with extensive desquamating dermatitis and enterocolitis giving rise 
to torrential diarrhoea and cholestasis causing relentless increases in bilirubin, was commonplace. This could 
be followed by a chronic variant that progressed to the equivalent of scleroderma and destroyed the quality of 
life.10 This situation was the frequent scenario on the transplant unit that devastated families as well as 
medical and nursing staff.  
 
The ominous occurrence of puritic rash on palms and soles accompanied by fulminating diarrhoea which was 
virtually impossible to control had by far the greatest impact on the post-transplant course. From a nursing 
stance, this complication created enormous problems with fluid and electrolyte balance and it was 
characteristically associated with progressive jaundice. This symptom complex, termed acute graft-versus-host 
disease with extensive skin desquamation resembling whole body burns in extent and severity, was a 
Stellenbosch University  https://scholar.sun.ac.za
 83 
destructive and potentially lethal complication. (Figure 14) Additionally, the superimposed infection, usually 
pulmonary, added to both morbidity and mortality. The immense burden of nursing these patients and 
supporting their families proved both a challenge and underpinned the team’s determination to work to 
abrogate the entity. This pattern was seen in early cases before standard use of the monoclonal Campath® 
antibody in-the-bag. Once the latter regimen became routine this severe complication virtually disappeared 
and the incidence decreased to very low levels.2  This entity was already recognised as one of the most 
undesirable and not infrequently lethal characteristics of transplantations.  
 
FIGURE 14 
ACUTE GRAFT-VERSUS-HOST DISEASE DURING PRE-CAMPATH® DAYS 
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The acute GVHD could advance over varying periods to severe fibrosis, similar to scleroderma, vastly 
compromising quality of life. This entity was progressive and almost impossible to reverse so that prevention 
became a special challenge. It, again, was the trademark of the earliest allografts – prior to ex vivo T 
lymphocyte depletion - and not seen in the Campath® era. 2 (Figure 15) 
 
FIGURE 15 
CHRONIC GRAFT-VERSUS-HOST DISEASE DURING USE OF UNMANIPULATED STEM CELLS 
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Many patients had a rash and histopathology characterisation separated allergic drug e.g. cotrimoxazole 
(Figure 16) and viral, frequently due to herpes zoster where painful vesicles occurred once routine post 
transplant prophylaxis had been discontinued (Figure 17) from transplant related graft-versus-host disease 
which was a significant aspect of this audit.  
 
FIGURE 16 
ACUTE ALLERGIC SKIN ERUPTION DUE TO DRUG SENSITIVITY 
 
 
 
 
 
FIGURE 17 
EXAMPLE OF A VIRAL RASH DUE TO HERPES ZOSTER 
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In graft-versus-host disease, grading11 and staging12 were combined to dictate management. In Grade I, 
following biopsy, the erythroderma was treated with steroid creams only in the first two weeks and then 
reassessed. This entailed ≤25% skin and no systemic involvement. In Grade II, non-response was treated with 
additional steroid in the first instance and failure at two weeks with cyclosporin A. In the latter, skinlesions 
were more extensive with liver and GIT also involved. Grade III and IV were not seen in this post Campath® 
study. 
 
Huge psychosocial problems occurred at all levels and it was a tribute to the trust and fortitude of patients, 
coupled with the compassionate understanding so evident throughout the multidisciplinary management 
team, that everybody recognised and rose to meet the challenge. Collectively these sequential events were 
balanced against the perspective of real benefit. External support and encouragement from others intensively 
studying this problem – both in experimental laboratory11 and in dedicated units – enabled our centre to 
weather a truly stormy period. 
 
5.2.4 ENGRAFTMENT SYNDROME13 
This was a non infectious syndrome presenting with fever, rash, diarrhoea and often abdominal pain. Less 
common pulmonary infiltrates and hepatic dysfunction could be present.  It could be potentially confused with 
graft-versus-host disease and was responsive to corticosteroids.14 This occurred also, and quite typically, with 
autografts when regeneration of bone marrow took place and could be confused with allergic or infectious 
cases.  
 
5.2.5 BLEEDING DUE TO THROMBOCYTOPENIA 
Bleeding occurred in about 10% of patients due to thrombocytopenia. Where platelet refractoriness was 
present, the risk could also be reduced by plasma exchange including high-dose gammaglobulin and, where 
appropriate, elective splenectomy. New options available were rituximab15 and thrombopoietin agents.16 
Other hazards were primarily diffuse alveolar haemorrhage and this complication needed to be avoided at all 
cost.  It was necessary to ensure that the INR was maintained.  Vigilance to emergence of post-transplant 
immune17 or thrombotic thrombocytopenic purpura (TTP) 18, 19 was important. Bleeding could also present as 
GIT or intracranial. 
 
Vaginal bleeding may occur during chemotherapy and particularly after transplantation. All patients were 
managed on cyclokapron® and mefenamic acid20 since the combination was believed to be more effective than 
either alone. Additional benefit appeared to be derived from Nordette® or an equivalent 
(levonorgestrel/oestrogens).  
 
Where breakthrough vaginal bleeding occurred, the preferred therapeutic approach was to use progestagens in 
the form of norethisterone 5mg three times a day: this dose could be titrated up to use 10mg six-hourly. An 
alternative was to replace the Primolut N® with micronised estradiol in the form of estrofem 2mg daily. An 
additional option, if both the above failed, was the use of an oestrogen-progestogen regimen21 such as liviferm. 
Premelle 2.5 was a combination in one tablet of premarin 0.625 mg and 2.5 mg provera. This was not used as a 
routine in the post-transplant patients. 
 
Prophylactic platelets were given usually at 10 x 109/L but with active bleeding, the level was adjusted 
upwards. There were many variables that could either accelerate or delay platelet recovery. (Table 7) 
Stellenbosch University  https://scholar.sun.ac.za
 87 
 
TABLE 7 
VARIABLES ASSOCIATED WITH ACCELERATED OR DELAYED PLATELET RECOVERY RESPECTIVELY 
Accelerated Delayed 
Higher CD34 count Fever 
Higher platelet count at start of myeloablative   conditioning VOD 
Graft from HLA identical sibling donors Use of post-transplant growth factor 
Prior stem cell transplant PBSC transplant 
Bone marrow as source for transplant Prior radiotherapy 
 
 
5.2.6 HEMORRHAGIC CYSTITIS 
This complication could be related to adenoviral infection22  and also due to thrombocytopenia. Management 
was multifactorial and difficult23 usually reflecting drugs used for conditioning such as cyclophosphamide, 
ifosfamide, busulphan and fludarabine.24,25  Once bleeding had occurred, intravenous or oral uromixetan was 
given.26  If this proved insufficient, it was combined with appropriate hydration  and  intravesical irrigation 
with 1L of sorbitol every three hours.27 ; this was repeated every 24 hours. Local anaesthetic was not needed. 
Development of any clots within the bladder required immediate evacuation and discontinuation of 
Cyclokapron®.  
 
The protocol dictated that all patients should maintain platelet counts of above 50 x 109/L: only then could 
cyclokapron® be restarted, provided bleeding had ceased. Premarin 0.625 mg daily could be added orally as 
empiric therapy. In patients who were refractory to sorbitol, various other options – such as silver nitrate, 
alum, uromitexan and formalin - were tried. 
 
5.2.7 FEVER  
Varying degrees of fever which occurred could be controlled with appropriate antimicrobials and typically 
improved with engraftment.  
 
Particularly during neutropenia, defined as 0.5 x 10 9/L, any increase in temperature above baseline was 
checked and if confirmed within one hour empiric antibiotics were commenced. These have over long periods 
of time been the subject of detailed results from isolate surveillance. In the absence of any positive cultures 
from blood, urine or stool, the policy to direct treatment comprised parenteral monotherapy with piperacillin 
and tazobactam or in combination with amikacin adjusted for any decrease in renal function to maintain 
therapeutic antimicrobial levels.28 Failure to achieve temperature resolution predicated escalation at 48 hours 
to gram-positive cover beginning with intravenous vancomycin at 20-mg/kg/24 hours including appropriate 
monitoring of plasma levels.29 In the next stage, again with pyrexia beyond a further 48 hours, the approach 
was to add a milligram per kilogram of amphotericin B in 200 ml of 5% dextrose water as a continuous 24 
hour infusion. This technique was shown to have virtually no side-effects including, particularly, 
nephrotoxicity.30 
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Culture studies and fungal surveillance were routine while recovery of organisms dictated change in the 
antibiotic regimen. 
 
Unusually opportunistic atypical infections, tuberculosis or pneumocystis clouded the diagnostic picture. For 
this reason efforts were made to isolate the offending pathogen with microbiological studies of blood and 
induced sputum, bronchoalveolar lavage and, in terms of aggressive diagnosis, bronchoscopy with biopsy and 
brushing may be unavoidable.  
 
Viral infections could be troublesome especially herpes simplex of the oropharynx31 and reactivation of 
cytomegalovirus requiring appropriate therapy which should be commenced as soon as possible.32 Of note, in 
sub-Saharan Africa, was the challenge of the Epstein Barr virus33 and in particular retroviral positivity 
presenting en route to the Acquired Immune Deficiency Syndrome.34,35 
 
There was increasing use of fluconazole and a shift towards the greater employment of itraconazole if fungal 
infections reoccurred or were slow to resolve. In these circumstances long term maintenance may have been 
necessary. Newer liposomal products or equivalents are under study as are later generation azoles exemplified 
by voriconazole and posaconazole.36 Prevention of opportunistic infections extended to the use of 
immunisation.37  Early onset of microbial events in patients undergoing bone marrow transplantation was a 
well-recognized problem. Mechanisms for avoidance led to guidelines from the Centre for Disease Control in 
Atlanta. These included recommendations which were applicable to children.38 Screening for cytomegaloviral 
infections was undertaken using DNA technology39 by PCR.  Strategies for management were evolving with 
importance placed on the value of ganciclovir, foscarnet and cidofovir. Adenoviral infections were troublesome 
and until recently had not been treated. 
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The data in table eight does not necessary apply to the cohort where different immunologic reconstitution may 
be found with Campath® conditioning and no post – transplant immunosuppression used. (Table 8) 
 
TABLE 8 
PHASES OF OPPORTUNISTIC INFECTIONS AMONG ALLOGENEIC STEM CELL RECIPIENTS 
 
 Phase 1,  
Pre-engraftment, 
<30 days 
Phase II,  
post-engraftment, 
30 – 100 days 
Phase III, 
Late phase, 
> 100 days 
 
Host immune 
System defect 
  
 
 
 
 
 
Device risk  
 
 
            Central line 
  
 
Allogeneic  
Patients  
 
   Respiratory and enteric viruses  
 
 
 
 
 
 
                                                            Epstein-Barr virus lymphoproliferative disease 
 
 
 
 
 
 
 
 
 
 
                                                                          Toxoplasma gondii 
                                                   Strongyloides stercoralis  
 
 
 
 
 
 
 
Neutropenia, 
mucositis and Acute 
graft-versus-host 
disease 
Impaired cellular 
immunity and acute 
and chronic graft-
versus-host disease 
Impaired cellular and 
humoral immunity and 
chronic graft-versus-
host disease 
Herpes simplex virus 
Cytomegalovirus  
Varicella-zoster virus  
Facultative Gram-negative bacilli 
Staphylococcus epidermidis  
Encapsulated bacteria 
(e.g. pneumococcus) 
 
Gastrointestinal tract enterococci species 
All candida species 
Aspergillus species Aspergillus species 
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In the audit cohort, it was found that in 198 allograft patients, 318 episodes of infection occurred, while in the  
177 autografts there  were 207 episodes.  In 93 MUD transplants, 157 episodes were present. It can be seen 
that infections occurred more frequently in the allografts. In total, in all groups, infectious episodes occurred 
in 376 (80%) subjects while in 92 (20%), no infections were noted. (Table 9) 
 
 
 
TABLE 9 
INFECTIOUS COMPLICATIONS IN AUDITED GROUP OF PATIENTS 
 
 
 
5.2.8 PAIN 
The major cause for pain was injury to the mucosal tissues induced by the conditioning regimes. It could occur 
in any transplant-related phase. Oral mucositis often involving ulcers spreading to the oesophagus caused 
secondary complications. During mobilization and neutropenia the growth factor used could lead to bone pain 
and less frequently to headaches.  If acute and chronic GVHD was present, desquamation of skin and in the 
latter, contractures caused pain. Infections such as cellulitis, abscesses as well as herpetic viruses, causing 
severe neuropathic pain, could be present. Marrow harvesting pain was more severe after anterior than after 
posterior iliac crest collection. Radiotherapy could cause a painful, inflammatory skin reaction. 
 
 
MUD 
Number 93 
NO INFECTIONS 
(16 PATIENTS) 
INFECTIONS 
(77 PATIENTS) 
BACTERIAL  
(91 EPISODES) 
VIRAL 
(45 EPISODES) 
FUNGAL 
(21 EPISODES) 
AUTOGRAFTS 
Number 177 
NO INFECTIONS 
(43 PATIENTS) 
INFECTIONS 
(134 PATIENTS) 
BACTERIAL  
(163 EPISODES) 
VIRAL 
(19 EPISODES) 
FUNGAL 
(25 EPISODES) 
ALLOGRAFTS 
Number 198 
NO INFECTIONS 
(33 PATIENTS) 
INFECTIONS 
(165 PATIENTS) 
BACTERIAL  
(207 EPISODES) 
VIRAL 
(68 EPISODES) 
FUNGAL 
(43 EPISODES) 
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During infusion the patient could develop severe abdominal cramps, thoracic pain and headaches due to 
DMSO toxicity or reaction to Campath®. Urinary bladder irritation caused by certain conditioning drugs 
(mentioned previously) could occur. In the later phases following BMT, osteolysis, osteopenia and 
osteoporosis could cause localised and sometimes radiating pain.  Bisphosphonates prophylactically, as well as 
for treatment, could be used. 
 
As pain was a major problem, the guiding principle was to use the World Health Organisation pain control. 
ladder.40  It was important to do regular assessments with  a rating  scale and also assess analgesia efficiency. 
Appropriate choice of analgesia involved balancing efficacy and avoidance of side-effects. For example, in 
thrombocytopenia to by-pass use of non-steroidal anti-inflammatory drugs which increases the risk of 
bleeding, was a crucial protocol consideration. In addition, symptomatic reflux of acidic gastric contents was 
surprisingly common and responded, in our experience, most efficiently to five or six hourly proton pump 
inhibition, or to a continuous 24 hour infusion.41 
 
In this situation consultation with a gastroenterologist was often needed to define aetiology by means of 
endoscopy. Haemorrhoids and anal fistulae were not particularly frequent but required prompt intervention 
using betadine® sitz baths and local pain control with 50% mixture of EMLA cream (lidocaine prilocaine 
eutectic mixture)42 and Scheriproct®.43 
 
Managing pain was crucial and if mild, started with paracetamol.  Moderate pain needed escalation to mild 
opioids (codeine and tramadol) and if pain was severe, we commenced oral, and progressed to intravenous, 
titrated doses of strong opioids (morphine).  Antidepressants and anticonvulsants could be added. 
 
Late complications appeared after day 100, a few of which will be discussed. Chronic GVHD was incorporated 
into the GVHD section. (Table 10) 
 
TABLE 10 
LATE COMPLICATIONS ≥ 100 DAYS 
Complication Test to be performed Time to complication 
OCULAR EFFECTS   
Cataracts slit lamp examination; Schirmer’s test 2-3  years 
Kerato-conjuntivitis  2-3 years 
   
SKIN & APPENDAGES   
Chronic  GVHD Clinical examination No time limit 
Dry skin Skin biopsy  
Hair loss   
Splinting/loss of nails   
Premature greying   
Pruritis   
   
ORAL & DENTAL   
Mucosal atrophy Regular examination No time limit 
Erythema   
Lichenoid lesions   
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ORAL & DENTAL (continued)   
Hyperkeratinoid lesions   
Salivary gland dysfunction   
Taste disorders   
Dental decay   
   
THYROID DYSFUNCTION   
Hypothyroid Thyroid function tests 2-3 years 
Hyperthyroid   
   
FERTILITY & GONODAL DYSFUNCTION  
Azoospermia Hormonal levels No time limit 
Premature menopause   
   
NON-INFECTIOUS RESPIRATORY    
BO Respiratory function tests 1-12 months 
COP Chest X-Ray  
IPS Bronchoalveolar lavage for histology 120 Days 
 High resolution tomography  
   
CARDIAC   
Cardiac failure ECG 10 years 
 Echocardiograph  
 Pro-PNB  
   
VASCULAR   
Cerobrovascular Brain scan 25 years 
Cardiovascular ECHO  
   
METABOLIC SYNDROME   
Hypertension Blood pressure measurements Any time 
Diabetes HbA1C  
Dyslipidaemia Lipogram  
   
CHRONIC KIDNEY DISEASE Renal function 5-10 years 
 Urine  protein analysis  
 Renal biopsy  
   
LIVER & IRON OVERLOAD   
Viral hepatitis Viral screens  PCR 10years 
Chronic GVHD Skin biopsy  
Iron overload Liver enzymes & function  
Cirrhosis Iron & ferritin  
 Liver biopsy  
   
MALIGNANCY Histology 5-10 years 
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BONE DISEASE   
Osteopaenia DXA 12-18 Months 
Osteoporosis Biomarkers  
 
 
5.2.9 MYELODYSPLASIA 
With greater experience and close hands-on contact, a variegated range of individual subtleties emerged 
scattered among different organ systems. These were sometimes in classical or traditional haematology 
exemplified by delayed onset of myelodysplasia or pre-leukaemia with cytomorphology showing dysplastic 
changes in erythrocytes (ringed sideroblasts), granulocytes and megakaryocytes. These features correlated 
with conventional karyotyping on fluorescent in situ hybridization for interphase cytogenetics. (Figure 18) 
 
FIGURE 18 
PHOTOMICROGRAPHS: POST TRANSPLANT MYELODYSPLASIA 
 
 
 
 
5.2.10 OSTEOPOROSIS 
Because premature menopause was present post transplant, it could often lead to bone loss. Minor symptoms 
and sometimes changes only demonstrable on specific testing in non-haematopoietic tissues were present.  
Occasionally these symptoms were a slight reduction in maximum effort tolerance and others developed a 
surprising degree of bone pain and osteoporosis.  
 
Osteopenia could progress rapidly to painful activity. Even minor trauma, such as a fall, could then result in 
fractures, typically vertebral compression. (Figure 19) 
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FIGURE 19 
LATERAL VIEW OF THE SPINE – COMPRESSION FRACTURE IN A PATIENT WITH OSTEOPOROSIS 
 
 
 
Courtesy Dr Derek Solomon – Tuft and Partners 
 
5.2.11 MISCELLANEOUS 
Minor abnormalities of bowel action and underplayed endocrine disturbances, typically involving thyroid 
integrity - both hypothyroidism and hyperthyroidism - were sometimes detected. Ocular changes in the form 
of cataracts occurred frequently following conditioning with radiation. Understandably when these problems 
occurred in different individuals, varying both in incidence and severity diluted among a large transplant 
population, a single coordinating influence was necessary for the realisation that, viewed globally, there was 
cumulative decrease in the quality of life. This point highlights the important concept of survivorship – an 
opinion needing much better definition and to be addressed in this research investigation taking into account 
extension beyond bone marrow re-growth. 
 
The onset of complaints of differing intensity located in different organ systems was sometimes overlooked 
and with their recognition compounded by not only presenting late but typically progressing gradually. 
Superimposed on this situation were many previously present psychological, psychosocial or even psychiatric 
disturbances.3 These could be subtle and, more often than not, correlated with the previous disease, 
chemotherapy or the multi-organ injuries inflicted by the bone marrow transplant. It became clear that with 
this substantial dataset, a systematic research study was not only relevant but urgently needed.  
 
 
5.3 THE PATIENT POPULATION 
At commencement of bone marrow transplantation there was a single centre in South Africa. This situation 
persisted for more than 15 years before a similar programme commenced at the University of Witwatersrand 
in 1985. The importance of that observation is that all patients - whether private or state and irrespective of 
where they came from in South Africa or further afield - were sent to our unit in the Groote Schuur Hospital.   
 
In many ways this process heightened the heterogeneity of those cases who were seen and treated. The most 
striking issue was probably the differences in psychosocial background with nutritional implications. Another 
notable feature was the relative paucity of children, largely because the viewpoint at the Red Cross War 
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Memorial Children’s Hospital was that these procedures, certainly those for haematological malignancy, had 
not yet become established as being superior to the available chemotherapy. 
 
For this thesis an audit was done on the 468 transplanted cases to provide data for the acute associations. The 
late effects involved a group of volunteers of survivors (n=55) available to do tests for the late effects.  
 
 
5.4 ACUTE ASSOCIATIONS –AUDIT ANALYSIS 
Deviation from normal, or at least from pre-transplant values, in the  four extra haematopoietic systems 
chosen for analysis were early events, which were transient, largely predictable and virtually constant features. 
For this reason they were part of the clinical record and proactively managed as integral to the standard 
programme and incorporated into this database.  Major organs were chosen as sufficient data was available for 
analysis on them. The results are documented in chapter 7. 
 
5.4.1 NEPHROLOGY 
This was closely monitored with serial determinations of urea, creatinine and electrolytes in plasma, weekly or 
more frequently as needed. When relevant, hydration was documented by means of plasma osmolality or 
urinary specific gravity. Strict attention was paid to fluid and electrolyte balance and the avoidance of any 
potentially nephrotoxic agents. Renal status was reviewed daily with a consultant.44 
 
5.4.2 CARDIOLOGY  
Rested on regular clinical assessment, which was supplemented objectively by 12 lead electrocardiogram45 and 
echocardiograph.46 These referrals were standard care and results were charted serially. 
 
5.4.3 DERMATOLOGY 
Involved routine and frequent consultation with a well-trained and experienced specialist with interest in this 
field.47 In case of doubt, adequate skin biopsy was obtained for interpretation by a specialist 
dermatopathologist.48 
 
5.4.4 GASTROENTEROLOGY 
Required moment-to-moment management and liver function and enzyme estimations done frequently. 
 
 
5.5 LATE EFFECTS – RESEARCH STUDY 
Once sufficient observations had been recorded in consecutive cases, to give confidence to these findings, the 
Stellenbosch University Bone Marrow Study Group was constituted to provide access to expertise and new 
technologies that had not been previously available due to cost constraints.  These systems were chosen as the 
specialised units were willing to participate. The subjects consisted of 55 volunteers from long term survivors. 
Others from the complete data base were not available for various reasons. Results are available in chapter 7 
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5.5.1 PULMONOLOGY 
This centred on the clinical assessment supported by high quality radiology and a selected series of lung 
function studies.49,50 Acute changes almost always resolved in the first 14-21 days when they were of bacterial 
or viral aetiology and in keeping with recovery of the granulocyte count supported by physiotherapy and 
appropriate protocolised antibiotics. Late consequences defined as non-infectious respiratory tract lesions, 51 
emerged as a specific aspect of this research study and necessitated further lung function testing. 
 
5.5.2 IMMUNOLOGY  
Both innate and adaptive immunologic reconstitution52 could be affected by prior disease, treatment and 
conditioning as well as choice of transplantation.52 Unfortunately in the early years of this long-running 
investigation such methodology was not available and, accordingly, a battery of standardised assays could now 
for the first time be applied to obtain this missing information.53 It was relevant in that exposure to Campath® 
monoclonal antibodies lead to impaired immune reconstitution.35  After transplantation, immunologic 
reconstitution took  place variably between three months and four years.54,55  In this period a number of 
infectious complications could arise.56 These included herpes type 6, cytomegalovirus, which was very 
common in our patients, adenovirus,57 hepatitis58 and influenza.59 Varicella zoster typically became a problem 
after withdrawal of acyclovir: if this occurred the trial by Whitley et al, 60 had shown that, albeit in relatively 
healthy patients, a tapered dose of prednisone with the acyclovir or zeletrix was of further benefit. The use of 
the current protected environment and locally collected stabilized human serum to provide immunoglobulin 
may well have been the key to the success of the programme. The whole question of re-immunisation61 was 
particularly important. An excellent series of guidelines for re-vaccination was published by the The European 
Group for Blood and Bone Marrow Tranplant Registry.62 At one year post-transplant a vaccination schedule as 
laid out by the group was utilised (Table 11). 
 
 
TABLE 11 
SCHEDULE FOR ROUTINE RE-IMMUNISATION   
VACCINE 
 
SCHEDULE 
 
23-valent pneumococcal polysaccharide 12 and 24 months 
Haemophilus influenza tybe b conjugate 12,14 and 24 months 
Varicella zoster virus Not licensed at present 
Infuenza Yearly lifelong resuming ≥ 6 months post HCST 
Tetanus-diphtheria toxoid 12,14 and 24 months  
Inactivated polio 12,14 and 24 months 
Hepatitis B 12,14 and 24 months 
Hepatitis A Routine administration not recommended.  
Meningococcal Routine administration not recommended 
MMR ≥ 24 months if immunocompetent 
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5.5.3 BONE DISEASE 
This was explored to examine any impact on bone mineral density of those patients having undergone 
transplant with the addition of anti-CD52 monoclonal antibody in-the-bag as opposed to the more traditional 
preparatory regimens employing cytotoxic agents and steroids typically with post-procedure graft-versus-host 
prophylaxis.63,64 
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5.6 SUMMARISING COMMENT 
 
 
 
The details in each of the inseparable yet consecutive components are specified because 
they were sequentially tested and, via translational research, transferred to a standard 
approach as the central activity of this doctoral project. They are the major source of 
observations making up the study and form the audited or reference database against 
which, firstly, outcome is defined. Secondly they delineated the cohort that qualified 
 to be entered into the characterisation of late effects in those managed exclusively in 
this centre designated for transplantation by European and American Registries – 
including the Centre for International Blood and Marrow Transplant Research. 
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CHAPTER 6   
 
OVERALL SURVIVAL BY AGE, PROCEDURE AND DIAGNOSIS 
 
 
 
FOCUS 
 
This section details the outcome of every consecutive immunohaematopoietic stem cell 
transplant carried out by this accredited team between 1995 and 2010. Each was 
reported to The Centre for the International Blood and Marrow Transplant Research, 
National Donor Program and the European Group for Blood and Bone Marrow 
Transplant Registry. The commitment to undertake the audit was given impetus by two 
feasibility studies, one in children1 and the other in adults2. These audits documented 
low rates of transplant related mortality, rejection and graft-versus-host disease, with 
the caution that these findings cannot necessarily be extrapolated to experiences outside 
academically orientated and supervised facilities. It had the basis for incorporation, 
after critical statistical analysis, of our data into annual geographical summaries from 
the EBMT Registry thereby providing stringent external quality control. During a 
prolonged period of close individualised monitoring of all variables, recognition of 
underappreciated side-effects accumulated. These symptoms were often accompanied 
by subtle signs and changes together with supporting laboratory data or other 
specialised studies that, collectively, signalled departure from normality – adverse 
impact on survivorship.  When these were assembled a pattern emerged in which this 
cohort, immunosuppressed with Campath® monoclonal antibodies in-the-bag, 
appeared to differ significantly in a number of aspects from matching groups that used 
traditional chemotherapy and steroid based preparations including post-transplant 
regimens for graft-versus-host disease. Accordingly, a study was designed to give 
greater emphasis to these discrepancies by documenting late effects in lung, patterns of 
immune reconstitution and, most striking of all, in bone mineral density.  
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6.1 INTRODUCTION 
Two steps preceded the definitive analysis for this study.  Initially, the priority was to control the environment 
or facility in which the grafting was carried out. Secondly, once consolidated over time, to incorporate 
protocols which generated local results and which could be compared with other centres. 
 
6.2 PATIENTS – GENERATION OF THE DATABASE 
Consecutive individuals, (n=468) who were eligible for immunohaematopoietic stem cell transplantation, 
were registered from April 1995 through December 2010 and their demographic details were captured on a 
standardised spreadsheet (Annexure 3). This opportunity of providing costly and high-technology served 
two further purposes. It provided a pivotal point for studies emanating from other groups in Africa, making 
possible national comparisons. Secondly it objectively demonstrated that, with proper selection of correct 
indications for these procedures, transplant was feasible.  It was however appropriate to compete for 
resources, albeit with some limitations imposed by the state for financial reasons and in the private sector by 
insurance plans. For the entire cohort, overall survival by Kaplan-Meier analysis split into children, defined as 
up to 20 years of age and young adults, and the remaining older group above 20 years of age. For each of these 
groups, outcome was compared by transplantation procedure being sibling allografts, autografts and matched 
unrelated volunteer donors. Using the latter three categories, a break-down of overall survival by diagnosis 
was done. Here there were sufficient numbers for only broad subdivision into aplasia, myeloid or lymphoid 
lineages and miscellaneous entities. Although sufficient data was available in acute myeloid leukaemia (AML) 
and lymphoma (NHL) the other diseases e.g. myeloma (MM) were not enough to provide survival data. The 
heterogenecity of the diseases was not taken into account as the numbers for each would then not have been 
sufficient for analysis. Despite this reality, attempts were made within each to test the possibility that 
significant differences might be revealed. 
 
It must be emphasised that this is a unique series in which immunosuppression centred on using the 
Campath® monoclonal antibodies ex vivo, in which the graft was exposed to the protein in-the-bag - prior to 
infusion. The latter universal manipulation made it possible to explore discrepancies that may be attributable 
to the very specific variation when compared to traditional alternatives using cytotoxic agents, with or without 
corticosteroids, and extending these into the post- transplant period.3 
 
6.3 METHODS 
6.3.1 ROUTINE DIAGNOSIS 
For patients entered into the transplant programmes following comprehensive clinical assessment, universal 
definitions were used for accurate diagnosis of congenital and acquired aplasia.4 The World Health 
Organisation (WHO) guidelines contained the criteria for acute and chronic leukaemias, Hodgkin and the 
remaining lymphomas as well as plasma cell neoplasms.5  This allowed diagnosis to be similar to the rest of 
the world.  Before the WHO guidelines became available, the French-American-British (FAB) classification for 
acute myeloid leukaemias and the Revised European American categorisation for Lymphomas (REAL)   were 
used. 
 
6.3.2 SPECIAL INVESTIGATIONS 
The WHO monograph contains, in each respective section, relevant information on lymph nodes and the bone 
Stellenbosch University  https://scholar.sun.ac.za
 107 
marrow as well as extranodal sites.5  Criteria are provided for diagnosis and classification with inclusion of 
immunohistochemistry, flow cytometry, karyotyping and molecular genetics. The current study retained these 
standardised definitions in the interests of uniformity and to make possible exchange of data from this 
research project with pertinent publications.6,7  
 
 
6.4 PRE-TRANSPLANTATION PHASE 
Individuals undergoing these procedures did so in a rigidly standardised environment developed to bring 
about the best possible return on investment of resources.  
 
The various interlocking components have been developed in the experimental haematology laboratory and 
subsequently translated into the clinic. Each section has been detailed in chapter four and this substantial 
infrastructure summarised.  
 
The standardisation of these aspects was particularly challenging yet an indispensable first step in this long 
running project. Thus the physical plant and uniform protocols exclusively used were each distinct research 
developments. (Table 12) 
 
TABLE 12 
COMPONENTS OF THE TRANSPLANT FACILITY 
 
Custom built protected environment 
Dedicated nursing and paramedical professional team 
Safe central venous access 
Actively participating infectious disease, dermatology and pulmonology consultants 
Gastroenterologist – dietician – nutritional programme 
Policy for transfusion and use of blood products 
Counselling and liaison psychiatry 
Standardised management and research protocols 
Haematology co-ordinator and data manager 
Optimal staff and patient information sharing 
 
A homogenous starting population was achieved to systematically explore the non-haematopoietic lesions 
arising in the course of stem cell transplantation. 
 
6.5 PRIOR TREATMENT EXPOSURE  
A major uncontrollable variable is the numerous diagnoses attached to otherwise eligible patients. (Figure 
20) Whenever possible, standardised regimens were employed. 
 
6.5.1 APLASIA (AA) (n=27) AND FANCONI ANAEMIA (FA) (n=16) 
Intensive support included limiting blood and other components as far as possible. Where suitable sibling 
donors were available, this remained the preferred treatment.8 In other instances, immunosuppressive 
regimens including high-dose methylprednisolone and antithymocyte globulin were standard.9 
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6.5.2 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) (n=40) 
Treatment was standardised to the Berlin–Frankfurt-Muenster or BFM protocols for adults and children 
respectively.10,11 
 
6.5.3 ACUTE MYELOID LEUKAEMIA (AML) (n=92) AND MYELODYSPLASIA (MDS) (n=15) 
Initially the combination of cytosine arabinoside and anthracycline antibiotic with one or other 
epipodophyllotoxin was employed.12 More recently treatment was extended to the British Medical Research 
Council AML 15 programme. It was unfortunate that in some instances, managed healthcare organisations 
restricted access to these programmes on advice of local consultants.  
 
Similarly, despite benefit from adding gemtuzumab ozogamicin, used in AML 15, this drug remains 
controversial and this option was generally unavailable.13 In the myelodysplastic cases, therapy was in line 
with international recommendations based on characterisation14 incorporating molecular genetics15 but gene-
profiling could not be carried out as the laboratory test was not available in South Africa.16 
 
 
6.5.4 CHRONIC MYELOID LEUKAEMIA (CML) (n=72) 
Disease control was rapidly achieved with hydroxyurea although, more recently, first-line therapy became 
imatinib mesylate.17 Transplantation was offered to fully matched recipients particularly following escalation 
in disease process after administration of first and second generation tyrosine kinase inhibitors,18 if 
cytogenetic abnormalities progressed or if this intervention was a specific patient choice.19 Transplants were 
initially , before imatinib became available, done while in chronic phase.  No patients were transplanted in 
blastic phase unless control was achieved by chemotherapy.  The numbers in the different categories are not 
available. 
 
6.5.5 CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) (n=4) 
Individuals received pulse chlorambucil or combinations of rituximab, fludarabine and cyclophosphamide.20 
Latterly, the anti CD52 monoclonal antibody Campath® or alemtuzumab21 was used. In selected refractory 
cases allografting remained an option.22 Patients were mostly transplanted if non responsive to therapy or 
early relapse, never as first line therapy except individuals who had a p53 deletion/mutation (del 17p13). 
 
6.5.6 MYELOMA (MM) (n=41) 
Stratification was by comorbidity23 and risk factors using guidelines from the international myeloma working 
group.24 The VECD regimen comprising vincristine, epirubicin, cyclophosphamide and dexamethasone was 
the preferred choice. Here the target was greater than 75% reduction in both paraprotein level and plasma cell 
infiltrate of the bone marrow trephine biopsy to qualify for autologous immunohaematopoietic stem cell 
grafting. Thalidomide was not approved by local third-party funders during these studies. With negotiation, 
appropriate cases could obtain bortezomib which was also not routinely available. Alternatives remain pulsed 
melphalan and methylprednisolone or salvage with dexamethasone and vinorelbine.25 
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6.5.7 HODGKIN (HL) (n=22) AND OTHER LYMPHOMAS (NHL) (n=107) 
Current protocols were those used by the European Organisation for Research and Treatment in Cancer 
(EORTC) 26,27 and the German Hodgkin Lymphoma Study Group.28,29 Patients proceeded to transplantation 
on the prevailing criteria. NHL and HL were not divided into different subgroups. 
 
6.5.8 MISCELLANEOUS DIAGNOSES (n=32) 
Numbers less than five in a particular category comprised thalassaemia, sickle cell disease, 
mucopolysaccharidosis and severe combined immunodeficiency disease (SCID). For statistical reasons these 
were analysed together but efforts made to generate survival by subtype were precluded due to small numbers. 
 
In Figure 20, aplastic anaemia included FA while CLL was combined with the NHL group (Figure 20a) 
indicates the total cohort (468), subdivided into (Figure 20b) the 107 patients equal or below 20 years and 
(Figure 20c) 361 greater than 20 years old. There were more adults as this is mainly an adult unit and 
children are transplanted only on referral. Whenever possible, standardised regimens were employed.  The 
diseases for which most transplants were done was AML (23%) and  NHL(24%). 
 
FIGURE 20 
TRANSPLANT CASES ACCORDING TO DISEASE CATEGORY AND AGE 
 
            (a) 
 
   (b)      (c) 
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6.6 TRANSPLANTATION PHASE - OVERVIEW 
6.6.1 CONDITIONING REGIMENS 
Myeloablative options were used and in this study no reduced intensity preparations were employed. 
 
6.6.1.1 RADIOTHERAPY  
The transplant procedure was designated day 0 and radiotherapy began with 12 gray fractionated whole-body 
exposure on days  -7, -6 and -5. This was followed by 60 mg per kilogram of cyclophosphamide intravenously 
on days -4 days -3 and 6 gray fractionated total nodal irradiation on day -2 and day -1. 
 
6.6.1.2 CHEMOTHERAPY  
Busulphan combined with cyclophosphamide was originally used in the four-day regimen.30 Latterly this was 
replaced by a two-day alternative31 and, additionally, intravenous agents were used in preference to the oral 
formulation.32 In selected individuals where this drug was contraindicated, it was replaced by fludarabine.33 
In over 80% of lymphoma cases the first choice was BEAM preparation. In congenital haematologic disorders 
fludarabine was combined with antilymphocyte globulin.34 
 
6.6.2 MOBILISATION AND QUALITY CONTROL 
Stimulatory peptide therapy in the form of granulocyte colony-stimulating factor (Roche) was commenced 
subcutaneously on day -5 at a flat dose of 300 µg given daily with the last injection at 04h00 on the day of the 
first large volume apheresis harvest. The circulating CD34 positive population was noted but not specifically 
used to time these collections.35 
 
6.6.3 GRAFT MANIPULATION 
6.6.3.1 BONE MARROW 
Initially only bone marrow was used. Although no longer routinely used, we continued to accommodate 
matched-unrelated volunteer programmes when predicated on requirements of the collaborating centres from 
different parts of the world.36 This was usually dictated by their donor preference. Specific diseases were not 
taken into consideration. Here the harvest was modified using the standard apheresis technology, and the 
2997 Cobe programme. Once more than 95% of the mononuclear cells had been recovered, the residual blood 
was re-infused to the donor or discarded: this practice is now obsolete.  
 
The immunohaematopoietic stem and progenitor cell concentrate had the standard ex vivo addition of 20 mg 
of Campath® 1H, then incubated for half an hour at 37°C and infused.37 
 
6.6.3.2 PERIPHERAL BLOOD 
Collections required a minimum of 6.5 x 108 /kg mononuclear cells and greater than 2 x 106 /kg CD34 positive 
population. Long-term colony initiating cells were determined in clonogenic assays.38,39   These assays were 
initially done to show how quickly patients would engraft.  The cells needed to be incubated for two weeks. 
Because it was time-consuming and the technologists found it difficult to count the colonies, and by the time 
they were counted, it was already known whether engraftment had occurred and it was then discontinued. 
Even in patients who failed to meet the required number of CD34 or mononuclear cells, rapid reconstitution of 
the bone marrow still occurred.  
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6.6.4 INFUSION TECHNIQUE 
Premedication was given half an hour before the graft containing the monoclonal antibody; this  consisted of 
100 mg hydrocortisone, 12.5 mg of promethazine hydrochloride intravenously and 500 mg paracetamol orally. 
Non-invasive cardiovascular and respiratory monitoring was continued until all vital signs were stable. 
Oxygen desaturation necessitated rate adjustment of the infusion and occurred in less than 5% of the 
procedures. In approximately 30%, pyrogenic reactions with abdominal discomfort were attributed to the 
immunoglobulin (Campath®) and treated symptomatically. There were no lasting side-effects. In autografts, 
transient fever was initially attributed to the presence of DMSO but more recently clarified and ascribed to the 
presence of contaminating granulocytes.40 
 
6.6.5 ALLOGENEIC TRANSPLANTS 
In fully histocompatible siblings, immunosuppression was not used. Conversely, in family members and 
matched-unrelated volunteers, recipients received cyclosporin-A and therapeutic levels of 1500ng/mL on the 
C 2 assay were maintained.41 The dose was cut to 50% at six months, 25% at nine months and discontinued at 
one year. The protocol included 400 ml stabilised human serum weekly42 in addition to 500 mg valaciclovir 
twice daily for viral prophylaxis in the initial three months and co-trimoxazole- comprising trimethoprim 80 
mg and sulfomethoxazole 400 mg daily- for one year.43 
 
6.6.6 AUTOGRAFTS 
PBSC was collected from the patient, then cryopreservation was undertaken as previously described.44  
Conditioning was given and the cryopreserved stem cells thawed and reinfused with no further manipulation. 
 
6.7 RESULTS 
6.7.1 STATISTICAL ANALYSIS 
Statistical analysis was performed using STATA software, version 11 (STATA Corporation, College Station, 
TX). The difference in frequency was compared using Pearson’s chi-square test.45 Where necessary, means 
were compared using the Student’s test.46 Patient survival was analysed with the Kaplan-Meier method47 and 
the results were compared by means of log-rank statistics.48 A p-value of <0.05 was considered statistically 
significant.  The median and an interquartile ranges (IQR) between the 1st quantile (Q1) and the 3rd quantile 
(Q3) were calculated. The median survival was the time it took to reach 50% survival. If more than 50% were 
alive at the end of the study, then the median survival time could not be defined. 
 
6.7.2 THE DISTRIBUTION OF TRANSPLANT PROCEDURES (ALLOGRAFT AUTOGRAFT AND MATCHED 
UNRELATED DONOR) 
In addition to the total cohort, there were differences between the under and over 20-year-old age groups. In 
the 198 (42%) that were allografts, 52 (49%) were children and 146 (40%) adults. The autografts 177 (38%) 
comprised 29 (28%) children and 148 (41%) adults.  In the 93 (20%) MUD transplants, 26 (23%) were 
children and 67 (19%) adults. 
  
Because of various conditions being transplanted, there were differences between adults and children e.g. 
adults have myeloma while this is rare in children, therefore showing a higher percentage of autografts in the 
adults. In total 107 (23%) children were transplanted and 361 (77%) adults. The adult transplants were in the 
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majority as children’s procedures were dependent on referral from paediatricians. (Figure 21) 
 
 
FIGURE 21 
DISTRIBUTION OF DIFFERENT TYPES OF TRANSPLANTS (ALLOGRAFT, AUTOGRAFT AND MATCHED 
UNRELATED DONOR) 
 
 
TRANSPLANT TYPE 
   468 
CHILDREN 
107 (23%) 
ADULTS 
361 (77%) 
Allograft   198 (42%)  52 (49%) 146 (40%) 
Autograft 177  (38%) 29 (27%) 148 (41%) 
      Mud           93  (20%) 26 (24%)                         67 (19%) 
 
 
6.7.3 STUDY POPULATION 
Table 13 shows the number of female and male patients, children and adults who were transplanted. The 
median ages for male and females were 39 and 37 respectively. There were far fewer children (as explained in 
6.7.2). 
 
TABLE 13 
TOTAL STUDY GROUP DIVIDED INTO SEX AND AGE 
 
TOTAL COHORT 
468 
CHILDREN 
107 (23%) 
ADULTS 
361 (77%) 
Females 195 (42%) 47 (24%) 148 (76%) 
Males     273 (58%) 60 (22%) 213 (78%) 
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6.7.4 OVERALL SURVIVAL DATA 
 
The total group (468) transplanted had an overall survival rate of 48%  at 15 years of follow up (Figure 22a) 
and in Figure 22b, the group was subdivided into children and adults showing overall survival rate of  58% 
and 42% respectively at 15 years follow up. There is no statistical difference in the curves between the age 
groups (p=0.220) 
 
 
FIGURE 22 
OVERALL SURVIVAL OF TOTAL GROUP AND SUB-DIVIDED INTO AGE DIFFERENCES 
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There was a further split within these two age groups by type of procedure; being allograft from sibling, 
autograft or volunteer donor. In Figure 23a the children showed no statistical difference between the curves 
(p=0.6151) and overall median survival for ALLO and MUD were undefined but 60 months for AUTO. In 
Figure 23b, the adults’ overall median survival for ALLO was 37 months, AUTO 73 months and MUD 75 
months. There was no statistical significant difference between the curves (p=0.4637). As MUD transplants 
started only in 1998, their follow up was shorter at 12 years and for the adults, even shorter at 10 years. This 
overall survival was difficult to compare with the literature as here individual types of transplants according to 
disease were usually evaluated separately and not as a group. Different types of transplants in children showed 
the lowest percentage survivial in autografts.  In the adults the results were very similar between the different 
types. 
 
FIGURE 23 
OVERALL SURVIVAL BY AGE AND TRANSPLANT TYPE 
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Grouped by disease category, it was appreciated that contrasting numbers and variable follow up rendered 
strict statistical comparison difficult but fortunately survival fell within published reference centre norms. 
Diseases were not divided into sub-types as the numbers would have been too small to analyse. They were 
grouped according to lineages. (Figure 24) The myeloid group (Figure 24a) consisted of AML, CML, MDS 
while the lymphoid group (Figure 24b) comprised ALL, HL, NHL, CLL and MM. In the myeloid lineage for 
both ages the majority of transplants were for AML. In the lymphoid group most of the children were 
transplanted for ALL (usually second remission) while for adults it was NHL. 
 
FIGURE 24 
DISTRIBUTION OF TRANSPLANTS BY MAJOR DISEASE LINEAGES  
 
MYELOID DISEASE 
(a) 
 
 
LYMPHOID DISEASE 
(b) 
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Aplasia included AA and FA.  The numbers were small and there were no statistical differences between the 
curves in the under 20 group (p=0.1636) and in over 20 (p=0.3177).  In the children the median overall 
survival time was undefined for both allografts and MUD. In the adults the median overall survival was 15 and 
five months respectively. (Figure 25) The children seemed to have had a better survival (52% - 82%) than the 
adults (42% ALLO) but it was not possible to analyse MUD as there were only three patients transplanted. In 
the published literature this is between 80% and 90%; the outcome being dependent on many variables but 
most importantly being time from diagnosis.   Children usually do better than adults, as seen in our group. 
 
FIGURE 25 
OVERALL SURVIVAL BY AGE, TRANSPLANT TYPE AND APLASIA  
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The under 20 age group (Figure 26a) again had very few numbers and there was no statistically significant 
difference between the curves (p=0.496). Median overall survival could not be determined for allografts and 
autografts but was one month for MUD.  
 
The adults (Figure 26b) showed no statistical difference between the curves (p=0.6029). Here for 46% the 
median overall survival was 56 months for allografts and for autografts 37% at 59 months. For the MUD group 
it was 56% at 120 months. It seems as if the autografts did worse most probably due to relapse of disease post 
transplant. 
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FIGURE 26 
OVERALL SURVIVAL BY AGE AND TRANSPLANT TYPE IN MYELOID DISEASES  
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The lymphoid lineages (Figure 27a) were also grouped together without taking into account the different 
types.  In the children there was no statistical difference between the curves (p=0.6680). The overall median 
survival was 14 months for ALLO, 40 months for AUTO and 87 months for MUD. Only 20% of AUTOs were 
alive at 12 years. This was a poor outcome but was most probably due to the majority being ALL and relapsing 
from their disease. 
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In the adults (Figure 27b) there was no statistical difference between the curves ( p=0.3233).  The overall 
median survival was 41 months for ALLO and 85 months for AUTO. The MUD group was undefined as 50% 
were still alive.  As the majority of the adults in the lymphoid group was NHL and their cure rate regarded as 
five years post transplant, it appeared as if 42% in this lineage were cured. 
 
 
FIGURE 27 
OVERALL SURVIVAL BY AGE, TRANSPLANT TYPE AND LYMPHOID DISEASES 
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The miscellaneous group constituted numbers less than five in a particular group comprising disease 
categories such as thalassaemia, sickle cell disease, neuroblastoma and SCID.  These were analysed together as 
statistically efforts made to generate survival by subtype were precluded because of small numbers. Figure 
28a showed a statistical difference between the curves where children had this procedure (p=0.0032). The 
overall median survival for ALLO and MUD was undefined while it was 16 months in the AUTO’s.  Figure 
28b showed that in the adults no statistical difference was present between the curves (p=0.2598). The 
median overall survival was 18 months for the ALLO, 61 months for AUTO and 75 months for MUD. These 
numbers were too small to draw a conclusion about the results. 
 
FIGURE 28 
OVERALL SURVIVAL BY AGE, TRANSPLANT TYPE AND MISCELLANEOUS DIAGNOSES  
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6.8 DISCUSSION 
The analysis was done to give insight into the overall survival of our transplanted patients. Even though the 
numbers were small it provided information that we could use for further guidelines. This data however, could 
not be compared with published literature as they use specific diseases with their sub-categories to provide 
overall survival data. It would be preferable if future analysis could be conducted on more specific diseases to 
be able to compare outcome with other centres. This will then provide a better understanding of the  success of  
our programme. 
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6.9 SUMMARISING COMMENT 
 
 
 
From the start of this project in 1972 that captured all demographic data via audit by 
European, American and CIBMTR registries, the decision to personally document 
outcome underpinned accountability for every procedure. To do this the most 
fundamental step was to control the environment in which transplants took place and 
considerable research development led to the prototype facility at Groote Schuur 
Hospital upon which all future units in South Africa were based (detailed in chapter 4). 
From this transplant unit the next research project was to employ absolute uniformity 
to each case, retaining a constantly reviewed protocol. Overall survival was tested 
between 1995 – 2006 in two feasibility studies1,2 and in this chapter brackets age 
spectrum, choice of procedure and, to the extent statistically possible within above 
subdivisions, split into diagnosis. The results were limited by numbers. These 
procedures permeated the private and public sector in subsequent development and 
became established in both university and private sectors. Survival outcome was 
reported previously,1,2 and updated in this chapter. Traditional immunohaematopoietic 
patient care allowed the final step in this research project of using a now clearly defined 
cohort to study, in specialised laboratories, changes in non-haematopoietic tissues. 
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CHAPTER 7   
 
A SPECTRUM OF POST-TRANSPLANT INJURY  
TO NON-HAEMATOPOIETIC TISSUES AND ORGANS 
 
 
 
FOCUS 
 
This section is the unifying point of the entire research project in that it encapsulates those 
varying degrees of change from normality that arise outside the blood and bone marrow as 
having the potential to adversely affect quality of life. They were first noted, then 
increasingly delineated, during the course of auditing consecutive immunohaematopoietic 
stem cell transplants carried out by a single designated team during the process of routine 
reporting to repositories. The latter included the Centre for International Blood and Marrow 
Transplant Research, National Donor Program and the European Group for Blood and 
Bone Marrow Transplant. Continued active participation in each was determined by 
inspections to ensure accuracy of data pertaining to physical facility, staff and protocols 
collated through the Annual Network Renewal System Complete Survey. This provided a 
constant source of transparency and accountability. Although initiated over a 22 year 
period at the University of Cape Town in the Groote Schuur Hospital, changing National 
resources made it necessary to continue the work in the private sector. Recognition between 
1995 and 2010 was achieved as an internationally accredited centre where formal outcome 
analysis matched international standards. With approval from appropriate Stellenbosch 
University Committees in 2011, it was possible to embark on the study of non-
haematopoietic phenomena in two consequential timeframes – acute associations within 
three months manifested in kidney, cardiovascular system, skin and gastrointestinal tract 
accrued from routine post-transplant measurements. Separately are previously 
underappreciated late effects requiring specialised research technology and reflected in lung 
function, immune reconstitution and skeletal changes. These problems led to the constitution 
of a multidisciplinary study group. In the final analysis an additional contribution would be 
anticipated from wide-ranging effects consequent upon conditioning with the anti CD52 
monoclonal antibody as opposed to traditional cytotoxic agents and corticosteroids. 
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7.1 INTRODUCTION - STUDY DESIGN 
Having established a state-of-the-art protected environment and standardised all aspects of management, it 
could be demonstrated that outcomes matched published literature. This now became a reliable reference 
point to shift focus from primarily bone marrow recovery to non-haematopoietic sequelae and was given 
appropriate University Ethics and Research approval. Specifically, the incidence and severity of abnormalities 
in a number of tissues or organ systems was recorded in some individuals who underwent these procedures 
over a 15 year period in a privately based - internationally accredited - donor, harvest and transplant centre. 
This collaborative investigation was designed to capitalise on laboratory diagnostic techniques, some of which 
had not been previously available due to cost constraints. The two endpoints were to define underappreciated 
complications which became evident after a year as a basis for proactive intervention where indicated. 
Secondly, to focus on differences in the approach used locally with the Campath® reagents rather than the 
more conventional regimens. The study supplied data for the acute associations from an audit, and for the late 
effects a number of surviving volunteers underwent tests which provided the information. 
 
7.2 PATIENTS - GENERATION OF THE DATABASE 
Every individual registered over the 15 year period between 1995 and 2010 (n = 468) was traced.  
 
Of all these volunteers, eight were too ill to undergo testing not necessarily attributable to the transplant or 
any related complaints. Six chose not to participate but shared residual anxiety about diagnosis and outcome 
of results that may show abnormalities. In 132, the distances and financial constraints were insurmountable. 
Fifty-one could not be contacted and the remaining 216 died. Fifty-five individuals comprised the final study 
cohort. (Figure 29) 
 
7.2.1 REFINEMENT AND VOLUNTEER PARTICIPATION 
Given the research nature of this investigation, the tests were provided at no cost to the patients. Funding for 
the study was from the Harry Crossley Foundation and from the Haematological Research Trust.  The latter 
was established for research and education.  Initial contact was telephonic and after detailed explanation, an 
extensive informed consent1 form was provided followed by further discussion in which all questions were 
clarified. This document was signed and entered into the research record. Additionally, because these studies 
were carried out in specialised units in Tygerberg Academic Hospital, approval was obtained from the  
relevant superintendent in charge of research at the hospital  (Stellenbosch University Ref: N11/07/242). 
 
Organisationally, all testing was co-ordinated in a single visit by professional and technical staff in the 
Divisions of Pulmonology, Immunology and Endocrinology within the Department of Internal Medicine at 
Stellenbosch University and Tygerberg Academic Hospital.  
 
The information which was generated was made available to the patients and then sent back to the referring 
general practitioners or physicians.  
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FIGURE 29 
DETAILS OF THE STUDY COHORT SELECTED TO DEFINE LATE EFFECTS IN A NUMBER OF ORGANS 
 
 
 
 
 NUMBER PERCENTAGE 
TOTAL 468 100 
DIED 216 46 
LOST TO FOLLOW UP 51 11 
GEOGRAPHICAL DISQUALIFICATION 132 28 
ELECTED NOT TO PARTICIPATE 6 1 
TOO SICK 8 2 
FINAL REGISTERED COHORT 55 12 
 
 
 
7.3 METHODS 
7.3.1 DEMOGRAPHIC DATA  
Demographic data on 468 individuals was collected by using symbols to capture the information. An example 
is shown on the format used to generate the database e.g. Ia represents bacterial infection with dates of 
occurrence (Annexure 3). 
 
In Annexure 1 the data is given on the total cohort and for the volunteer group, demographic data was also 
extracted from this database (Annexure 2). 
 
7.3.2 ETHICS APPROVAL 
Informed consent was obtained from all the patients. Details on the research project as well as the audit were 
approved by the Health Ethics Research and the PhD Evaluation Committee; ethics number (N11/07/242). 
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7.3.3 STANDARD LABORATORY TESTS 
In the first three months following transplantation a small number of carefully selected measurements are 
essential for optimum patient care. These tests were performed regularly during the post transplant period 
and are listed below.  The time interval varied according to the tests done. Abnormalities developing before 
day 100 are designated as acute associations and find expression in terms of kidney function, cardiovascular 
symptomatology, skin manifestations and bowel disturbances encompassing nutritional status and hepatic 
biochemistry.  
 
 
7.3.3.1 HAEMATOLOGY 
Automatically 
Full blood count including smear examination (FBC)2 
Reticulocyte production index3 
Erythrocyte sedimentation rate (ESR)4 
 
Selectively  
Bone marrow aspiration5 and trephine biopsy (BMBX)6 
Tests for haemolysis including haptoglobin7 
Metaphase karyotyping8 
Molecular genetics including short terminal repeat assay9 
Fluorescent in situ hybridisation panels (FISH)10 
HLA immunogenetic class I and, where appropriate, class II tissue-typing11 
 
7.3.3.2 BIOCHEMISTRY 
Automatically  
Renal function including urea, urate, electrolytes and creatinine12 
Liver function tests (LFT)13 and lactic dehydrogenase (LDH)14 
 
Selectively  
Inflammatory markers including C-reactive protein (CRP)15 and procalcitonin16 
Serum protein electrophoresis and quantitative immunoglobulins17  
Free light chain assay18 
Β2 microglobulin19 
 
7.3.3.3 MICROBIOLOGY 
Automatically 
Gram stain from superficial wounds20 
Blood cultures from central venous placement sites and peripheral vessels simultaneously21 
Appropriate samples for fungi22 and mycobacteria23 
 
 
Selectively  
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Viral serology24 and polymerase chain reaction particularly for Ebstein Barr Virus (EBV)25 and 
cytomegalovirus (CMV)26. 
 
7.3.3.4 RADIOLOGY 
Automatically 
Calibrated chest films in deep inspiration with posterior, anterior (PA) and lateral projections27 
 
Selectively    
Skeletal survey28 
High resolution computerised axial tomography29 
Pulmonary angiography30 
Positron emission tomography (PET)31 
 
 
7.3.4 SPECIAL INVESTIGATIONS 
In contrast to the acute associations where the pertinent information was automatically collected as part of the 
established protocol and routinely audited, parallel changes in other non-haematopoietic systems were not 
appreciated at first and only gradually declared themselves over the passage of years in personal follow-up. 
However, their elucidation posed a quite different problem in that they required access to methodology only 
available in research facilities and therefore not previously accessible, primarily for financial reasons. These 
late effects, the reason for this segment of the investigation, were addressed in an expanded evaluation of lung 
function32, patterns of immune reconstitution and bone mineral density. This initiative necessitated the 
establishment of the Stellenbosch University Bone Marrow Transplant Study Group with involvement of 
colleagues from the three respective disciplines. 
 
The following tests were all done, once only, for the study. 
 
7.3.4.1   BONE DISEASE 
Clinical information 
Initial assessment 
DXA33 
QCT34 
Biomarkers 
 
7.3.4.2 PULMONOLOGY 
Clinical information 
Clinical information was provided to enable interpretation of the results. 
 
Initial assessment 
History of respiratory tract disease including sinuses and upper airways 
Smoking habits 
Chest symptoms especially performance status over time 
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Examination of lung fields 
Baseline radiology – PA and lateral projection in deep inspiration 
Review of previous studies35,36 
 
Calibrated methodology 
A battery of tests for investigation was established by the Pulmonary Unit to evaluate lung function.  The 
results were expressed as percentage of normal predicated by age, height and weight. 
 
Spirometry37 
Forced expiratory ratio in the first second (FEV1)38 
Forced vital capacity (FVC)39 
Forced expiratory flow FER (FEV1/FVC)39 
Peak expiratory flow rate  (PEFR)40 
Forced expiratory flow at 25 – 75% of forced vital capacity (FEF 25 – 75) 
 
Body plethysmography 
Body box41 
Airway resistance42 
Total lung capacity (TLC)43 
Residual volume (RV)39 
Diffusing capacity for carbon monoxide (DLCO)39 
Bronchoscopy when indicated44 
 
Format for reporting 
The interpretation of serial pulmonary function testing results according to the American Thoracic 
Society/European Respiratory Society (ATS/ERS) 200545 
Obstructive – FEV1/FVC < 70% and FVC > 80% of predicted  
Obstructive with reduced vital capacity – FEV1/FVC < 70% and FVC < 80% of predicted 
Restriction – FEV1/FVC > 70% and FVC < 80% of predicted 
FEV1 used to grade the impairment as being obstructive or restrictive 
Combination of above was deduced from plethysmography 
 
7.3.4.3 IMMUNOLOGY – EVALUATION OF IMMUNE RECONSTITUTION 
Samples uniquely identified were tested and results used, post hoc, to interpret subsequently obtained 
information on symptoms and signs through interaction with patients and referring primary care physicians. 
Both the innate and adaptive pathways were studied. 
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7.4 ACUTE ASSOCIATIONS - THE FIRST THREE MONTHS 
This audit data, described as early complications, was readily reversible within the first 100 days post 
procedure and early improvement usually commenced when neutrophil recovery occurred. These findings 
were in keeping with published outcome47 
 
 
7.4.1 NEPHROLOGY 
7.4.1.1 INTRODUCTION 
Transplantation almost inevitably exposed recipient kidneys to a range of injuries including fluid and 
electrolyte imbalance, antimicrobial as well as cytotoxic agents and less frequent occurrences amongst which 
were graft-versus-host disease and microangiopathy.48 We took the opportunity to document the incidence 
and severity of acute kidney injury in this cohort of patients and at the same time, to explore any impact that 
might arise from the unique immunosuppressive regimen centred on the use of monoclonal antibodies ex 
vivo49. An increase in serum creatinine of approximately 1.5 times the baseline figure was accepted as 
indicating acute kidney injury (AKI). 
 
7.4.1.2 PATIENTS  
Between 1995 and 2010 a total number of 468 patients were transplanted in the Mediclinic Centre.  Adequate 
data for assessment of kidney function was available in 76 individuals. 
 
7.4.1.3 METHODS 
Derived from the complete biochemical profile, entry to this analysis was determined by serum creatinine level 
as the index of renal function in kidney injury.50  It was accepted that estimated glomerular filtration rates 
were inaccurate in unstable patients.  The progression of oliguria to anuria aided in the assessment of AKI. 
The creatinine level was recorded pre-day of transplant and weekly thereafter for three months.  The 
creatinine measurement was done on a Beckman Coulter.AU and processed with a “Modified kinetic Jaffer 
method.” 
 
7.4.1.4 RESULTS  
Forty patients (53%) had normal creatinine levels and this did not change during the course of follow-up. 
Observation numbers in the table showed a drop particularly, in the later weeks, attributable to the decreasing 
number of patients attending the clinic. The highest level of creatinine was 969µmol/L. The median creatinine 
and IQR was used to do the analyses. (Table 14) Of this cohort, four died with septicaemia with no alteration 
in kidney function and a further nine demised under similar circumstances beyond the 12 week observation 
period. Twenty-seven remained alive and well. 
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TABLE 14 
SEQUENTIAL CREATININE VALUES IN THOSE THAT DID AND DID NOT DEVELOP ACUTE KIDNEY 
INJURY  
 
 
 No injury 
Median 
μmol/L 
(Obs) 
 
Injury  
Median 
μmol/L 
(Obs) 
 
No injury 
IQR 
μmol/L 
Q1;Q3 
Injury 
IQR 
μmol/L 
Q1;Q3 
No Injury 
Range 
μmol/L 
Min;Max 
Injury 
Range 
μmol/L 
Min;Max 
Pre  69      (40) 84.5     (36) 58; 78.5 74.5; 94 38; 103 47; 139 
D-O  63      (39) 72        (35) 53; 75 59; 87 41; 118 46; 158 
1 week  69.5   (38) 110.5   (36) 57; 84 83.5; 159.5 33; 98 46; 284 
2 week  66     (39) 138      (35) 50; 89 82; 192 37; 107 47; 763 
3 week  66     (30) 130      (21) 53; 80 96; 160 33; 98 55; 969 
4 week  67     (31) 129      (26) 57; 78 90; 159 4; 90 55; 564 
5 week  53.5  (10) 129      (9) 51; 57 79; 192 45; 65 52; 212 
6 week  77     (7) 175      (7) 53; 85 151; 187 48; 93 131; 283 
7 week  62     (5) 124      (7) 53; 63 120; 237 48; 68 79; 712 
8 weeks  70     (26) 136     (21) 61; 85 93; 176 41; 118 71; 318 
12 weeks  75.5  (22) 107     (19) 63;79 84; 136 44; 94 66; 275 
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Thirty-six patients (47%) developed AKI, 29 (80%) related to infection, predominantly septicaemia. (Figure 
30)  Of the group, 12 recovered spontaneously within 12 weeks and in a further 11, response occurred after the 
end of this period making a total of 23 survivors. The remaining 13 patients died at variable times during the 
three months.  Of these, four were dialysed and a further two were excluded from this intervention as they 
were clinically unstable. All participants underwent myeloablative conditioning that included Campath® ex 
vivo in 24, while the remaining 12 were prepared similarly but without the monoclonal antibody.  
 
AKI was due to infection in 29 (80%) patients. In many instances the infective agent was not identified as 
patients were started on empiric antibiotics (refer to point 5.2.7).  Drugs such as cyclosporin A, conditioning 
cytotoxics and antibiotics (e.g.Amikacin, Gentamycin, Amphoterecin B) may have been partially responsible 
for this injury. Underlying disease such as Multiple Myeloma may have contributed to AKI. Fluid and 
electrolytes played a major part as patients could become dehydrated due to secondary causes such as 
vomiting and diarrhoea. 
 
 
FIGURE 30 
CAUSES OF KIDNEY INJURY IN THE 36 PATIENTS  
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Of the 36 patients who had AKI, 24 (67%) were allografts receiving Campath® and 12 (33%) were autografts 
and had no exposure to the antibody  -  a relative difference of 50%. (Table 15a) In those with AKI there was 
a slightly higher incidence of AKI in patients with MM, 7 patients (19%). (Table 15b) It was not significantly 
different from the other disease categories. 
 
 
TABLE 15 
DEMOGRAPHICS: AKI AND NORMAL RENAL FUNCTION IN TYPE OF TRANSPLANT AND DISEASE 
CATEGORY   
 Renal Injury (F,M) No Renal Injury (F,M) Total 
Allograft 24     (8F    16M)  (67%) 23   (10F   13M)    (58%) 47   (18F  29M) (62%) 
Autograft 12     (3F      9M)  (33%) 17     (8F      9M)   (42%) 29   (11F  18M) (38%) 
Total 36   (11F    25M) 40   (18F  22M) 76   (28F  47M) 
(a) 
 
No kidney injury 
Disease Frequency   (F,M) Percentage 
AA 3    (2F, 1M) 7.5 
ALL 5    (2F, 3M) 12.5 
AML 15  (6F, 9M) 37.5 
CML 4   (1F, 3M) 10 
MDS 3   (2F, 1M) 7.5 
MM 4   (1F, 3M) 10 
NHL 6   (4F, 2M) 15 
 
Kidney injury 
Disease Frequency   (F, M) Percentage 
AML 5   (3F, 2M) 13.9 
APL 3   (0F, 3M) 8.3 
CLL 1   (0F, 1M) 2.8 
CML 6   (3F, 3M) 16.7 
Fanconi 2   (2F, 0M) 5.6 
HL 2   (0F, 2M) 5.6 
MDS 3   (0F, 2M) 8.3 
MM 7   (3F, 4M) 19.4 
Myelofibrosis 1   (0F, 1M) 2.8 
NHL 5   (0F, 5M) 13.9 
PolycythemiaVera 1   (0F, 1M) 2.8 
(b) 
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When adding the monoclonal antibody, the median creatinine in the allografts (129µmol/L) seemed to be no 
different from that of the autografts (137µmol/l) where none was added, (Table 16) making an assumption 
that adding Campath® was not additionally nephrotoxic. 
 
TABLE 16 
SEQUENTIAL CREATININE MEASUREMENTS  FOR KIDNEY INJURY IN ALLOGRAFTS AND 
AUTOGRAFTS 
 
 ALLO 
Median 
μmol/L 
(Obs) 
 
AUTO 
Median 
μmol/L 
(Obs) 
 
ALLO 
IQR 
μmol/L 
Q1;Q3 
AUTO 
IQR 
μmol/L 
Q1;Q3 
ALLO 
Range 
μmol/L 
Min;Max 
AUTO 
Range 
μmol/L 
Min;Max 
Pre  82      (24) 90        (12) 72;         89  80;       109   47;   108   63;  139 
D-O  71       (23) 80.5     (12) 57;         83  65;         89   46;   109   46;  158 
Week 1  99.5   (24) 103.5   (12) 80;       134.5  96.5;   200.5   46;   204   60;  259 
Week 2 113     (24) 162       (11) 75;        165.5 107;      218   47;   265   75;  763 
Week 3 128    (21) 134.5    (8) 95;        159  96.5;    177.5   76;   220   55;  969 
Week 4 129    (19) 137        (7) 90;        158  68;        255   74;   282   55;  564 
Week 5 148      (9) 124        (2) 66;        210 *   52;   212 119;  129 
Week 6 175       (6) 151         (1) 146.5;   235 * 131;   283 151;  151 
Week 7 175       (6) 79          (1) 121;      474.5 * 120;   712   79;   79 
Week 8 137.5  (16) 108        (5) 108;     184.5  75.5;    206.5   71;   308   74;  249 
Week 12 107     (14) 111         (5)   82.5;  124  83.5;    223.5   63;   162   79;  275 
*- numbers too small to calculate 
 
7.4.1.5 DISCUSSION  
The incidence of AKI in this series was 47% which was comparable with figures in published data.51  The need 
for dialysis following AKI was a bad prognostic indicator.48,50  Assuming the criteria for performing dialysis 
were comparable with other transplant units then it could be argued, on the basis of patients requiring such 
intervention, that it did not differ widely between this study population and reference centres – the latter with 
a frequency  between 2 and 5%51 corresponding to our figure of 5%.  The reasons for AKI were multifactorial 
and using myeloablative regimens, with or without additional Campath®, no differences in AKI were apparent. 
This observation was in keeping with the suggestion that adding the monoclonal antibody was not additionally 
nephrotoxic. However, renal injury was less frequent with autologous as opposed to allogeneic bone marrow 
transplant.48  
 
7.4.1.6 CONCLUSION 
The incidence of AKI did not differ from those reported in publications48. This observation provided 
endorsement for standards achievable in South African University level programmes. 
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7.4.2 CARDIOLOGY 
7.4.2.1 INTRODUCTION 
From the time that various forms of transplantation were introduced into the prototype unit at Groote Schuur 
Hospital, three patterns of cardiovascular complications were noted. Although not initially appreciated, dose-
dependent anthracycline induced toxicity was often present but overlooked upon referral, the model being that 
of Hodgkin Lymphoma where cumulative doses of anthracycline and radiotherapy increase cardiac 
complications.52 Similarly, also underappreciated, was the presence of prior heart disease in the elderly with 
diffuse B-cell lymphoma and comorbidity of hypertension.53 Complications due to conditioning regimens are 
recognised, although these range from 1-26% in various studies. The main cause was cyclophosphamide 
producing cardiotoxicity.54 Apart from reduced left ventricular ejection fraction (LVEF) (< 45%) none of the 
other standard measurements (2-D;M-mode calculations; pulsed wave and colour doppler evaluation)  
reflected by echocardiography usefully predicted adverse reactions after grafting.  On multivariate analysis 
however, cumulative dose of anthracyclines emerged as a risk factor.55 Cardiac and cardiovascular 
complications occurred at a much lower frequency during the first 12 weeks than other post-transplant causes 
of morbidity and mortality. This has drawn attention to adverse events that occur years or even decades later. 
With increasing numbers of long-term survivors these side effects are expected to show rising incidence of this 
problem as had been predicated from the Hodgkin lymphoma data.56,57      
 
Cardiac dysfunction could be either systolic or diastolic. Systolic dysfunction was characteristic of dilated 
cardiac myopathy and a LVEF of less than 43%. Diastolic dysfunction related to abnormal filling and LVEF 
usually greater than 60%.  
 
7.4.2.2 PATIENTS 
A total of 119 individuals having fully audited data were seen by a single consulting cardiologist with particular 
expertise in the context of transplantation between 1998 and 2004.   
 
7.4.2.3 METHODS 
A carefully taken family and drug history was combined with clinical examination including blood pressure 
monitoring. Figures 31a & 31b show normal pattern M-mode trans-thoracic echocardiogram (ECHO) which 
assesses cardiac dimensions and left ventricular ejection fraction. The standard 12 lead electrocardiogram with 
rhythm strip was undertaken (Figure 32) where a normal pattern is seen. These procedures were performed 
to detect abnormalities that might have compromised cardiac function during the post transplant period.  To 
perform the ECG, a Hewlett Page Writer Xli 12 lead ECG Machine (configured to the specifications attached) 
was used. For the echocardiogram, the Micromax ultrasound system with cardiac imaging applications and 
P17/5-MHz broadband transducer was utilised. The procedures were done by the same cardiologist.  
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FIGURE 31 
M-MODE TRANS-THORACIC ECHOCARDIOGRAMWITH MEASUREMENTS 
 
(a)  
 
 
(b) 
 
Courtesy Dr Phillip Barlow Mills 
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FIGURE 32 
TWELVE LEAD ELECTROCARDIOGRAM WITH RHYTHM STRIP 
 
Courtesy Dr Phillip Barlow Mills 
 
 
Routine laboratory studies included full blood count with attention to haematocrit and screens for 
hypercoagulability, fasting lipogram, urea and electrolytes, determination of blood sugar and brain natriuretic 
peptide (Pro-BNP).57 Inflammatory markers were limited to sensitive C-reactive protein.58  There was no 
conclusive data for blood tests on the patients.  Assessment was done at completion of chemotherapy where 
this was part of the protocol. Whenever the subject had a cardiac event during transplantation phase defined 
practically as three months from the procedure, a full assessment was done. Serial studies were undertaken for 
the entire duration of long-term patient follow up.59 Particular attention was given to patients with diabetes60 
and systemic hypertension.61 Heart failure was noted in terms of the European Society of Cardiology 
Guidelines62 or the combined approach from the American College of Cardiology – American Heart 
Association concurrently with the New York Heart Association Functional Class.63 Management broadly fell 
into additional pharmacology for systolic64 or diastolic subtypes65 but at all times in the specific care of the 
consultant cardiologist as an integral member of a multidisciplinary team throughout the entire chemotherapy 
transplantation and subsequent follow-up course. 
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7.4.2.4 RESULTS  
Performance status was good in 66% of patients: but this was compromised, for a variety of reasons, in 10%. 
Should a patient commence the transplant procedure with poor performance status, his recovery could be 
compromised.  Of the initially registered cases, electrocardiograms were normal in 66 (55%) individuals and 
abnormal in a further 26 (22%). Abnormalities were mild such as right or left bundle branch block (RBBB, 
LBBB) and sinus bradycardia. Echocardiogram (ECHO) was normal in 110 (92%) and abnormal in only 9 
(8%).  The latter related to small effusions or diastolic dysfunction. All abnormalities were evaluated for their 
significance. (Figure 33) Although not included in this analysis, two illustrations highlight the way in which 
conventional management can be moderated on the basis of results in a multidisciplinary cardiovascular and 
haematology combined clinic. 
 
 
FIGURE 33 
NON-INVASIVE CARDIAC ASSESSMENT PRE-TRANSPLANTATION 
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Case one  
An asymptomatic 24-year-old colleague was screened on the basis of prior chemotherapy for leukaemia and 
shown to have low voltage complexes with a reduced left ventricular ejection fraction of 45% interpreted, as 
early cardiomyopathy. 
 
She was offered a matched-unrelated volunteer donor transplant for refractory disease after which left 
ventricular ejection fraction fell to 37% and she developed symptoms of heart failure. She was conventionally 
treated and remained with a raised pro-BNP and biochemical markers of cardiac injury. Currently she is back 
to normal and her systolic function recovered, leaving only mild diastolic dysfunction on carefully monitored 
therapy. This, as with others in the series, cannot be too strongly used to emphasise what can be achieved in 
the real world setting of cross-disciplinary combined management.  
 
Case two  
A 31-year-old male was referred after extensive treatment for refractory diffuse large B-cell lymphoma. He had 
reduced ejection fraction of 36% and was in symptomatic heart failure. He was considered as having no 
realistic option for survival without BEAM conditioning and transplantation. There were mild 
electrocardiographic changes and ECHO showed four chamber dilated cardiomyopathy. Following autologous 
salvage there was further deterioration in left ventricular ejection fraction of 15% that gradually stabilised 
between 1998 and 2000 only on medical management. Nevertheless, further decompensation necessitated 
cardiac transplantation that had a good outcome and he is currently well.  
 
This case again underlines the absolute importance of people embarking on either type of organ 
transplantation management to be thoroughly conversant with what is reported internationally and 
particularly in the context of local experience. The emphasis is that, while careful judgement and the 
dependence on a fully supportive group of co-investigators can often create a medical environment of 
informed consent, the outcome is not universally futile.  
 
7.4.2.5 DISCUSSION 
There are three striking and overriding imperatives. 
 
As has emerged throughout this research project there was the obligation to operate a state of the art 
transplantation unit. Within this environment, to constantly employ supervised protocols with publication of 
outcome for comparison with the literature. Even in this setting to offer these high-risk procedures exclusively 
in the context of a thoroughly committed and compliant cross-disciplinary team that, by definition, is based in 
transplantation medicine.  
 
There should be interaction with specialists in infectious diseases, pulmonology, haematology and other target 
organs of which particularly successful outcomes from stem cell grafting is achievable. This was dependent on 
prior preparation, scrupulous surveillance throughout the procedure and continued maintenance and long-
term follow-up. On this basis the logical question is what has been learned from this uniquely African 
investigation. There seem to be a number of points allowing a clear guideline. 
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Left ventricular dysfunction, as measured by reduction in left ventricular ejection fraction, predicted for 
increased problems following transplantation. Even with good recipient performance status and normal 
cardiac function, outcome could not be predicted with any degree of certainty.  
 
A multidisciplinary team must be prepared, and expertise available, to deal with complexities arising from 
cardiac toxicities of the transplant procedure. In the presence of comorbidities they were not, in isolation, 
necessarily sufficient to exclude management in respect of each individual patient. These procedures should 
never be run on guidelines but on strictly supervised protocols with outcome analysed and reported both 
locally as well as internationally. 
 
Definitively, and every bit as crucial to lessons learnt, was the fact that all survivors should continue to be 
managed within the cross disciplinary group for duration of natural life. This approach allowed not only the 
experience of the group, but also the subtle changes emerging over time to be available for proactive 
supervision and management thereby extending survivorship to the absolute maximum and very often, with a 
surprising outcome – in both directions. 
 
7.4.2.6 CONCLUDING SUMMARY 
The conclusions drawn from this analysis were consistent with findings in the literature. Specifically, there 
was neither automatic inclusion nor exclusion of different transplant procedures based on the underlying 
disease but rather on the expertise cultivated in multidisciplinary interaction between cardiovascular disease 
and haematology – both benign and malignant.  
 
Cardiac consequences occurred at a lower frequency than other post-transplant complications.55 
 
There was a high incidence in haematological oncology of myocardial injury but with regular monitoring, this 
could be managed by intervening early to minimize this risk by refucing exposure to cardiotoxic drugs.  
 
 
7.4.3 DERMATOLOGY 
7.4.3.1 INTRODUCTION 
Initially, as with other centres worldwide, the use of unmanipulated stem cells from bone marrow resulted in 
an almost universal occurrence of acute GVHD66,67 presenting with a rash commencing on palms and the 
dorsum of hands as erythema. (Figure 34)  It may then progress to epidural necrosis followed by stripping 
and subsequently followed by chronic graft-versus-host disease (GVHD).68 Here the skin had generalised 
violaceous scaly plagues of the lichenoid variant (Figure 35) with very high morbidity and mortality69. 
During the development of the standardised programme cyclosporin A became available and reduced the 
incidence and severity of these immunologically mediated injuries to the skin, biliary endothelium and 
enterocytes of the small bowel70,71 but these features were not entirely abrogated.72  The addition of 
monoclonal antibody to the bag then followed which led to a reduction in GVHD.  
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FIGURE 34 
ACUTE GVHD FOLLOWING INFUSION OF UNMANIPULATED STEM CELLS PRESENTING AS A RASH 
ON PALMS AND DORSUM OF HANDS 
 
 
 
FIGURE 35  
CHRONIC GVHD IN PRE-CAMPATH® PERIOD SHOWING VIOLACEOUS SCALY PLAQUES OF 
LICHENOID VARIANT 
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Gratifyingly, the safety of this alternative approach, and the generally outstanding results achieved, was later 
confirmed by the Leiden group, 73 among others. This success brought about the necessary endorsement for us 
to be encouraged to further characterise this preliminary experience.  
 
7.4.3.2 PATIENTS 
Between 1995 and 2010 a total of 468 patients were transplanted and in all of these, adequate data for 
evaluating specific abnormalities in the skin, appendages around the eyes and mucous membranes were 
available. 
 
7.4.3.3 METHODS 
Cases were seen daily by the investigator and all cutaneous manifestations were referred to a specialised 
dermatologist with a research interest in GVHD. The majority of these lesions could be confidently diagnosed 
as drug hypersensitivity74 such as rash due to trimethoprim and sulfamethoxazole (Bactrim®) or viral resulting 
from herpes zoster following discontinuation of prophylactic antiviral therapy and managed accordingly but 
not discussed any further.  Where any doubt existed, photographs supplemented by a skin biopsy which were 
interpreted by a histopathologist, were required to sustain the diagnosis of GVHD.75  The definitions for acute 
and chronic GVHD are provided in Table 17. Figure 36a illustrates acute GVHD showing necrotic 
keratinocytes, vacuolar degeneration, dermal oedema and pigment incontinence and in Figure 36b, chronic 
GVHD showing hyperkeratosis, parakeratosis, scattered necrotic keratinocytes, vacuolar degeneration and 
pigmentary incontinence. 
 
 
FIGURE 36 
PHOTOMICROGRAPHS OF ACUTE AND CHRONIC GVHD DIAGNOSED BY SKIN BIOPSY 
 
 
 
 
 
 
   
(a) ACUTE                                                                           (b) CHRONIC 
 
Courtesy Dr Kathy Taylor 
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Table 17 
GVHD DEFINITIONS 
 
Category Time symptoms 
develop 
Presence of 
acute GVHD 
features 
Presence of 
chronic GVHD 
features 
ACUTE GVHD    
Classic ≤ 100 days Yes  No 
Recurrent/Late onset ≥ 100 days Yes  No 
    
CHRONIC GVHD    
Classic No time limit No Yes 
Overlap syndrome No time limit Yes Yes 
    
Forme frust ≤ 100 days Mild and non-
specific 
No 
 
Grading was done according to skin and organ involvement. Grade I only involved skin approximately 25% 
and Grade II had a combination of skin (25-50%) and mild liver and gut involvement. Grade III and IV are 
delineated by progressively more severe changes in these 3 organs.  Forme frust was a mild non-specific rash 
with no systemic signs.  
 
7.4.3.4 RESULTS 
Twenty-eight cases fully met the criteria for the newly emerged variant of GVHD or forme frust. The latter had 
its most striking expression on the reduced extent and severity of the cutaneous injury. Although it was not 
possible to compare this subgroup to the total earlier pre-Campath® population, experienced medical and 
nursing personnel were in agreement that it caused less hyperbilirubinaemia. There was less involvement in 
these two major target organs with the forme frust variant than the acute GVHD. 
 
Initially it was difficult to appreciate the significance in comparison to the traditional acute graft-versus-host 
disease and a number of distinctive features were rapidly confirmed within the study group. GVHD presented 
with cutaneous manifestations centred on palms and soles. They were florid, aggressive and sometimes 
explosive lesions.  On the other hand those patients exposed to monoclonal antibody showed rashes which 
extended more slowly and developed usually two or three days later. These rashes were also less centred on 
the palms and soles. They were invariably less than 20% of the body surface area76 seldom requiring anything 
more than topical corticosteroids for reversal.77 (Figure 37) Grade III and IV were never seen. Parental 
steroid therapy was infrequently required. Other immunosuppressants including cyclosporin A or 
methotrexate were not needed. In the group of patients with GVHD there was no recognisable chronic graft-
versus-host disease except for three cases each of which followed donor lymphocyte infusion. This observation 
showed the impact of using the monoclonal antibody Campath® ex vivo. (Table 18) 
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FIGURE 37 
FORME FRUST – A MILDER FORM OF GVHD SEEN WITH CAMPATH® 1H ex vivo – REDUCED 
CUTANEOUS INJURY 
 
 
Courtesy Dr Ranks Lehloenya 
TABLE 18  
NUMBER OF GVHD IN THE PERIOD 1998-2010 
YEARS NUMBER TRANSPLANTS 
1998 7 24 
1999 7 (1*) 38 
2000 4 23 
2001 1 (1*) 38 
2002 2 (1*) 23 
2003 2 19 
2004 2 18 
2005 1 12 
2006 1 14 
2007 1 10 
2008-2010 0 26 
TOTAL 28 245 
 
*This followed donor lymphocyte infusion leading to chronic GVHD 
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7.4.3.5 DISCUSSION 
The skin, being a vast organ, is constantly bombarded by environmental antigens and may undergo many 
acute changes, some of which are non-specific and of little relevance. Experience, as a steep learning curve, 
was needed to crystallise the dominant post-transplantation injury. Once rashes due to drug hypersensitivity 
and infectious causes were identified and excluded, the complex immunologic syndromes of acute and chronic 
graft-versus-host disease continued to demand attention.  
 
The striking multisystem presentation of GVHD, relentless progression and often lethal outcome, made it one 
of the most feared complications, to the extent that on more than one occasion, it threatened to compromise 
continuation of an entire programme when faced with ethical dilemmas and a range of psychosocial 
challenges.  
 
It remains a tribute to the pioneers in the field that these daunting experiences were shaped, largely by the 
ingenuity of transplant team activity, to produce the protocol linking staging and grading.78,79 The initial 
experience with GVHD was with immunosuppressive regimens comprising corticosteroids, methotrexate and 
cyclosporin A.80,81 
 
It was rewarding that the cutaneous manifestations were amongst the first to show a reproducible sharp 
downturn once monoclonal antibody was used. The link of these to the corresponding reduction in the damage 
to the biliary epithelium and enterocytes lining, primarily the small intestine, was difficult to objectively 
measure but gratifying paralleled with a striking shift towards increasing manifestation of lesser grades of the 
chronic graft-versus-host disease.76,82 
 
Due to blunting of immunologic process, occurrence of GVHD was reduced. The pathophysiology has been 
explored by colleagues within the Campath® Users’ Group.49,83  There seems to be a higher occurrence of 
infections, particularly viral, due to delayed or abnormal lymphocyte reconstitution.84 
 
7.4.3.6 CONCLUDING SUMMARY 
The cardinal point emerges that this innovative exposure to Campath® 1H significantly improved outcome by 
reducing the incidence and severity of both acute and chronic graft-versus-host disease. Quality of 
survivorship, in its broadest terms, was further enhanced by psychosocial benefits to the family and staff of the 
treating transplant team. Significant cost saving, particularly in a resource constrained country translated into 
greater access in the private as well as public sector. At a more basic scientific level these outcomes were 
widely replicated within the Campath® Users’ Group and added support for continuation with further 
investigations into the effect of adding the monoclonal antibody to the graft ex vivo.  
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7.4.4 GASTROENTEROLOGY  
7.4.4.1 INTRODUCTION 
Three interlocking practicalities arose in the bowel and biliary system and were of sufficient magnitude for 
analysis. 
 
Firstly, a patient-centred group of problems, defined as mucositis with dysphagia resulting in anorexia, 
nausea, vomiting and diarrhoea,85, 86 that generally reversed simultaneously with the reappearance of 
monocytes and neutrophils in the peripheral blood. The relevance that the dramatic dermatologic features 
may find parallel in the foregut, raised the anticipation of benefit accruing from blunting the graft-versus-host 
disease as part of the Campath® in-the-bag protocol therapy. This challenge clearly justified audit within the 
broad spectrum of extra haematopoietic post-transplant acute associations. 
 
Secondly, appreciating the importance of nutrition, at every level, a feasibility study was undertaken over 15 
years with two significant end points.87 The results established that 24 hour continuous fine bore naso-jejunal, 
as opposed to nasogastric placement, in any individual with absolute indication for supplementation was 
uniformly effective.  A comparison was not done between the two methods. 
 
The need for total parenteral nutrition (TPN) largely became obsolete with major cost saving and significant 
improvement in quality of life or survivorship. Additionally, major safety considerations emerged without the 
need for TPN in that vascular thromboembolism and catheter sepsis simply did not occur.88 Given the still 
largely controversial status of available publications, this authoritative statement remains a crucial 
observation impacting on world practice by demonstrating that utilising the intravenous route for total 
parenteral nutrition was virtually never necessary. 
 
Thirdly, even once these variables had been eliminated, there remained a cohort with non-resolving symptoms 
at two levels requiring further study in consultation with an experienced gastroenterologist. In one of these, 
after exhaustion of all conservative approaches, the issue deemed to be best approached by endoscopy. In the 
second, subtle residual changes in the hepatic biochemistry dictated recourse for further investigation. 
 
7.4.4.2 PATIENTS 
Between 1995 and 2010 a total of 468 consecutive individuals were transplanted. Starting in 2000 the 
multidisciplinary team routinely included expertise from gastroenterology and hepatology applicable to the 
next 265 procedures. From these 18 cases were identified that remained sufficiently problematic for 
specialised evaluation. From the combined clinic, three distinctive cohorts were separable. 
 
A domestic analysis of 89 post-transplant cases,89  characterised by mucositis with dysphagia, accompanied by 
anorexia, nausea, vomiting and diarrhoea delineated a syndrome restricted to the first three weeks after graft 
infusion. The condition very strongly stressed the central importance of optimal nutritional management and 
had two components.  The first of these was documentation that adequate caloric and all other requirements 
could be achieved, exclusively by the enteral route thereby making intravenous access unnecessary. Secondly, 
that a very high degree of patient acceptability attended continuous supplementation using fine bore naso-
jejunal in preference to naso-gastric placement. 
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There were 18 individuals in whom original symptoms did not resolve and consultation dictated recourse to 
endoscopy as a basis for further treatment. 
 
A separate cohort of 39 cases, whose dominant clinical problem on routine post-transplant surveillance was 
unexplained altered liver-function and enzyme tests, had variable outcome and therefore a need for serial 
follow-up.  
 
7.4.4.3 METHODS  
As part of protocol management any delay in delivering optimum daily nutrition necessitated placement, by 
the interventional radiologist, of a fine bore naso-jejunal – specifically not nasogastric – tube for 
supplementation. In groups two and three, persistent abnormalities in routine liver function and enzyme tests, 
which were done twice a week, called for viral serology or polymerase chain reaction to detect CMV, EBV and 
hepatitis A, B and C.  Cases with appropriate indications of diagnostic difficulty were resolved by referral to a 
gastroenterologist for upper or lower endoscopy.90,91 
 
7.4.4.4 RESULTS 
In this population the foregut syndrome occurred in 80 (90%) of patients following transplantation. This is in 
keeping with our earlier experience and that reported in the literature.85  The combination of chemotherapy 
with radiotherapy gave rise to more severe symptoms and longer duration although resolution occurred in the 
majority.92 
 
Sixty-seven (75%) of the 89 could not achieve adequate oral intake and required continuous supplementation 
with a fine bore enteral tube. Somewhat surprisingly, there was no significant difference in weight, at starting 
conditioning, from those who did, or did not, require enteral feeding. 
 
Placement of enteral tubes had high patient acceptability but were more efficient when nutritional 
supplements were delivered in the jejunum as opposed to the stomach.88,93 Importantly, maintenance of 
nutritional requirements in almost all these patients was sufficient to reserve total parenteral nutrition for 
those very rare instances where these criteria could not be achieved.94  
 
Eighteen of 89 patients (20.2%) with gastrointestinal symptoms were referred to the gastroenterology service. 
Endoscopy was needed in 10 (55%).  Two had upper GI endoscopies and three had colonoscopies alone. In 
another five combined procedures were done.  In four (40%) the procedure was normal. In the eight (44%) 
who did not have endoscopies a clinical diagnosis was made. (Table 19) 
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TABLE 19 
GASTROINTESTINAL SYMPTOMS AND FINDINGS IN PATIENTS REFERRED FOR ENDOSCOPY  
 
SYMPTOMS COLONOSCOPY GASTROSCOPY DIAGNOSIS 
Diarrhoea Normal ND IBS Infectious &Bile acid 
Diarrhoea* 
Chonic Constipation Normal Normal IBS Constipation* 
Septicaemia ND Erosive Oesophagitis   
    Haemorrhagic Gastrites   
    Bleeding Prepyloric Gastric 
ulcer 
  
Deranged LFT+ Ascites ND ND Drug induced VOD 
Septicaemic ND ND Severe Ileus – Typhlitis 
Pain & Diarrhoea Active Crohn’s Disease ND Crohns Disease 
  Right Colonic Disease     
Deranged LFT ND ND Drug induced liver injury 
Dysphagia Dyspepsia N&V   Prepyloric Gastritis Prepyloric gastritis 
Persistent Diarrhoea Infective Colitis   Infective colitis 
Deranged LFT ND ND Liver Bx-Extramedullary 
Haemopoiesis 
Nausea & Vomiting ND Mild Corpus Gastritis Gastritis 
Abdominal Pain   Haemorrhagic Gastritis + 
Erosions 
IBS Constipaton* 
Deranged LFT     Drug induced Hepatitis 
Abdominal Pain Normal Erosive Gastritis Gastritis 
Diarrhoea     Bile acid diarrhoea 
Abdominal Pain+Diarrhoea ND ND Neutropenic Ileus 
Recurrent Diarrhoea ND ND C.Difficile Colitis 
Deranged LFT ND ND Drug induced liver injury 
Ileus 
Recurrent Diarrhoea Normal ND Internal Haemorrhoids 
Rectal Bleeding       
Deranged LFT ND ND Drug induced 
Hepatotoxicity 
      CMV+ Hepatitis 
Abdominal Pain  Diarrhoea Normal Gastric erosions Gastritis 
    Haemorrhagic Gastritis   
Epigastric pain Normal Oesophageal Candida Liver Bx-Siderosis 
    Multiple Gastric ulcers + 
erosions 
Varicella 
 
*IBS – irritable bowel syndrome 
Normal – no abnormalities 
ND – not done  
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In the stomach and proximal duodenum, no malignancy was encountered. Two persons had gastric erosions 
(Figure 38a) and healing gastric ulcer (Figure 38b) present on gastroscopy. One had a pre-pyloric gastric 
ulcer. (Figure 39)  
 
FIGURE 38 
ILLUSTRATIVE GASTROSCOPY: (a) GASTRIC EROSIONS (b) HEALING GASTRIC ULCER 
 
   
(a)         (b)  
 
Courtesy of Dr Melvyn Letier 
 
FIGURE 39 
ILLUSTRATIVE  GASTROSCOPY: PRE-PYLORIC GASTRIC ULCER 
 
 
 
Courtesy of Dr Melvyn Letier 
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A single individual had viral inclusion bodies with oesophageal candida, (Figure 40a) varicella 
gastroenteritis (Figure 40b) and a varicella superficial gastric ulcer. (Figure 40c)  The virus was confirmed 
on biopsy and responded to conventional conservative therapy. 
 
 
FIGURE 40 
GASTROSCOPY AND COLONOSCOPY: MULTIPLE GASTRIC ULCERS, EROSIONS-SUBSEQUENTLY 
ATTIBUTED TO VARICELLA ZOSTER 
 
 
(a)       (b)  
       
 
                           (c) 
 
Courtesy of Dr Melvyn Letier 
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In the large bowel there was one instance of active Crohn's disease which was proven on biopsy seen at the 
ileocaecal junction with ulceration, oedema and narrowing (Figure 41) and one of infective colitis.  In the 
remainder no additional information was obtained from these procedures. 
 
FIGURE 41 
COLONOSCOPY DEMONSTRATING ACTIVE CROHN’S DISEASE 
 
       
 
Courtesy of Dr Melvyn Letier 
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In the separate cohort of 39 individuals, seven died of an unknown cause in the first three weeks. This was 
clinically ascribed to sepsis.95 Tabulated data over a 12 week period is presented for bilirubin, alanine 
aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT). Corresponding data which was available 
for albumin, lactic dehydrogenase (LDH), Aspartate aminotransferase (AST) and alkaline phosphatase added 
little to disentangling these liver enzyme and function studies. Variations in the number of observations 
recorded during this four-week period do not represent loss of patients but non-attendance at the clinic due to 
personal preference for scheduling. 
 
The highest level of bilirubin noted in any patient was 385 at week six (he had pseudomonas infection). Of the 
39 patients, 23 (59%) remained normal and in 16 (41%) abnormal enzymes were present. Seven (44%) of these 
reversed to normal by week 12 and in only nine (56%) did this fail to reverse. (Table 20) The highest median 
ALT elevation of 51.5 was present at week three and the highest level of 683 was seen in a subject with sepsis, 
who had received antibiotics and had been hypotensive raising the possibility of hypoxic-ischaemia. Of the 39 
patients, 12 (31%) remained normal and of the 27 (69%) with abnormal enzymes 15 (56%) reversed and 12 
(44%) did not by three months. Drug induced as well as septic aetiologies all contributed to the liver 
dysfunction. (Table 21) The GGT had the highest median of 195.5 at week two and the highest GGT level was 
735 in a patient with likely multifactorial liver insult.  Here only 9 (23%) of the 39 patients remained normal 
with 30 (77%) being abnormal. Of these 17 (57%) reversed by week 12 and 13 (43%) did not. (Table 22) Of the 
39 individuals with abnormal LFT 9 – 12 patients (23-30%) in terms of bilirubin, ALT and GGT levels, did not 
revert to normal at three months. 
 
 
TABLE 20 
LIVER FUNCTION – SEQUENTIAL BILIRUBIN LEVELS DURING FIRST TWELVE WEEKS POST 
TRANSPLANT 
Bilirubin 
μmol/L 
Obs 
N 
Median 
μmol/L 
IQR 
μmol/L 
Range 
2 to 20 μmol/L 
Pre 37 10 9 - 14 2 to 28 
Tx 38 14 11 -18 6 to 43 
Week 1 39 15 12 - 24 6 to 70 
Week 2 38 11.5 8 - 19 5 to 65 
Week 3 33 13 11 - 24 4 to 101 
Week 4 27 15 11 - 19 9 to 85 
Week 5 29 17 12 - 23 6 to 132 
Week 6 21 17 13 - 26 7 to 385 
Week 7 22 16.5 13 - 29 7 to 184 
Week 8 20 17 13.5 - 29 11 to 78 
Week 9 20 23 12.5 – 37.5 7 to 164 
Week 10 16 18.5 11 - 38 6 to 123 
Week 11 13 20 11 - 28 8 to 48 
Week 12 16 17.5 11 - 25 8 to 59 
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TABLE 21 
LIVER ENZYME –SEQUENTIAL  ALT DURING FIRST THREE MONTHS POST TRANSPLANT 
ALT 
U/L 
Obs 
N 
Median 
U/L 
IQR 
U/L 
Range 
10 to 40 U/L 
Pre 37 24 17 - 38 8 to 80 
Tx 38 29.5 22 - 46 9  to 131 
Week 1 39 39 26 - 61 13 to 336 
Week 2 38 44 27 - 75 8 to 257 
Week 3 34 51.5 26 - 74 7 to 275 
Week 4 26 49.5 29 - 100 14 to 287 
Week 5 30 39.5 21 - 66 16 to 397 
Week 6 22 32 22 - 42 10 to 168 
Week 7 21 30 21 - 65 8 to 178 
Week 8 22 24.5 20 - 32 14 to 189 
Week 9 19 22 17 - 33 13 to 683 
Week 10 16 24.5 18 - 36 7 to 66 
Week 11 13 33 29 - 45 14 to 77 
Week 12 16 27.5 24 - 42 17 to 70 
 
 
 
TABLE 22 
LIVER ENZYME –SEQUENTIAL  GGT MEASUREMENTS IN THE FIRST 100 DAYS POST TRANSPLANT 
GGT 
U/L 
Obs 
N 
Median 
U/L 
IQR 
U/L 
Range 
5 to 50 U/L 
Pre 37 36 25 - 54 11 to 387 
Tx 38 68 35 - 136 14 to 694 
Week 1 39 177 76 - 294 21 to 667 
Week 2 38 195.5 105 - 326 34 to 612 
Week 3 33 115 57 - 225 14 to 661 
Week 4 27 100 56 - 163 30 to 735 
Week 5 29 75 39 - 175 22 to 416 
Week 6 21 57 38 - 142 19 to 288 
Week 7 22 74.5 41 - 144 15 to 336 
Week 8 21 56 27 - 113 18 to 323 
Week 9 19 64 22 - 123 14 to 357 
Week 10 16 79 26.5 – 116.5 14 to 336 
Week 11 13 94 26 - 157 16 to 281 
Week 12 16 46.5 24.5 – 117.5 11 to 258 
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7.4.4.5 DISCUSSION 
Gastrointestinal complications following bone marrow transplantation are common and referral rates for 
gastroenterology consultation (GEC) vary widely in different series. Symptoms are fairly uniform and reflected 
in our experience – persistent nausea and vomiting, abdominal pain, dysphagia and odynophagia, diarrhoea 
and gastrointestinal bleeding. Gastrointestinal (GI) bleeding occurred in our population to a lesser degree 
than reported, perhaps due to routine proton pump inhibitor (PPI) prophylaxis.96 Graft-versus-host disease 
(GVHD) which was a cause of diarrhoea in the early transplant phase, was not seen at all in this cohort, largely 
as a result of a specific preconditioning regimen. Of the total 468 patients that underwent BMT, 89 (19%) had 
gastrointestinal tract (GIT) symptoms and 18 (20.2%) of these were referred for gastroenterology consultation.  
 
Endoscopy was performed in only 6 patients referred for GIT evaluation, since the relatively fragile nature of 
the post-transplant mucosa increases the risk of endoscopic complications such as tears and perforation. In 
some publications, fatal endoscopic complication rates of up to 1.8% (much higher than in the 
immunocompetent patient rates of 0.01 to 0.5%) have been reported.85  Two deaths occurred and were 
ascribed to septicaemia and subsequent multi-organ failure unrelated to the GI pathology. In only two patients 
(11%) referred, one with Crohn’s disease and another with oesophageal candidiasis and varicella 
gastroenteritis, did endoscopy make a profound impact on medical management. In a study of 197 patients 
post BMT a 40% GEC rate was seen with acute GVHD (46%), gastrointestinal bleeding (25%), dysphagia/ 
odynophagia (20%), vomiting (29%), diarrhoea (36%) and abdominal pain (13%) being the presenting 
complaints.85  
 
An analysis done showed that in 77% of GEC referrals, a definitive diagnosis was reached and  management 
effected in 54%  of cases.85  In our significantly larger cohort, the impact of GEC was similar with a change in 
management in nine (50%) of subjects even though the referral rate was much lower than the published 
data.85 
 
Liver function and enzyme derangement post BMT is relatively common and the levels of abnormality in our 
series were quite mild and did not suggest a specific pattern of injury. It could likely be ascribed to a 
combination of sepsis, chemotherapy and other drug (antibiotics, etc.) induced hepatotoxicity.97 In our study, 
it proved difficult to conclusively ascribe liver dysfunction to drug induced liver injury (DILI), but in the face 
of a chemotherapeutic conditioning regimen as well as extensive broad spectrum antibiotic therapy and 
antifungal use for neutropenic fever, it is reasonable to assume that these drugs were responsible.98  
 
No liver biopsies were performed due to bleeding risk and recovery of the abnormalities within a reasonable 
period occurred after discontinuation of treatment with potential offending drugs.  
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 157 
All liver function (LFT) and enzyme tests were documented but monitoring was centred around bilirubin, ALT 
(representing transaminitis) and GGT (representing cannalicular liver damage). It is well known that the bile 
transporter “knockout” effect is the primary cause of rapidly escalating bilirubin in septic patients. GVHD is a 
well described potential source of liver dysfunction99 but this complication was not observed in any of the 
patients as a result of a specific Campath® T cell depleted conditioning programme. All patients with liver 
function derangement were routinely screened for viral infections, including Hepatitis A, B and C, CMV, EBV 
and Herpes Simplex viruses. Only one patient was found to have a proven varicella zoster infection.  Veno-
occlusive disease (VOD) was always considered but usually additional signs except elevated LFT and liver 
enzymes would be present. 
 
7.4.4.6 CONCLUDING SUMMARY  
The large area of the gastrointestinal tract and exposure to environmental antigens has parallels to the skin 
and the lung and, in each, short-term or acute associations feature prominently but reverse with myeloid 
regeneration. In the bowel there remains a subset of patients in whom the lesion extends beyond the first few 
weeks and necessitates access to specialised investigations including experienced gastroenterology 
consultation and endoscopy with appropriate biopsy. These non-haematopoietic complications are relatively 
heterogenous, most have a viral aetiology and with accurate diagnosis, resolve with appropriate treatment. In 
this series no particular pattern occurred or could be attributed to anything specific including retroviral 
infection or in consequence of the Campath® conditioning programme. In this way, the complications do not 
differ in a significant way from experience in the literature.100 
 
7.5 LATE EFFECTS - BEYOND ONE YEAR  
Increasing the number of transplants successfully performed annually, and the improvement in outcome, 
remains cure of the primary disease but shifting to survivorship with the expectation of recipients to recover 
normal health whether this be physical and psychological or social. As a generalisation a number of variables 
contributed to changing the pattern of clinical manifestations. These included decreasing use of total body 
irradiation, increasing age of patients and more frequent employment of volunteer donors altering the 
expression of acute and chronic graft-versus-host disease with nuances between benign and malignant 
primary disorders.101 
 
7.5.1 PULMONOLOGY 
7.5.1.1 INTRODUCTION 
From the earliest days of our embarking on these life-saving interventions, two quite different patterns of 
outcome were noted. This was in keeping with experience in other centres. Firstly  there were acute infectious 
episodes correlating with neutropenia and having a universally high morbidity and mortality.101 Reported lung 
complications developed in parenchyma between 25 and 60% of recipients and account for approximately half 
of transplant related deaths.102-104 These observations were not dissimilar to previous reports from our 
team.36 With advances in antimicrobial therapy there has been a distinct shift in focus to defining late onset 
non-infectious pulmonary side effects since these still remain potentially life-threatening.103,105 Many of these 
are related to viral infections106 but not readily distinguished from acute and chronic graft-versus-host 
disease. At issue is whether the increased risk in our patients on the Campath® in-the-bag program for viral 
infections is offset by the reduction in the two subtypes of GVHD. 
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To bring clarity to this issue, these phenomena (GVHD and viral infections) were investigated in our specific 
setting. In the earlier study of the 78 consecutive patients with sufficient data on 48, none of the 
measurements used proved to have a predictive role for subsequent complications 35,36 In an extension of 
those two earlier investigations, this doctoral study included closer examination of the larger cohort of 
patients. In some cases direct comparison was possible. However, the benefits of function studies in a research 
setting now added additional expertise imparted by interaction with highly experienced technologists and 
pulmonologists. 
 
7.5.1.2 PATIENTS 
The starting base was a total of 468 patients transplanted between 1995 and 2010 and from these, 55 
volunteers were available for this investigation.  
 
Included were 19 cases from the previous pulmonology studies enabling analysis between pre and post-
transplant changes over time to be carried out directly. Chest x-rays were performed on 45 individuals because 
ten of the cohort studied were unable to attend for this procedure. 
 
7.5.1.3 METHODS  
These procedures are all established, calibrated and are detailed in the above section on special investigations 
and each was appropriately referenced in point 7.3.3. The European Community of Coal and Steel Workers 
Programme (ECCS) was used to establish the values or percentage prediction as this is the most widely used 
and validated. This is the actual value compared to predicted based on age, height, gender and race.107  The 
tests were all done on  the Jaeger Masterlab Version 5.32.0 from Carefusion according to the American 
Thoracic Society/ European Respiratory Society (ATS/ERS)  guidelines 2005. The standard spirometry “flow-
volume- Loop” was performed to determine the FVC, FEV1, FEV1/ FVC.  For the diffusion parameters, the 
“single breath carbon monoxide” test and plethysmography for TLC were done.  Chest x-rays posterior, 
anterior (PA) and lateral views were done using the conventional procedure.108   Format for reporting was set 
out in point 7.3.4.2. 
 
7.5.1.4 RESULTS 
From the 468 consecutive patients comprising the audit database, 48 were categorised as early associations 
and a further 20 met the criteria for late effects with only one survivor in each.  The early complications, 
occurring before day 100, were mostly related to sepsis while the majority of late effects were also infectious 
and most probably due (not confirmed) to a compromised immune system. (Table 23) 
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TABLE 23 
RESPIRATORY: EARLY ASSOCIATIONS SEPERATED FROM LATE EFFECTS – AUDIT DATA 
 
 
 
(CMV) Cytomegalovirus 
(LONIP) Late onset non-infectious pulmonary complications  
(BOOP) Bronchiolitis obliterans with organising pneumonia 
 
In the cohort comprising the study done on surviving volunteers (n = 55), all the lung function studies were 
within the predicted normal range apart from some marginal reduction in diffusing capacity.  It was not 
regarded as being of significance. (Table 24) 
 
TABLE 24 
SPIROMETRIC DATA AND DIFFUSING CAPACITY IN THE 55 POST-TRANSPLANT PATIENTS 
 Median IQR Obs Range 
%FVC 108.9 96.1 – 114.4 55 67.3 to 138.3 
%FEV1 100.6 88.6 – 109.5 55 43.5 to 135.2 
%TLC 102.2 89.7 – 113.9 55 51.8 to 131.3 
%TLCO* 73.9 64.5 – 81.5 45 52.2 to 118.8 
*10 patients were excluded from TLCO because of technical problems. 
 
EARLY ASSOCIATION     n = 48 
17 CMV Pneumonitis 
11 Bacterial Pneumonia 
12 Septicaemia 
7 Multiple Organ Failure 
1 Miscellaneous 
LATE EFFECTS   n = 20 
Infections 
2 Fungal 
9 Bacterial and Multiple Organ Failure 
1 Viral 
1 Protozoa 
1 Tuberculosis 
 
LONIP109 
4 BOOP 
 
Miscellaneous 
2 Carcinoma 
n = 468 
Audit 
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Furthermore, of this group, 19 (34%) were available from the previous study making direct comparison 
available between the two time periods in the same individuals. Here the values are seen to be matched apart 
from diffusing capacity where a statistically significant (p=0.0004) improvement was noted over 10 years. 
(Table 25) It could be postulated that the pre TLCO was low because it was done immediately after 
chemotherapy for treatment of their disease. At the time when it was repeated, some of the patients were 10 
years post transplant and completely well. Lung function studies were compared by type of transplant and 
showed no significant difference and were normal in all spirometry and diffusing capacity. (Table 26) 
Similarly, when analysed by disease category comparing myeloid to lymphoid lineages, there was no 
significant difference with all parameters within normal limits. (Table 27) Similarly, comparison between the 
different conditioning regimens was without any significant effect. (Table 28) Chest x-ray (CXR) results were 
normal in 44 with slight abnormality in one person who was investigated for tuberculosis but not found to be 
infected. 
 
TABLE 25 
SPIROMETRIC DATA AND DIFFUSING CAPACITY FOR 19 PATIENTS PRE AND POST-TRANSPLANT 
  Obs Median IQR Range 
Pre %FVC 19 107 93 – 133.3 86.0 to 126.1 
Post %FVC 19 108.9 103.2 – 114.3 67.3 to 133.7 
Pre %FEV1 19 103.8 90.7 – 112.6 61.8 to 126.1 
Post %FEV1 19 101.2 95.9 – 111.3 43.5 to 123.9 
Pre %TLC 18 95 87.7 - 104 77.6 to 136.9 
Post %TLC 19 102.2 94.3 – 113.3 82.3 to 131.3 
Pre %TLCO 18 63.8 52 – 71.4 42.8 to 87.4 
Post%TLCO 15 76 70.8 – 84.9 57.2 to 95.0 
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TABLE 26 
SPIROMETRY AND DIFFUSING CAPACITY ASSESSMENT FOR ALLOGENEIC, AUTOGRAFTS AND 
MATCHED UNRELATED TRANSPLANTS 
% FVC Obs Median IQR Range 
ALLO 15 112.6 100.3 – 124.6 72.7 to 138.3 
AUTO 23 108.9 91.7 – 113.4 76.1 to 133.7 
MUD 17 106.3 99 – 112.6 67.8 to 127.4 
 
% FEV1 Obs Median IQR Range 
ALLO 15 108.3 101.2 – 112.1 72.0 to 126.5 
AUTO 23 93.6 86.6 – 106.9 74.5 to 135.2 
MUD 17 98.3 91.3 – 106.8 43.5 to 115.9 
 
% TLC Obs Median IQR Range 
ALLO 15 102.2 94.3 – 115.8 51.8 to 131.1 
AUTO 23 104.1 89.5 – 113.3 64.5 to 124.2 
MUD 17 100.4 92.1 – 110.8 80.5 to 131.3 
 
% TLCO Obs Median IQR Range 
ALLO 10 80.7 67.8 – 93.5 53.1 to 118.8 
AUTO 20 74.1 66.05 - 79 58.5 to 102.5 
MUD 15 72.5 61.5 - 81 52.2 to 95.0 
 
 
 
TABLE 27 
SPIROMETRY AND DIFFUSING CAPACITY ASSESSMENT FRACTIONATED FOR MYELOID AND 
LYMPHOID PRE-TRANSPLANT MALIGNANCIES  
  
%FVC Obs Median IQR Range 
Lymphoid 22 108.2 91.7 – 113.4 75.9 to 133.7 
Myeloid 32  109.05 100.3 – 118.5 67.3 to 138.3 
 
%FEV1 Obs Median IQR Range 
Lymphoid 22 92.65 84.8 – 106.2 54.7 to 123.9 
Myeloid 32 103.5 95.65 – 110.35 43.5 to 135.2 
 
%TLC Obs Median IQR Range 
Lymphoid 22 99.05 88.5 – 112.7 64.5 to 124.2 
Myeloid 32 102.65 92.2 – 116.15 51.8 to 131.3 
 
%TLCO Obs Median IQR Range 
Lymphoid 19 73.5 68.6 – 81.5 58.5 to 102.5 
Myeloid 25 74.1 64.1 – 83.8 53.1 to 118.8 
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TABLE 28 
TYPE OF CONDITIONING: CHEMOTHERAPY VS CHEMOTHERAPY PLUS RADIOTHERAPY AND THE 
EFFECT ON SPIROMETRIC VARIABLES 
 
 Obs Median IQR Range 
Chem %FVC 30 110 96.8 – 115.7 72.7 to 138.3 
ChemRad %FVC 25 106.3 96.1 – 112.6 67.3 to 127.8 
Chem %FEV1 30 96.65 88.3 – 110.9 54.7 to 126.5 
ChemRad %FEV1 25 102.6 91.7 – 108.3 43.5 to 135.2 
Chem %TLC 30 108.3 89.7 – 116.4 51.8 to 131.1 
ChemRad %TLC 25 99.5 91.3 – 109.4 69.3 to 131.3 
Chem %TLCO 24 74.5 64.05 – 82.65 53.1 to 118.8 
ChemRad %TLCO 21 72.5 67.8 - 81 52.2 to 95.0 
 
 
 
7.5.1.5 DISCUSSION 
The entire group remained asymptomatic although a single individual had abnormal radiology showing bi-
basal subsegmental atelectasis and bilateral pleural effusions despite nothing being found clinically or on 
sputum microscopy.  
 
In this research setting results were uniformly normal except for a marginal reduction demonstrated 
exclusively in the diffusion capacity determined by predicted normal values.  
 
7.5.1.6 CONCLUDING SUMMARY 
In contrast to the acute complications, chronic or inflammatory syndromes encompass a wide range of non-
infectious entities that are insidious in onset and progress silently over long periods of time.109 The most 
common of these is bronchiolitis obliterans with organising pneumonia (BOOP)110 with insidious onset over 
12 months accompanied by dry cough, progressive dyspnoea and wheezing. Initially obstruction results from 
deposits of fibrous tissue around the bronchus adding restrictive change. The incidence varies widely and 
appears to be associated with chronic graft-versus-host disease.111 It occurs more commonly with peripheral 
blood as compared to marrow cell grafts source112 although other risk factors include methotrexate, age, 
radiotherapy and a number of respiratory viral infections.113 A variant known as cryptogenic organising 
pneumonia (COP)101 also associated with a non-productive cough, shortness of breath and fever involving 
bronchioles, alveolar ducts and the alveoli themselves becoming filled with granulation tissue. Causes have 
been ascribed to infections, drugs and radiotherapy. 
 
Thirdly, the idiopathic pneumonia syndrome is more non-specific, encountered earlier in the post-transplant 
course with the closest relationship being to total or whole-body irradiation and severe chronic graft-versus-
host disease, typically the sclerodermatous cutaneous subtype.114 The absence of these late effects in this 
cohort may be related to the conditioning regimen and very particularly absence of acute and chronic graft-
versus-host disease. No respiratory data is available for comparison with the research subjects (n=55). It 
appears that they have an improved outcome and better clinical post-transplant course. The latter seems to be 
as a result of addition of Campath® 1H in-the-bag leading to less GVHD and therefore respiratory 
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complications are reduced. Although these were long term survivors, they were still prone to develop late 
complications of the respiratory system. Cytomegalovirus reactivation occurred frequently as with other 
centres using Campath®.115 The patients showing positive PCR’s for CMV were treated early preventing 
development of pneumonitis.115  An earlier study showed that pulmonary side-effects occurred in 30-50% of 
patients with unmanipulated graft and 16.5% in those where CD 52+ antibody was  used as conditioning.116 
 
 
7.5.2 IMMUNOLOGY 
7.5.2.1 INTRODUCTION 
It is a long accepted generalisation that underlying disease, primary chemotherapy, conditioning and various 
forms of immunosuppression combine to leave the post-transplant recipient at risk for severe morbidity and 
potential mortality. Reasons include disease relapse, infections of varying severity from a wide range of 
environmental pathogens and autoimmune disorders, particularly ominous being acute and chronic graft-
versus-host disease.117 As part of this view are statements that global immune reconstitution is delayed and, 
when more incisively expressed for functional recovery, is slow and often incomplete. The innate mechanism 
reconstitutes quickly whereas adaptive B and especially T-cell lymphopoiesis may be compromised for 
years118, 119. Experience with our patients to disentangle relative contributions in the lymphocyte sublineages 
was precluded primarily for financial reasons.  
 
With this limitation overcome, the opportunity was taken to  study, with informed consent and ethics 
approval, both innate and adaptive in vitro immune responses with special emphasis on how this may differ 
from findings in a first world environment less encumbered by viral infections. Additionally, and a special 
impact, changes that might reflect the quite different immunosuppressive conditioning used in this cohort 
with Campath® immunoglobulins in-the-bag49 rather than in vivo. Also in contrast to conventional 
chemotherapy combined with corticosteroids our population received only monoclonal antibodies known to 
exert a more generalised effect on cells of the immune system.  
 
7.5.2.2 PATIENTS 
Fifty five volunteers were entered into this study.  
 
7.5.2.3 METHODS 
The immune parameters evaluated included both the innate120 as well as adaptive pathways.121 For the innate 
segment, the in vitro response of the granulocytes to stimuli was defined in the so-called Burst-test.122  This 
assay measures the ability of the granulocytes to generate oxygen radicals when stimulated with opsonized E 
coli bacteria (considered as being physiological), fMLP123 (a chemotactic factor representing a sub-optimal 
stimulus) and the positive driver, namely phorbol-myristate acetate (PMA), a potent Protein Kinase C 
activator.124   
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These outcomes were measured by flow cytometry using a commercial kit (PhagoBurst, Becton Dickinson) 
where the generation of the oxygen radical is visualized using a dye which fluoresces in the presence of the O2- 
radical. For comparative purposes, the manufacturer of the kit provides ranges for E Coli normal expected 
responses when using blood samples from healthy subjects.  These are as follows: 
 
 WASH E. Coli fMLP PMA 
Normal PhagoBurst Results 1-20% 95-100% 1-20% 99-100% 
 
 
In parallel, the adaptive immune response was evaluated in vitro by determining the ability of T cells subsets 
(CD4+ or CD8+ cells) to generate cytokines once activated using PMA.125 Two types of cytokines were 
measured, IFN- (a potent TH 1 cytokine able to activate the cellular arm of immunity) and IL 4, the counter-
balancing TH 2 derived cytokine (able to drive a more humoral response). These cytokines were determined 
by making use of specific monoclonal antibodies detecting the intra-cellular cytokines of the surface labeled 
cells (CD4 or CD8 specific markers) following permeabilisation in order to allow the penetration of the 
antibodies into the cells.  Multi-parameter flow cytometry was used for the analysis.126 
 
Although normal ranges are not available, scientific literature suggests that cells from healthy controls, once 
activated in vitro, should display a response at least double that of unstimulated cells.  For instance, when the 
CD4+ T cells are activated in vitro, their IFN-   production should be at least 2-3 times that produced when 
the cells are not activated.  Similarly, the IL4 output should be 2-3 times compared to the non-activated cells.  
For ease of comparison between subjects, the ratio of TH1: Th2 cells in each subject was calculated and 
tabulated. 
 
The flow cytometer (FACSCalibur, Becton Dickinson) was calibrated daily using Autocomp beads to ensure the 
correct alignment of the laser and also to optimize the compensation of the different fluorochromes to ensure 
minimal spectral overlap. 
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7.5.2.4 RESULTS 
The data set generated was analysed separately according to several subsets: type of transplant, date (age) of 
transplant, disease category at diagnosis and pre-transplant conditioning administered. 
 
Innate immune response profiling 
When the data was tabulated according to the type of transplant, it appeared that the autografts showed more 
“intact” responses in vitro to the physiological stimulus E.Coli when compared to the other types of transplant 
conducted: autografts (median 56.68% versus 34.44% and 42.88% for allo- and matched unrelated grafts 
respectively). This was the most normal reaction, albeit reduced, when compared to the expected normal 
ranges. (Tables 29, 29a, 29b) 
 
 
TABLE 29 
GRANULOCYTE BURST-TEST ACCORDING TO TYPE OF TRANSPLANT (ALLOGRAFT) 
 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
A
L
L
O
T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 (
A
L
L
O
G
R
A
F
T
) 
 WH   2125 9.23% 19.50% 59.69% 64.39% 
WH   2246 1.88% 31.05% 15.58% 37.68% 
WH   2138 3.45% 56.01% 4.25% 40.07% 
WH   2321 1.89% 34.44% 2.25% 25.89% 
WH   2342 0.69% 39.44% 0.79% 31.50% 
WH   9821 0.66% 23.29% 28.50% 47.53% 
WH   2258 44.73% 37.38% 31.72% 33.11% 
WH   2350 4.93% 55.15% 4.98% 50.90% 
WH   2259 2.08% 36.54% 2.28% 12.90% 
WH   2330 10.20% 60.00% 11.40% 41.40% 
WH   9814 1.32% 69.66% 2.19% 40.63% 
WH   2359 12.45% 12.27% 8.69% 13.37% 
WH   2361 3.00% 2.99% 5.86% 6.99% 
WH   2284 3.90% 3.87% 2.83% 3.16% 
WH   9717 0.70% 1.15% 0.76% 0.68% 
Median 3% 34.44% 4.98% 33.11% 
 Maximum 44.73% 69.66% 59.69% 64.39% 
 Minimum 0.66% 1.15% 0.76% 0.68% 
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TABLE 29a 
GRANULOCYTE BURST-TEST ACCORDING TO TYPE OF TRANSPLANT (AUTOGRAFT) 
 
BURST 
Type  Subjects Wash E.Coli fMLP PMA 
A
U
T
O
T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 (
A
U
T
O
G
R
A
F
T
) 
WHA    9715 3.13% 60.70% 4.41% 51.56% 
WHA    9908 1.86% 61.09% 3.85% 55.55% 
WH       9720 3.71% 58.44% 4.52% 42.55% 
U           2056 0.36% 58.35% 1.47% 49.90% 
U           2044 2.97% 35.64% 5.25% 32.16% 
WH       9704 2.13% 60.31% 2.35% 53.18% 
WHA    9809 1.61% 43.39% 3.24% 34.61% 
U           2065 2.85% 56.68% 2.71% 54.29% 
WHA    2061 3.48% 22.72% 0.49% 44.02% 
WHA    9716 2.62% 9.15% 3.78% 9.58% 
WHA    9909 1.29% 51.96% 2.00% 40.74% 
WHA    9810 6.00% 54.50% 3.50% 61.20% 
U           2046 7.00% 99.80% 9.50% 99.90% 
WHA    9823 2.70% 93.70% 9.60% 95.10% 
U           2037 6.10% 18.10% 6.60% 26.70% 
WHA    9829 10.10% 25.10% 11.60% 29.50% 
WHA    9825 13.30% 44.90% 21.50% 36.50% 
U           2023 10.40% 63.90% 21.10% 34.80% 
WHA    2062 6.38% 14.52% 10.59% 51.97% 
U           2054 46.33% 40.47% 39.72% 49.55% 
U           2047 47.30% 62.43% 36.55% 45.33% 
WHA    2067 46.19% 61.36% 39.98% 44.06% 
WHA    9718 5.60% 57.60% 10.40% 57.90% 
Median 3.71% 56.68% 5.25% 45.33% 
Maximum 47.30% 99.80% 39.98% 99.90% 
Minimum 0.36% 9.15% 0.49% 9.58% 
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TABLE 29b 
GRANULOCYTE BURST-TEST ACCORDING TO TYPE OF TRANSPLANT (MUD) 
 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
M
A
T
C
H
E
D
 U
N
R
E
L
A
T
E
D
 D
O
N
O
R
  
T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 
WH   2263 1.71% 31.01% 2.47% 42.63% 
WH   2343 1.90% 68.54% 1.85% 66.18% 
WH   2309 2.27% 32.63% 2.67% 27.37% 
WH   2280 2.29% 73.21% 3.28% 68.60% 
WH   2277 1.26% 61.15% 2.79% 31.16% 
WH   2256 5.99% 22.09% 7.18% 54.93% 
WH   2101 7.29% 10.44% 1.33% 8.98% 
WH   2128 6.06% 12.46% 6.12% 13.44% 
WH   2293 10.16% 18.12% 9.07% 13.68% 
WH   2305 9.30% 39.20% 6.90% 37.30% 
U       9704 5.60% 49.60% 5.00% 53.90% 
WH   2347 13.50% 42.80% 25.10% 48.20% 
WH   2288 4.60% 99.50% 12.80% 99.80% 
WH   2253 3.30% 14.00% 11.00% 40.80% 
WH   2311 3.80% 72.50% 11.30% 73.50% 
WH   2268 6.60% 55.50% 5.60% 62.10% 
WH 2285 6.00% 52.60% 9.00% 63.50% 
Median 5.60% 42.80% 6.12% 48.20% 
Maximum 13.50% 99.50% 25.10% 99.80% 
Minimum 1.26% 10.44% 1.33% 8.98% 
 
 
Arbitrary times were allocated to determine whether the time from transplantation to recruitment for testing 
had any effects on the parameters measured.  It was decided to regroup the data as recent transplants (0-5 
years), intermediate (6-10 years) and older transplants (>10 years). Once again, the in vitro innate immune 
response was determined according to these groupings. 
 
Interestingly, it appears that those patients that were transplanted the longest (>10 years) displayed the more 
“intact” profile in vitro in that their reaction was shown to be most normal to E.Coli  stimulation: median 
58.02% when compared to 37.38% and 46.20% for intermediate and recent transplants respectively.  This was 
however reduced according to normal ranges provided by the manufacturer of the kit. (Tables 30,30a,30b) 
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TABLE 30 
GRANULOCYTE BURST-TEST ACCORDING TO PERIOD POST TRANSPLANT (0-5 YRS) 
 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
Y
E
A
R
S
 A
B
O
V
E
 2
0
0
3
 (
0
-5
 Y
E
A
R
S
) 
WH    2263 1.71% 31.01% 2.47% 42.63% 
WH    2343 1.90% 68.54% 1.85% 66.18% 
WH    2309 2.27% 32.63% 2.67% 27.37% 
WH    2321 1.89% 34.44% 2.25% 25.89% 
WH    2342 0.69% 39.44% 0.79% 31.50% 
WH    2280 2.29% 73.21% 3.28% 68.60% 
WH    2277 1.26% 61.15% 2.79% 31.16% 
U        2056 0.36% 58.35% 1.47% 49.90% 
U        2044 2.97% 35.64% 5.25% 32.16% 
WH    2350 4.93% 55.15% 4.98% 50.90% 
U        2065 2.85% 56.68% 2.71% 54.29% 
WHA 2061 3.48% 22.72% 0.49% 44.02% 
WH    2330 10.20% 60.00% 11.40% 41.40% 
U        2046 7.00% 99.80% 9.50% 99.90% 
WH    2293 10.16% 18.12% 9.07% 13.68% 
U        2037 6.10% 18.10% 6.60% 26.70% 
WH    2305 9.30% 39.20% 6.90% 37.30% 
U        9704 5.60% 49.60% 5.00% 53.90% 
WH    2347 13.50% 42.80% 25.10% 48.20% 
U        2032 10.40% 63.90% 21.10% 34.80% 
WH    2288 4.60% 99.50% 12.80% 99.80% 
WH    2311 3.80% 72.50% 11.30% 73.50% 
WHA 2062 6.38% 14.52% 10.59% 51.97% 
WH    2359 12.45% 12.27% 8.69% 13.37% 
U        2054 46.33% 40.47% 39.72% 49.55% 
U        2047 47.30% 62.43% 36.55% 45.33% 
WH    2361 3.00% 2.99% 5.86% 6.99% 
WH     2284 3.90% 3.87% 2.83% 3.16% 
WHA 2067 46.19% 61.36% 39.98% 44.06% 
WH    2285 6.00% 52.60% 9.00% 63.50% 
Median 4.77% 46.20% 2.36% 44.04% 
Maximum 47.30% 99.80% 39.98% 99.90% 
Minimum 0.36% 2.99% 0.49% 3.16% 
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TABLE 30a 
GRANULOCYTE BURST-TEST ACCORDING TO PERIOD POST TRANSPLANT (6-10YRS) 
 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
1
9
9
8
 -
 2
0
0
2
 (
6
 -
 1
0
 Y
E
A
R
S
) 
 
WH   2155 9.23% 19.50% 59.69% 64.39% 
WH   2246 1.88% 31.05% 15.58% 37.68% 
WH   2138 3.45% 56.01% 4.25% 40.07% 
WHA 9908 1.86% 61.09% 3.85% 55.55% 
WH    9821 0.66% 23.29% 28.50% 47.53% 
WH    2258 44.73% 37.38% 31.72% 33.11% 
WHA 9809 1.61% 43.39% 3.24% 34.61% 
WH    2259 2.08% 36.54% 2.28% 12.90% 
WH    2256 5.99% 22.09% 7.18% 54.93% 
WH    2101 7.29% 10.44% 1.33% 8.98% 
WH    9814 1.32% 69.66% 2.19% 40.63% 
WHA 9909 1.29% 51.96% 2.00% 40.74% 
WHA 9810 6.00% 54.50% 3.50% 61.20% 
WH    2128 6.06% 12.46% 6.12% 13.44% 
WHA 9823 2.70% 93.70% 9.60% 95.10% 
WHA 9829 10.10% 25.10% 11.60% 29.50% 
WHA 9825 13.30% 44.90% 21.50% 36.50% 
WH    2253 3.30% 14.00% 11.00% 40.80% 
WH    2268 6.60% 55.50% 5.60% 62.10% 
Median 3.45% 37.38% 6.12% 40.63% 
Maximum 44.73% 93.70% 59.69% 95.10% 
Minimum 0.66% 10.44% 1.33% 8.98% 
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TABLE 30b 
GRANULOCYTE BURST-TEST ACCORDING TO PERIOD POST TRANSPLANT (>10YRS) 
 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
Y
e
a
r
s
 B
e
fo
r
e
 1
9
9
7
 (
>
1
0
 Y
e
a
r
s
) WHA 9715 3.13% 60.70% 4.41% 51.56% 
WH   9720 3.71% 58.44% 4.52% 42.55% 
WH   9704 2.13% 60.31% 2.35% 53.18% 
WHA 9716 2.62% 9.15% 3.78% 9.58% 
WH    9717 0.70% 1.15% 0.76% 0.68% 
WHA 9718 5.60% 57.60% 10.40% 57.90% 
Median 2.88% 58.02% 4.10% 47.06% 
Maximum 5.60% 60.70% 10.40% 57.90% 
Minimum 0.70% 1.15% 0.76% 0.68% 
 
 
The data was analysed according to myeloid and lymphoid lineages at the time of the diagnosis: both these 
groups had abnormal responses in vitro when compared to expected healthy controls as per kit insert. 
However the lymphoid group displayed better responses in comparison with the myeloid neoplasms where it 
was severely decreased: 57.14% versus 36.54% for lymphoid and myeloid respectively.   This is possibly related 
to the fact that the myeloid lineage was affected originally and although the peripheral elements normalize 
with time, their functional potential never seems to fully recover. (Tables 31, 31a) 
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TABLE 31 
GRANULOCYTE BURST-TEST ACCORDING TO DIAGNOSTIC LINEAGE (MYELOID) 
 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
M
Y
E
L
O
ID
 
WH    2125 9.23% 19.50% 59.69% 64.39% 
WHA  9715 3.13% 60.70% 4.41% 51.56% 
WH     2246 1.88% 31.05% 15.58% 37.68% 
WH     2363 1.71% 31.01% 2.47% 42.63% 
WH     2138 3.45% 56.01% 4.25% 40.07% 
WH     2321 1.89% 34.44% 2.25% 25.89% 
WH     2342 0.69% 39.44% 0.79% 31.50% 
WH     2280 2.29% 73.21% 3.28% 68.60% 
U         2056 0.36% 58.35% 1.47% 49.90% 
WH     2350 4.93% 55.15% 4.98% 50.90% 
WH     2259 2.08% 36.54% 2.28% 12.90% 
WH     2256 5.99% 22.09% 7.18% 54.93% 
WHA  2716 2.62% 9.15% 3.78% 9.58% 
WH     2101 7.29% 10.44% 1.33% 8.98% 
WH     2330 10.20% 60.00% 11.40% 41.40% 
WH     9814 1.32% 69.66% 2.19% 40.63% 
WHA  9909 1.29% 51.96% 2.00% 40.74% 
WHA  9810 6.00% 54.50% 3.50% 61.20% 
WH     2128 6.06% 12.46% 6.12% 13.44% 
WH     2293 10.16% 18.12% 9.07% 13.68% 
WHA  9822 10.10% 25.10% 11.60% 29.50% 
WH     2305 9.30% 39.20% 6.90% 37.30% 
U         9704 5.60% 49.60% 5.00% 53.90% 
WH     2347 13.50% 42.80% 25.10% 48.20% 
WH     2288 4.60% 99.50% 12.80% 99.80% 
WH     2253 3.30% 14.00% 11.00% 40.80% 
WH     2285 3.80% 72.50% 11.30% 73.50% 
U         2062 6.38% 14.52% 10.59% 51.97% 
WH     2359 12.45% 12.27% 8.69% 13.37% 
WH     2361 3.00% 2.99% 5.86% 6.99% 
WH     2284 3.90% 3.87% 2.83% 3.16% 
WH     9717 0.70% 1.15% 0.76% 0.68% 
WH     2268 6.60% 55.50% 5.60% 62.10% 
Median 3.90% 36.54% 5.00% 40.74% 
Maximum 13.50% 99.50% 59.69% 99.80% 
Minimum 0.36% 1.15% 0.76% 0.68% 
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TABLE 31a 
GRANULOCYTE BURST-TEST ACCORDING TO DIAGNOSTIC LINEAGE (LYMPHOID) 
 
BURST 
Type  Subjects Wash E.Coli fMLP PMA 
L
Y
M
P
H
O
ID
 
WH      2343 1.90% 68.54% 1.85% 66.18% 
WHA   9908 1.86% 61.09% 3.85% 55.55% 
WH      2309 2.27% 32.63% 2.67% 27.37% 
WH      9720 3.71% 58.44% 4.52% 42.55% 
WH      2277 1.26% 61.15% 2.79% 31.16% 
WH      9821 0.66% 23.29% 28.50% 47.53% 
WH     2258 44.73% 37.38% 31.72% 33.11% 
U         2044 2.97% 35.64% 5.25% 32.16% 
WH     9704 2.13% 60.31% 2.35% 53.18% 
WHA  9809 1.61% 43.39% 3.24% 34.61% 
U         2065 2.85% 56.68% 2.71% 54.29% 
WHA  2061 3.48% 22.72% 0.49% 44.02% 
U         2046 7.00% 99.80% 9.50% 99.90% 
WHA  9823 2.70% 93.70% 9.60% 95.10% 
U         2037 6.10% 18.10% 6.60% 26.70% 
WHA  9828 13.30% 44.90% 21.50% 36.50% 
U         2032 10.40% 63.90% 21.10% 34.80% 
U         2054 46.33% 40.47% 39.72% 49.55% 
U         2047 47.30% 62.43% 36.55% 45.33% 
U         2067 46.19% 61.36% 39.98% 44.06% 
WHA  9718 5.60% 57.60% 10.40% 57.90% 
WH      2285 6.00% 52.60% 9.00% 63.50% 
Median 3.60% 57.14% 7.80% 44.70% 
Maximum 47.30% 99.80% 39.98% 99.90% 
Minimum 0.66% 18.10% 0.49% 26.70% 
 
 
When the conditioning regimes for transplantation (chemotherapy vs combination chemotherapy and 
radiotherapy) were analysed, the combination treatment group was more “intact” (median response of 
53.55%) when their innate responses in vitro were compared to preparation with chemotherapy alone (median 
response of 39.44%). However, these were also reduced according to the normal values supplied by the 
manufacturer of the kit. The patients receiving chemotherapy alone consisted of different regimens according 
to disease category e.g. BEAM,127 BU2128 or BU and melphalan.129 The chemo-radiotherapy programme was 
similar for all the patients: 12 gray fractionated whole body exposure for three days, 60mg/kg 
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cyclophosphamide for two days and 6 gray fractionated total nodal irradiation for two days.130 (Tables 32, 
32a)  It implies therefore that the cyclophosphamide plus radiotherapy conditioning had less impact long 
term on the ability of the granulocytes to respond to a physiological stimulus when compared to the heavier 
chemotherapeutic agents in combination. 
 
TABLE 32 
GRANULOCYTE BURST-TEST ACCORDING TO CONDITIONING REGIMEN (CHEMOTHERAPY) 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
C
H
E
M
O
T
H
E
R
A
P
Y
 
WH     2125 9.23% 19.50% 59.69% 64.39% 
WH     2363 1.71% 31.01% 2.47% 42.63% 
WH     2343 1.90% 68.54% 1.85% 66.18% 
WHA  9908 1.86% 61.09% 3.85% 55.55% 
WH     9720 3.71% 58.44% 4.52% 42.55% 
WH     2342 0.69% 39.44% 0.79% 31.50% 
WH     9821 0.66% 23.29% 28.50% 47.53% 
WH     2258 44.73% 37.38% 31.72% 33.11% 
U         2056 0.36% 58.35% 1.47% 49.90% 
U         2044 2.97% 35.64% 5.25% 32.16% 
WH     2350 4.93% 55.15% 4.98% 50.90% 
WHA  9809 1.61% 43.39% 3.24% 34.61% 
U         2065 2.85% 56.68% 2.71% 54.29% 
WH     2259 2.08% 36.54% 2.28% 12.90% 
WHA  2061 3.48% 22.72% 0.49% 44.02% 
WHA  9716 2.62% 9.15% 3.78% 9.58% 
WHA  9909 1.29% 51.96% 2.00% 40.74% 
U         2046 7.00% 99.80% 9.50% 99.90% 
WHA  9823 2.70% 93.70% 9.60% 95.10% 
U         2037 6.10% 18.10% 6.60% 26.70% 
WHA  9822 10.10% 25.10% 11.60% 29.50% 
WHA  9828 13.30% 44.90% 21.50% 36.50% 
WH     2347 13.50% 42.80% 25.10% 48.20% 
U        2032 10.40% 36.90% 21.10% 34.80% 
U        2062 6.38% 14.52% 10.59% 51.97% 
WH    2359 12.45% 12.27% 8.69% 13.37% 
U        2054 46.33% 40.47% 39.72% 49.55% 
WH     2361 3.00% 2.99% 5.86% 6.99% 
U         2067 46.19% 61.36% 39.98% 44.06% 
Median 3.48% 39.44% 5.86% 42.63% 
Maximum 46.33% 99.80% 59.69% 99.90% 
Minimum 0.36% 2.99% 2.49% 6.99% 
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TABLE 32a 
GRANULOCYTE BURST-TEST ACCORDING TO CONDITIONING REGIME (CHEMOTHERAPY & 
RADIOTHERAPY) 
 
BURST 
Type Subjects Wash E.Coli fMLP PMA 
C
H
E
M
O
T
H
E
R
A
P
Y
 A
N
D
 R
A
D
IO
T
H
E
R
A
P
Y
 
WHA  9715 3.13% 60.70% 4.41% 51.56% 
WH     2246 1.88% 31.05% 15.58% 37.68% 
WH     2138 3.45% 56.01% 4.25% 40.07% 
WH     2309 2.27% 32.63% 2.67% 27.37% 
WH     2321 1.89% 34.44% 2.25% 25.89% 
WH     2280 2.29% 73.21% 3.28% 68.60% 
WH     2277 1.26% 61.15% 2.79% 31.16% 
WH     9704 2.13% 60.31% 2.35% 53.18% 
WH     2256 5.99% 22.09% 7.18% 54.93% 
WH     2101 7.29% 20.44% 1.33% 8.98% 
WH     2330 10.20% 60.00% 11.40% 41.40% 
WH     9814 1.32% 69.66% 2.19% 40.63% 
WHA  9810 6.00% 54.50% 3.50% 61.20% 
WH     2128 6.06% 12.46% 6.12% 13.44% 
WH     2293 10.16% 28.12% 9.07% 13.68% 
WH     2305 9.30% 39.20% 6.90% 37.30% 
U         9704 5.60% 49.60% 5.00% 53.90% 
WH     2288 4.60% 99.50% 12.80% 99.80% 
WH     2253 3.30% 14.00% 11.00% 40.80% 
WH     2285 3.80% 72.50% 11.30% 73.50% 
U         2047 47.30% 62.43% 36.55% 45.33% 
WH     2284 3.90% 3.87% 2.83% 3.16% 
WH     9717 0.70% 1.15% 0.76% 0.68% 
WH     2268 6.60% 55.50% 5.60% 62.10% 
WHA  9718 5.60% 57.60% 10.40% 57.90% 
WH     2285 6.00% 52.60% 9.00% 63.50% 
Median 4.25% 53.55% 5.305 41.10% 
Maximum 47.30% 99.50% 36.55% 99.80% 
Minimum 0.70% 1.15% 0.76% 0.68% 
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 Adaptive immune response: CD4+ and CD8+ cell subsets 
The data for the adaptative immune response reflected very similar results across all three types of 
transplants. It appears that the subjects exhibit normal TH 1 and TH 2 cytokine responses of the T cell subset 
CD4+ helper cells: the stimulated responses when compared to the non-stimulated responses all were greater 
that 2 as expected. 
 
However it seems that those who received autografts had slightly better cytokine profiles when one compares 
the ratio of the TH1 versus TH2 cytokine profiles within the CD4+ T cell subset.  This corresponds to the 
earlier observation that the same individuals had better innate responses. (Tables 33, 33a, 33b) 
 
TABLE 33 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS IN DIFFERENT TYPES OF 
TRANSPLANTS (ALLOGRAFT) 
 
 
CD4+CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects IFN-γ IL-4 IFN-γ IL-4 IFN-γ IL-4 
A
L
L
O
T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 (
A
L
L
O
G
R
A
F
T
) 
WH     2125 1.3% 3.2% 4.1% 4.1% 3.15 1.28 
WH     2246 2.1% 2.5% 8.1% 7.1% 3.86 2.84 
WH     2138 2.6% 2.4% 7.6% 4.7% 2.92 1.96 
WH     2321 0.7% 1.5% 3.9% 2.7% 5.57 1.80 
WH     2342 0.2% 0.5% 2.1% 1.4% 10.50 2.80 
WH     9821 1.6% 2.0% 13.9% 7.1% 8.69 3.55 
WH     2258 0.6% 0.5% 13.7% 7.9% 22.83 15.80 
WH     2350 2.3% 1.2% 10.3% 3.2% 4.48 2.67 
WH     2259 0.5% 0.4% 7.8% 5.3% 15.60 13.25 
WH     2330 0.4% 0.2% 1.9% 0.4% 4.75 2.00 
WH     9814 0.9% 1.1% 13.8% 2.7% 15.33 2.45 
WH     2359 0.5% 1.0% 2.4% 1.5% 4.80 1.50 
WH     2361 0.1% 0.1% 0.7% 0.3% 7.00 3.00 
WH     2284 0.4% 0.4% 10.1% 4.6% 24.59 11.55 
WH     9717 0.3% 0.4% 6.4% 2.7% 19.91 6.38 
Median 0.6% 1.0% 7.6% 3.2% 7.0% 2.8% 
Maximum 2.6% 3.2% 13.9% 7.9% 24.6% 15.8% 
Minimum 0.1% 0.1% 0.7% 0.3% 2.9% 1.3% 
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TABLE 33a 
IN VITRO PRODUCTION IFN- AND IL4 WITHIN THE CD4+ T CELLS IN DIFFERENT TYPES OF 
TRANSPLANTS (AUTOGRAFT) 
 
 
   
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects IFN-γ IL-4 IFN-γ IL-4 IFN-γ IL-4 
A
U
T
O
T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 (
A
U
T
O
G
R
A
F
T
) 
WHA  9715 1.3% 1.8% 9.6% 5.4% 7.38 3.00 
WHA  9908 0.9% 0.6% 9.8% 7.1% 10.89 11.83 
WH     9720 1.2% 0.4% 2.9% 1.4% 2.42 3.50 
U         2056 0.6% 0.6% 15.1% 4.9% 25.17 8.17 
U         2044 1.6% 2.5% 5.0% 4.7% 3.13 1.88 
WH     9704 2.9% 1.5% 6.4% 2.5% 2.21 1.67 
WHA  9809 0.4% 0.5% 3.2% 2.2% 8.00 4.40 
U         2065 2.0% 4.9% 7.6% 18.5% 3.80 3.78 
WHA   2061 1.7% 1.1% 15.9% 11.6% 9.35 10.55 
WHA  9716 0.6% 0.8% 8.2% 5.3% 13.67 6.63 
WHA  9909 2.2% 2.3% 12.8% 7.6% 5.82 3.30 
WHA  9810 0.2% 0.2% 3.0% 0.5% 15.00 2.50 
U         2046 0.1% 1.1% 4.4% 5.3% 44.00 4.82 
WHA  9823 0.3% 0.2% 11.0% 2.3% 36.67 11.50 
U         2037 0.5% 0.5% 4.2% 1.6% 8.40 3.20 
WHA  9829 0.2% 0.6% 4.1% 2.2% 20.50 3.67 
WHA  9825 0.7% 0.9% 8.0% 3.6% 11.43 4.00 
U         2032 0.7% 1.0% 1.5% 0.8% 2.14 0.80 
WHA  2062 0.6% 1.6% 2.6% 2.2% 4.33 1.38 
U         3054 0.9% 0.7% 3.9% 2.5% 4.33 3.57 
U         2047 0.7% 0.5% 5.0% 1.9% 7.14 3.80 
WHA  2067 0.8% 0.6% 3.2% 2.1% 4.00 3.56 
WHA  9718 0.5% 0.9% 3.2% 2.9% 6.4 3.22 
Median 0.7% 0.8% 5.0% 2.5% 7.4% 3.6% 
Maximum 2.9% 4.9% 15.9% 18.5% 44.0% 11.8% 
Minimum 0.1% 0.2% 1.5% 0.5% 2.1% 0.8% 
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TABLE 33b 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS IN DIFFERENT TYPES OF 
TRANSPLANTS (MUD) 
 
 
 
 
 
 
 
 
 
 
 
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects IFN-γ IL-4 IFN-γ IL-4 IFN-γ IL-4 
M
A
T
C
H
E
D
 U
N
R
E
L
A
T
E
D
 D
O
N
O
R
 T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 
WH    2263 1.1% 1.6% 5.3% 5.1% 4.82 3.19 
WH    2343 2.6% 2.5% 14.0% 10.0% 5.38 4.00 
WH    2309 1.2% 2.5% 2.7% 2.2% 2.25 0.88 
WH    2280 0.5% 0.8% 7.3% 5.2% 14.60 6.50 
WH    2277 0.6% 0.7% 4.2% 4.2% 7.00 6.00 
WH    2256 2.4% 3.3% 6.1% 7.5% 2.54 2.27 
WH    2101 1.5% 1.3% 2.8% 1.6% 1.87 1.23 
WH    2128 0.6% 0.8% 4.8% 2.0% 8.00 2.50 
WH    2293 0.5% 1.0% 3.1% 1.9% 6.20 1.90 
WH    2305 0.1% 0.7% 4.9% 2.4% 49.00 3.43 
U        9704 1.6% 2.3% 10.9% 6.7% 6.81 2.91 
WH    2347 0.5% 1.0% 11.4% 5.5% 22.80 5.50 
WH    2288 0.6% 1.6% 0.8% 2.2% 1.33 1.38 
WH    2253 0.5% 0.5% 2.3% 2.1% 4.60 4.20 
WH    2311 0.2% 0.3% 6.8% 2.5% 34.00 8.33 
WH    2268 0.5% 1.3% 2.3% 1.1% 4.60 0.85 
WH    2285 0.5% 0.4% 4.5% 1.2% 9 3 
Median 0.5% 0.45 4.5% 1.2% 9.0% 3.0% 
Maximum 2.6% 3.3% 14.0% 10.0% 49.0% 8.3% 
Minimum 0.1% 0.3% 0.8% 1.1% 1.3% 0.8% 
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The type of transplant did not impact negatively on the ability of the T cell CD8+ subset to produce the 
immune regulatory cytokines.  All three subgroups display similar cytokine secretion outputs post activation: 
however in the case of those who had received allografts, their CD8+ T cell subset had markedly better IFN- 
and IL4 cytokine production implying that their CD8+ cells were more active when stimulated in vitro as 
compared to the other two groups of patients studied. (Tables 34, 34a, 34b) 
 
TABLE 34 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS IN DIFFERENT TYPES OF 
TRANSPLANTS (ALLOGRAFT) 
 
 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects IFN-γ IL-4 IFN-γ IL-4 IFN-γ IL-4 
A
L
L
O
T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 (
A
L
L
O
G
R
A
F
T
) 
WH    2125 1.6% 3.2% 23.5% 16.6% 14.69 5.19 
WH    2246 0.4% 0.6% 9.1% 4.8% 22.75 8.00 
WH    2138 0.2% 0.2% 2.0% 0.9% 10.00 4.50 
WH    2321 0.4% 0.7% 9.6% 3.3% 24.00 4.71 
WH    2342 0.1% 0.4% 12.3% 2.0% 123.00 5.00 
WH    9821 0.8% 1.0% 14.8% 6.1% 18.50 6.10 
WH    2258 0.7% 0.6% 18.0% 8.1% 25.71 13.50 
WH    2350 1.3% 1.0% 12.4% 3.3% 9.54 3.30 
WH    2259 1.1% 1.0% 16.3% 8.0% 14.82 8.00 
WH    2330 0.3% 0.2% 8.4% 1.6% 28.00 8.00 
WH    9814 0.9% 0.8% 22.4% 2.7% 24.89 3.38 
WH    2359 0.6% 0.5% 16.9% 8.6% 28.17 17.20 
WH    2361 1.5% 0.2% 2.5% 1.3% 1.67 6.50 
WH    2284 0.1% 0.3% 22.0% 8.3% 219.50 27.77 
WH    9717 0.3% 0.5% 15.8% 5.4% 52.80 9.96 
Median 0.6% 0.6% 14.8% 4.8% 24.0% 6.5% 
Maximum 1.6% 3.2% 23.5% 16.6% 219.5% 27.8% 
Minimum 0.1% 0.2% 2.0% 0.9% 1.7% 3.3% 
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TABLE 34a 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS IN DIFFERENT TYPES OF 
TRANSPLANTS (AUTOGRAFT) 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects IFN-γ IL-4 IFN-γ IL-4 IFN-γ IL-4 
A
U
T
O
T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 (
A
U
T
O
G
R
A
F
T
) 
WHA  9715 0.9% 0.9% 18.9% 10.1% 21.00 11.22 
WHA  9908 2.1% 0.5% 45.4% 24.9% 21.62 49.80 
WH     9720 0.8% 0.4% 4.8% 0.8% 6.00 2.00 
U         2056 0.6% 0.6% 16.4% 4.5% 27.33 7.50 
U         2044 1.9% 2.7% 9.0% 4.9% 4.74 1.81 
WH     9704 1.6% 0.9% 11.3% 2.2% 7.06 2.44 
WHA  9809 0.5% 0.8% 9.5% 5.1% 19.00 6.38 
U         2065 6.9% 10.5% 12.0% 20.4% 1.74 1.94 
WHA  2061 2.9% 1.8% 19.8% 16.8% 6.83 9.33 
WHA  9716 0.6% 0.5% 11.4% 4.8% 19.00 9.60 
WHA  9909 1.5% 1.9% 20.4% 8.7% 13.60 4.58 
WHA  9810 0.1% 0.2% 6.1% 0.7% 61.00 3.50 
U         2046 0.1% 0.9% 9.3% 9.1% 93.00 10.11 
WHA  9823 0.2% 0.1% 9.9% 1.6% 49.50 16.00 
U         2037 0.5% 0.6% 13.8% 3.2% 27.60 5.33 
WHA  9829 0.2% 0.3% 11.0% 4.4% 55.00 14.67 
WHA  9825 0.3% 0.4% 15.0% 4.7% 50.00 11.75 
U        2023 1.0% 2.1% 4.8% 1.7% 4.80 0.81 
WHA 2062 0.2% 0.8% 6.1% 3.2% 30.50 4.00 
U        2054 0.5% 0.4% 9.0% 2.6% 18.00 6.50 
U        2047 0.4% 0.3% 13.9% 4.1% 34.75 13.67 
WHA  2067 0.5% 0.5% 3.4% 1.8% 6.80 3.60 
WHA  9718 0.3% 0.7% 4.6% 3.6% 15.33 5.14 
Median 0.3% 0.7% 4.6% 3.6% 15.30% 5.10% 
Maximum 6.9% 10.5% 45.4% 24.9% 93.0% 49.8% 
Minimum 0.3% 0.7% 4.6% 3.6% 15.3% 5.1% 
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TABLE 34b 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS IN DIFFERENT TYPES OF 
TRANSPLANTS (MUD) 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects IFN-γ IL-4 IFN-γ IL-4 IFN-γ IL-4 
M
A
T
C
H
E
D
 U
N
R
E
L
A
T
E
D
 D
O
N
O
R
 T
R
A
N
S
P
L
A
N
T
A
T
IO
N
 
WH    2263 0.8% 0.7% 26.0% 12.4% 32.50 17.71 
WH    2343 2.0% 1.0% 26.7% 9.8% 13.35 9.80 
WH    2309 0.5% 0.8% 3.0% 1.9% 6.00 2.38 
WH    2280 0.4% 0.5% 14.8% 7.4% 37.00 14.80 
WH    2277 0.3% 0.4% 8.3% 4.7% 27.67 11.75 
WH    2256 1.0% 1.5% 7.1% 4.4% 7.10 2.93 
WH    2101 1.7% 1.6% 12.9% 5.6% 7.59 3.50 
WH    2128 0.3% 0.4% 11.8% 3.6% 39.33 9.00 
WH    2293 0.2% 0.3% 3.1% 3.3% 15.50 11.00 
WH    2305 0.3% 1.5% 14.6% 4.1% 48.67 2.73 
U        9704 0.9% 1.3% 16.5% 6.5% 18.33 5.00 
WH    2347 0.3% 0.5% 13.3% 4.4% 44.33 8.80 
WH    2288 0.3% 0.9% 1.5% 2.4% 5.00 2.67 
WH    2253 0.1% 0.2% 3.0% 2.5% 30.00 12.50 
WH    2311 0.2% 0.3% 11.2% 2.0% 56.00 6.67 
WH    2268 0.4% 1.0% 7.9% 2.3% 19.75 2.30 
WH    2285 0.4% 0.3% 5.8% 1.3% 14.50 4.33 
Median 0.4% 0.7% 11.2% 4.1% 19.8% 6.7% 
Maximum 2.0% 1.6% 26.7% 12.4% 56.0% 17.7% 
Minimum 0.1% 0.2% 1.5% 1.3% 5.0% 2.3% 
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The subjects exhibited normal TH 1 and TH 2 cytokine reactions of the T cell subset CD4+ helper cells, 
irrespective to the date of transplant. (Tables 35, 35a, 35b)  There are no published data to indicate “normal 
cytokine profiles”. It has been shown that healthy individuals generally have a 2:1 ratio when one compares 
the response of IFN- to IL4. There is some literature which confirms that a ratio of 2:1 or greater is observed 
in healthy individuals.   This ratio may change during bouts of viral disease (influenza for example) when one 
would expect a greater TH 1 output (IFN- production). 
 
TABLE 35 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS ACCORDING TO DATE POST 
TRANSPLANT (0-5 YEARS) 
 
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
Y
E
A
R
S
 A
B
O
V
E
 2
0
0
3
 (
0
-5
 Y
E
A
R
S
) 
WH   2263 1.1% 1.6% 5.3% 5.1% 4.82 3.19 
WH   2343 2.6% 2.5% 14.0% 10.0% 5.38 4.00 
WH   2309 1.2% 2.5% 2.7% 2.2% 2.25 0.88 
WH   2321 0.7% 1.5% 3.9% 2.7% 5.57 1.80 
WH   2342 0.2% 0.5% 2.1% 1.4% 10.50 2.80 
WH   2280 0.5% 0.8% 7.3% 5.2% 14.60 6.50 
WH   2277 0.6% 0.7% 4.2% 4.2% 7.00 6.00 
U       2056 0.6% 0.6% 15.1% 4.9% 25.17 8.17 
U       2044 1.6% 2.5% 5.0% 4.7% 3.13 1.88 
WH  2350 2.3% 1.2% 10.3% 3.2% 4.48 2.67 
U      2065 2.0% 4.9% 7.6% 18.5% 3.80 3.78 
WHA 2061 1.7% 1.1% 15.9% 11.6% 9.35 10.55 
WH   2330 0.4% 0.2% 1.9% 0.4% 4.75 2.00 
U       2046 0.1% 1.1% 4.4% 5.3% 44.00 4.82 
WH   2293 0.5% 1.0% 3.1% 1.9% 6.20 1.90 
U      2037 0.5% 0.5% 4.2% 1.6% 8.40 3.20 
WH   2035 0.1% 0.7% 4.9% 2.4% 49.00 3.43 
U       9074 1.6% 2.3% 10.9% 6.7% 6.81 2.91 
WH   2347 0.5% 1.0% 11.4% 5.5% 22.80 5.50 
U      2032 0.7% 1.0% 1.5% 0.8% 2.14 0.80 
WH  2288 0.6% 1.6% 0.8% 2.2% 1.33 1.38 
WH   2311 0.2% 0.3% 6.8% 2.5% 34.00 8.33 
WHA 2062 0.6% 1.6% 2.6% 2.2% 4.33 1.38 
WH   2359 0.5% 1.0% 2.4% 1.5% 4.80 1.50 
U      2054 0.9% 0.7% 3.9% 2.5% 4.33 3.57 
U      2047 0.7% 0.5% 5.0% 1.9% 7.14 3.80 
WH  2361 0.1% 0.1% 0.7% 0.3% 7.00 3.00 
WH   2284 0.4% 0.4% 10.1% 4.6% 24.59 11.55 
WHA 2067 0.8% 0.6% 3.2% 2.1% 4.00 3.56 
WH    2285 0.5% 0.4% 4.5% 1.2% 9 3 
Median 0.6% 1.0% 4.5% 2.5% 6.5% 3.2% 
Maximum 2.6% 4.9% 15.9% 18.5% 49.0% 11.55% 
Minimum 0.1% 0.1% 0.7% 0.3% 1.3% 0.8% 
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TABLE 35a 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS ACCORDING TO DATE POST 
TRANSPLANT (6-10 YEARS) 
 
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
1
9
9
8
 -
 2
0
0
2
 (
6
 -
 1
0
 Y
E
A
R
S
) 
WH   2155 1.3% 3.2% 4.1% 4.1% 3.15 1.28 
WH   2246 2.1% 2.5% 8.1% 7.1% 3.86 2.84 
WH   2138 2.6% 2.4% 7.6% 4.7% 2.92 1.96 
WHA 9908 0.9% 0.6% 9.8% 7.1% 10.89 11.83 
WH   9821 1.6% 2.0% 13.9% 7.1% 8.69 3.55 
WH   2258 0.6% 0.5% 13.7% 7.9% 22.83 15.80 
WHA 9809 0.4% 0.5% 3.2% 2.2% 8.00 4.40 
WH   2259 0.5% 0.4% 7.8% 5.3% 15.60 13.25 
WH   2256 2.4% 3.3% 6.1% 7.5% 2.54 2.27 
WH   2101 1.5% 1.3% 2.8% 1.6% 1.87 1.23 
WH   9814 0.9% 1.1% 13.8% 2.7% 15.33 2.45 
WH   9909 2.2% 2.3% 12.8% 7.6% 5.82 3.30 
WHA 9810 0.2% 0.2% 3.0% 0.5% 15.00 2.50 
WH   2128 0.6% 0.8% 4.8% 2.0% 8.00 2.50 
WHA 9823 0.3% 0.2% 11.0% 2.3% 36.67 11.50 
WHA 9829 0.2% 0.6% 4.1% 2.2% 20.50 3.67 
WHA 9825 0.7% 0.9% 8.0% 3.6% 11.43 4.00 
WH   2253 0.5% 0.5% 2.3% 2.1% 4.60 4.20 
WH   2268 0.5% 1.3% 2.3% 1.1% 4.60 0.85 
Median 0.7% 0.9% 7.6% 3.6% 8.0% 3.3% 
Maximum 2.6% 3.3% 13.9% 7.9% 36.7% 15.8% 
Minimum 0.2% 0.2% 2.3% 0.5% 1.9% 0.8% 
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TABLE 35b 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS ACCORDING TO DATE POST 
TRANSPLANT (> 10YEARS ) 
 
CD4 + CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
Y
E
A
R
S
 B
E
F
O
R
E
 1
9
9
7
  
(>
1
0
 Y
E
A
R
S
) 
WHA  9715 1.3% 1.8% 9.6% 5.4% 7.38 3.00 
WH    9720 1.2% 0.4% 2.9% 1.4% 2.42 3.50 
WH    9704 2.9% 1.5% 6.4% 2.5% 2.21 1.67 
WHA  9716 0.6% 0.8% 8.2% 5.3% 13.67 6.63 
WH     9717 0.3% 0.4% 6.4% 2.7% 19.91 6.38 
WHA   9718 0.5% 0.9% 3.2% 2.9% 6.4% 3.22 
Median 0.9% 0.9% 6.4% 2.8% 4.9% 3.4% 
Maximum 2.9% 1.8% 9.6% 5.4% 19.9% 6.6% 
Minimum 0.3% 0.4% 2.9% 1.4% 6.4% 1.7% 
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The age of the transplant did not impact on the ability of the T cell CD8+ subset to produce the immune 
regulatory cytokines.  Although all three subgroups displayed similar results post-activation, it appeared that 
the more recently transplanted individuals had the best CD8 responses in vitro, implying that these subjects 
would be the most protected vis-à-vis viruses or intra-cellular pathogens.  Unfortunately we could not 
correlate the incidence of infections and type of infections within these groups and to compare this to the in 
vitro CD8 response but it would be an interesting exercise to undertake. (Tables 36, 36a, 36b) 
 
TABLE 36 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS ACCORDING TO DATE POST 
TRANSPLANT 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
Y
E
A
R
S
 A
B
O
V
E
 2
0
0
3
 (
0
-5
 Y
E
A
R
S
) 
WH 2263 0.8% 0.7% 26.0% 12.4% 32.50 17.71 
WH 2343 2.0% 1.0% 26.7% 9.8% 13.35 9.80 
WH 2309 0.5% 0.8% 3.0% 1.9% 6.00 2.38 
WH 2321 0.4% 0.7% 9.6% 3.3% 24.00 4.71 
WH 2342 0.1% 0.4% 12.3% 2.0% 123.00 5.00 
WH 2280 0.4% 0.5% 14.8% 7.4% 37.00 14.80 
WH 2277 0.3% 0.4% 8.3% 4.7% 27.67 11.75 
U 2056 0.6% 0.6% 16.4% 4.5% 27.33 7.50 
U 2044 1.9% 2.7% 9.0% 4.9% 4.74 1.81 
WH 2350 1.3% 1.0% 12.4% 3.3% 9.54 3.30 
U 2065 6.9% 10.5% 12.0% 20.4% 1.74 1.94 
WHA 2061 2.9% 1.8% 19.8% 16.8% 6.83 9.33 
WH 2330 0.3% 0.2% 8.4% 1.6% 28.00 8.00 
U 2046 0.1% 0.9% 9.3% 9.1% 93.00 10.11 
WH 2293 0.2% 0.3% 3.1% 3.3% 15.50 11.00 
U 2037 0.5% 0.6% 13.8% 3.2% 27.60 5.33 
WH 2035 0.3% 1.5% 14.6% 4.1% 48.67 2.73 
U 9704 0.9% 1.3% 16.5% 6.5% 18.33 5.00 
WH 2347 0.3% 0.5% 13.3% 4.4% 44.33 8.80 
U 2032 1.0% 2.1% 4.8% 1.7% 4.80 0.81 
WH 2288 0.3% 0.9% 1.5% 2.4% 5.00 2.67 
WH 2311 0.2% 0.3% 11.2% 2.0% 56.00 6.67 
WHA 2062 0.2% 0.8% 6.1% 3.2% 30.50 4.00 
WH 2359 0.6% 0.5% 16.9% 8.6% 28.17 17.20 
U 2054 0.5% 0.4% 9.0% 2.6% 18.00 6.50 
U 2047 0.4% 0.3% 13.9% 4.1% 34.75 13.67 
WH 2361 1.5% 0.2% 2.5% 1.3% 1.67 6.50 
WH 2284 0.1% 0.3% 22.0% 8.3% 219.50 27.77 
WHA 2067 0.5% 0.5% 3.4% 1.8% 6.80 3.60 
WH 2285 0.4% 0.3% 5.8% 1.3% 14.50 4.33 
Median 0.5% 0.6% 11.6% 3.7% 25.7% 6.5% 
Maximum 6.9% 10.5%  26.7% 20.4% 219.5% 27.767% 
Minimum 0.1% 0.2% 1.5% 1.3% 166.7% 81.0% 
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TABLE 36a 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS ACCORDING TO DATE POST 
TRANSPLANT (6-10 YEARS) 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
1
9
9
8
 -
 2
0
0
2
 (
6
 -
 1
0
 Y
E
A
R
S
) 
WH 2155 1.6% 3.2% 23.5% 16.6% 14.69 5.19 
WH 2246 0.4% 0.6% 9.1% 4.8% 22.75 8.00 
WH 2138 0.2% 0.2% 2.0% 0.9% 10.00 4.50 
WHA 9908 2.1% 0.5% 45.4% 24.9% 21.62 49.80 
WH 9821 0.8% 1.0% 14.8% 6.1% 18.50 6.10 
WH 2258 0.7% 0.6% 18.0% 8.1% 25.71 13.50 
WHA 9809 0.5% 0.8% 9.5% 5.1% 19.00 6.38 
WH 2259 1.1% 1.0% 16.3% 8.0% 14.82 8.00 
WH 2256 1.0% 1.5% 7.1% 4.4% 7.10 2.93 
WH 2101 1.7% 1.6% 12.9% 5.6% 7.59 3.50 
WH 9814 0.9% 0.8% 22.4% 2.7% 24.89 3.38 
WHA 9909 1.5% 1.9% 20.4% 8.7% 13.60 4.58 
WHA 9810 0.1% 0.2% 6.1% 0.7% 61.00 3.50 
WH 2128 0.3% 0.4% 11.8% 3.6% 39.33 9.00 
WHA 9823 0.2% 0.1% 9.9% 1.6% 49.50 16.00 
WHA 9829 0.2% 0.3% 11.0% 4.4% 55.00 14.67 
WHA 9825 0.3% 0.4% 15.0% 4.7% 50.00 11.75 
WH 2253 0.1% 0.2% 3.0% 2.5% 30.00 12.50 
WH 2268 0.4% 1.0% 7.9% 2.3% 19.75 2.30 
Median 0.5% 0.6% 11.8% 4.7% 21.6% 6.4% 
Maximum 2.1% 3.2% 45.4% 24.9% 61.0% 49.8% 
Minimum 0.1% 0.1% 2.0% 0.7% 7.1% 2.3% 
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TABLE 36b 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS ACCORDING TO DATE POST 
TRANSPLANT (>10 YEARS) 
 
CD8+ cells 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
Y
E
A
R
S
 B
E
F
O
R
E
 1
9
9
7
 (
>
1
0
 Y
E
A
R
S
) WHA 9715 0.9% 0.9% 18.9% 10.1% 21.00 11.22 
WH 9720 0.8% 0.4% 4.8% 0.8% 6.00 2.00 
WH 9704 1.6% 0.9% 11.3% 2.2% 7.06 2.44 
WHA 9716 0.6% 0.5% 11.4% 4.8% 19.00 9.60 
WH 9717 0.3% 0.5% 15.8% 5.4% 52.80 9.96 
WHA 9718 0.3% 0.7% 4.6% 3.6% 15.33 5.14 
Median 0.7% 0,6% 11.4% 4.2% 17.2% 7.4% 
Maximum 1.6% 0.9% 18.9% 10.1% 52.8% 11.2% 
Minimum 0.3% 0.4% 4.6% 0.8% 6.0% 2.0% 
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When the myeloid and lymphoid groupings were compared as far as their CD4+ or CD8+ responses in vitro, 
the subjects exhibited normal TH1 and TH2 cytokine release patterns of the T cell subset CD4+ helper cells. 
(Tables 37, 37a)  
 
TABLE 37 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS ACCORDING TO DIAGNOSIS 
LINEAGE (MYELOID) 
 
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
M
Y
E
L
O
ID
 
WH      2125 1.3% 3.2% 4.1% 4.1% 3.15 1.28 
WHA   9715 1.3% 1.8% 9.6% 5.4% 7.38 3.00 
WH      2246 2.1% 2.5% 8.1% 7.1% 3.86 2.84 
WH      2363 1.1% 1.6% 5.3% 5.1% 4.82 3.19 
WH      2138 2.6% 2.4% 7.6% 4.7% 2.92 1.96 
WH      2321 0.7% 1.5% 3.9% 2.7% 5.57 1.80 
WH      2342 0.2% 0.5% 2.1% 1.4% 10.50 2.80 
WH      2280 0.5% 0.8% 7.3% 5.2% 14.60 6.50 
U          2056 0.6% 0.6% 15.1% 4.9% 25.17 8.17 
WH      2350 2.3% 1.2% 10.3% 3.2% 4.48 2.67 
WH      2259 13.5% 9.4% 7.8% 5.3% N/A N/A 
WH      2256 2.4% 3.3% 6.1% 7.5% 2.54 2.27 
WHA   9716 0.6% 0.8% 8.2% 5.3% 13.67 6.63 
WH      2101 1.5% 1.3% 2.8% 1.6% 1.87 1.23 
WH      2330 0.4% 0.2% 1.9% 0.4% 4.75 2.00 
WH      9814 0.9% 1.1% 13.8% 2.7% 15.33 2.45 
WHA   9909 2.2% 2.3% 12.8% 7.6% 5.82 3.30 
WHA   9810 0.2% 0.2% 3.0% 0.5% 15.00 2.50 
WH      2128 0.6% 0.8% 4.8% 2.0% 8.00 2.50 
WH      2293 0.5% 1.0% 3.1% 1.9% 6.20 1.90 
WHA   9822 0.2% 0.6% 4.1% 2.2% 20.50 3.67 
WH      2305 0.1% 0.7% 4.9% 2.4% 49.00 3.43 
U          9704 1.6% 2.3% 10.9% 6.7% 6.81 2.91 
WH      2347 0.5% 1.0% 11.4% 5.5% 22.80 5.50 
WH      2288 0.6% 1.6% 0.8% 2.2% 1.33 1.38 
WH      2253 0.5% 0.5% 2.3% 2.1% 4.60 4.20 
WH      2285 0.2% 0.3% 6.8% 2.5% 34.00 8.33 
U          2062 0.6% 1.6% 2.6% 2.2% 4.33 1.38 
WH      2359 0.5% 1.0% 2.4% 1.5% 4.80 1.50 
WH      2361 0.1% 0.1% 0.7% 0.3% 7.00 3.00 
WH      2284 0.4% 0.4% 10.1% 4.6% 24.59 11.55 
WH      9717 0.3% 0.4% 6.4% 2.7% 19.91 6.38 
WH      2268 0.5% 1.3% 2.3% 1.1% 4.60 0.85 
Median 0.6% 1.0% 5.3% 2.7% 6.5% 2.8% 
Maximum 13.5% 9.4% 15.1% 7.6% 49.0% 11.6% 
Minimum 0.1% 0.1% 0.7% 0.3% 1.3% 0.8% 
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TABLE 37a 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS ACCORDING TO DIAGNOSIS 
LINEAGE (LYMPHOID) 
 
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
L
Y
M
P
H
O
ID
 
WH       2343 2.6% 2.5% 14.0% 10.0% 5.38 4.00 
WHA    9908 0.9% 0.6% 9.8% 7.1% 10.89 11.83 
WH       2309 1.2% 2.5% 2.7% 2.2% 2.25 0.88 
WHA    9720 1.2% 0.4% 2.9% 1.4% 2.42 3.50 
WH       2277 0.6% 0.7% 4.2% 4.2% 7.00 6.00 
WH       9821 1.6% 2.0% 13.9% 7.1% 8.69 3.55 
WH       2258 0.6% 0.5% 13.7% 7.9% 22.83 15.80 
U           2044 1.6% 2.5% 5.0% 4.7% 3.13 1.88 
WH        9704 2.9% 1.5% 6.4% 2.5% 2.21 1.67 
WHA     9809 0.4% 0.5% 3.2% 2.2% 8.00 4.40 
U            2065 2.0% 4.9% 7.6% 18.5% 3.80 3.78 
WHA     2061 1.7% 1.1% 15.9% 11.6% 9.35 10.55 
U            2045 0.1% 1.1% 4.4% 5.3% 44.00 4.82 
WHA     9823 0.3% 0.2% 11.0% 2.3% 36.67 11.50 
U            2037 0.5% 0.5% 4.2% 1.6% 8.40 3.20 
WHA     9828 0.7% 0.9% 8.0% 3.6% 11.43 4.00 
U            2032 0.7% 1.0% 1.5% 0.8% 2.14 0.80 
U            2054 0.9% 0.7% 3.9% 2.5% 4.33 3.57 
U            2047 0.7% 0.5% 5.0% 1.9% 7.14 3.80 
U            2067 0.8% 0.6% 3.2% 2.1% 4.00 3.56 
WHA     9718 0.5% 0.9% 3.2% 2.9% 6.4 3.22 
WH        2285 0.5% 0.4% 4.5% 1.2% 9 3 
Median 0.8% 0.8% 4.8% 2.7% 7.1% 3.7% 
Maximum 2.9% 4.9% 15.9% 18.5% 44.0% 15.8% 
Minimum 0.1% 0.2% 1.5% 0.8% 2.1% 0.8% 
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There was no negative impact on the ability of the T cell CD8+subset to produce the immune regulatory 
cytokines. Both disease categories show similar responses post activation although the myeloid group displays 
a marginally greater IFN-y cytokine profile when CD8+T cells are activated in vitro. (Tables 38, 38a) 
 
TABLE 38 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS ACCORDING TO DIAGNOSIS 
LINEAGE (MYELOID) 
 
CD8+ cells 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
M
Y
E
L
O
ID
 
WH      2125 1.6% 3.2% 23.5% 16.6% 14.69 5.19 
WHA   9715 0.9% 0.9% 18.9% 10.1% 21.00 11.22 
WH      2246 0.4% 0.6% 9.1% 4.8% 22.75 8.00 
WH      2363 0.8% 0.7% 26.0% 12.4% 32.50 17.71 
WH      2138 0.2% 0.2% 2.0% 0.9% 10.00 4.50 
WH      2321 0.4% 0.7% 9.6% 3.3% 24.00 4.71 
WH      2342 0.1% 0.4% 12.3% 2.0% 123.00 5.00 
WH      2280 0.4% 0.5% 14.8% 7.4% 37.00 14.80 
U          2056 0.6% 0.6% 16.4% 4.5% 27.33 7.50 
WH      2350 1.3% 1.0% 12.4% 3.3% 9.54 3.30 
WH      2259 50.0% 49.0% 16.3% 8.0% N/A N/A 
WH      2256 1.0% 1.5% 7.1% 4.4% 7.10 2.93 
WHA   9716 0.6% 0.5% 11.4% 4.8% 19.00 9.60 
WH      2101 1.7% 1.6% 12.9% 5.6% 7.59 3.50 
WH      2330 0.3% 0.2% 8.4% 1.6% 28.00 8.00 
WH      9814 0.9% 0.8% 22.4% 2.7% 24.89 3.38 
WHA   9909 1.5% 1.9% 20.4% 8.7% 13.60 4.58 
WHA   9810 0.1% 0.2% 6.1% 0.7% 61.00 3.50 
WH      2128 0.3% 0.4% 11.8% 3.6% 39.33 9.00 
WH      2293 0.2% 0.3% 3.1% 3.3% 15.50 11.00 
WHA   9822 0.2% 0.3% 11.0% 4.4% 55.00 14.67 
WH      2305 0.3% 1.5% 14.6% 4.1% 48.67 2.73 
U          9704 0.9% 1.3% 16.5% 6.5% 18.33 5.00 
WH      2347 0.3% 0.5% 13.3% 4.4% 44.33 8.80 
WH      2288 0.3% 0.9% 1.5% 2.4% 5.00 2.67 
WH      2253 0.1% 0.2% 3.0% 2.5% 30.00 12.50 
WH      2285 0.2% 0.3% 11.2% 2.0% 56.00 6.67 
U          2062 0.2% 0.8% 6.1% 3.2% 30.50 4.00 
WH      2359 0.6% 0.5% 16.9% 8.6% 28.17 17.20 
WH      2361 1.5% 0.2% 2.5% 1.3% 1.67 6.50 
WH      2284 0.1% 0.3% 22.0% 8.3% 219.50 27.77 
WH      9717 0.3% 0.5% 15.8% 5.4% 52.80 9.96 
WH      2268 0.4% 1.0% 7.9% 2.3% 19.75 2.30 
Median 0.4% 0.6% 12.3% 4.4% 26.1% 6.6% 
Maximum 50.0% 49.0% 26.0% 16.6% 219.5% 27.8% 
Minimum 0.1% 0.2% 1.5% 0.7% 1.7% 2.3% 
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TABLE 38a 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS ACCORDING TO DIAGNOSIS 
LINEAGE (LYMPHOID) 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
L
Y
M
P
H
O
ID
 
WH      2343 2.0% 1.0% 26.7% 9.8% 13.35 9.80 
WHA   9908 2.1% 0.5% 45.4% 24.9% 21.62 49.80 
WH      2309 0.5% 0.8% 3.0% 1.9% 6.00 2.38 
WHA   9720 0.8% 0.4% 4.8% 0.8% 6.00 2.00 
WH      2277 0.3% 0.4% 8.3% 4.7% 27.67 11.75 
WH      9821 0.8% 1.0% 14.8% 6.1% 18.50 6.10 
WH      2258 0.7% 0.6% 18.0% 8.1% 25.71 13.50 
U          2044 1.9% 2.7% 9.0% 4.9% 4.74 1.81 
WH      9704 1.6% 0.9% 11.3% 2.2% 7.06 2.44 
WHA   9809 0.5% 0.8% 9.5% 5.1% 19.00 6.38 
U        2065 6.9% 10.5% 12.0% 20.4% 1.74 1.94 
     WHA   2061 2.9% 1.8% 19.8% 16.8% 6.83 9.33 
U          2046 0.1% 0.9% 9.3% 9.1% 93.00 10.11 
WHA   9823 0.2% 0.1% 9.9% 1.6% 49.50 16.00 
U          2037 0.5% 0.6% 13.8% 3.2% 27.60 5.33 
WHA   9828 0.3% 0.4% 15.0% 4.7% 50.00 11.75 
U          2032 1.0% 2.1% 4.8% 1.7% 4.80 0.81 
U          2054 0.5% 0.4% 9.0% 2.6% 18.00 6.50 
U          2047 0.4% 0.3% 13.9% 4.1% 34.75 13.67 
U          2067 0.5% 0.5% 3.4% 1.8% 6.80 3.60 
WHA   9718 0.3% 0.7% 4.6% 3.6% 15.33 5.14 
WH      2285 0.4% 0.3% 5.8% 1.3% 14.50 4.33 
Median 0.4% 0.3% 5.8% 1.3% 14.5% 4.3% 
Maximum 6.9% 10.5% 45.4% 24.9% 93.0% 49.8% 
Minimum 0.1% 0.1% 3.0% 0.8% 1.7% 0.8% 
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Using different conditioning regimens the patients reflected very similar results as they exhibited normal TH1 
and TH2 cytokine responses to the T subset CD4+ helper cells. (Tables 39, 39a) 
 
TABLE 39 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS ACCORDING TO 
CONDITIONING REGIMEN (CHEMOTHERAPY) 
 
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy      IL-4 INFy          IL-4 INFy      IL-4 
C
H
E
M
O
T
H
E
R
A
P
Y
 
WH      2125 1.3% 3.2% 4.1% 4.1% 3.15 1.28 
WH      2263 1.1% 1.6% 5.3% 5.1% 4.82 3.19 
WH      2343 2.6% 2.5% 14.0% 10.0% 5.38 4.00 
WHA   9908 0.9% 0.6% 9.8% 7.1% 10.89 11.83 
WHA   9720 1.2% 0.4% 2.9% 1.4% 2.42 3.50 
WH      2342 0.2% 0.5% 2.1% 1.4% 10.50 2.80 
WH      9821 1.6% 2.0% 13.9% 7.1% 8.69 3.55 
WH      2258 0.6% 0.5% 13.7% 7.9% 22.83 15.80 
U          2056 0.6% 0.6% 15.1% 4.9% 25.17 8.17 
U          2044 1.6% 2.5% 5.0% 4.7% 3.13 1.88 
WH      2350 2.3% 1.2% 10.3% 3.2% 4.48 2.67 
WHA   9809 0.4% 0.5% 3.2% 2.2% 8.00 4.40 
U        2065 2.0% 4.9% 7.6% 18.5% 3.80 3.78 
WH     2259 0.5% 0.4% 7.8% 5.3% 15.60 13.25 
WHA  2061 1.7% 1.1% 15.9% 11.6% 9.35 10.55 
WHA  9716 0.6% 0.8% 8.2% 5.3% 13.67 6.63 
WHA  9909 2.2% 2.3% 12.8% 7.6% 5.82 3.30 
U         2046 0.1% 1.1% 4.4% 5.3% 44.00 4.82 
WHA  9823 0.3% 0.2% 11.0% 2.3% 36.67 11.50 
U         2037 0.5% 0.5% 4.2% 1.6% 8.40 3.20 
WHA  9822 0.2% 0.6% 4.1% 2.2% 20.50 3.67 
WHA  2347 0.7% 0.9% 8.0% 3.6% 11.43 4.00 
WH     2347 0.5% 1.0% 11.4% 5.5% 22.80 5.50 
U         2032 0.7% 1.0% 1.5% 0.8% 2.14 0.80 
U         2062 0.6% 1.6% 2.6% 2.2% 4.33 1.38 
WH     2359 0.5% 1.0% 2.4% 1.5% 4.80 1.50 
U         2054 0.9% 0.7% 3.9% 2.5% 4.33 3.57 
WH     2361 0.1% 0.1% 0.7% 0.3% 7.00 3.00 
U          2067 0.8% 0.6% 3.2% 2.1% 4.00 3.56 
Median 0.7% 0.9% 5.3% 4.1% 8.0% 3.6% 
Maximum 2.6% 4.9% 15.9% 18.5% 44.0% 15.8% 
Minimum 0.1% 0.1% 0.7% 0.3% 2.1% 0.8% 
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TABLE 39a 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD4+ T CELLS ACCORDING TO 
CONDITIONING REGIMEN (CHEMOTHERAPY AND RADIOTHERAPY) 
 
CD4+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
C
H
E
M
O
T
H
E
R
A
P
Y
 A
N
D
 R
A
D
IO
O
T
H
E
R
A
P
Y
 
WHA  9715 1.3% 1.8% 9.6% 5.4% 7.38 3.00 
WH     2246 2.1% 2.5% 8.1% 7.1% 3.86 2.84 
WH     3138 2.6% 2.4% 7.6% 4.7% 2.92 1.96 
WH     2309 1.2% 2.5% 2.7% 2.2% 2.25 0.88 
WH     2321 0.7% 1.5% 3.9% 2.7% 5.57 1.80 
WH     2280 0.5% 0.8% 7.3% 5.2% 14.60 6.50 
WH     2277 0.6% 0.7% 4.2% 4.2% 7.00 6.00 
WH     9704 2.9% 1.5% 6.4% 2.5% 2.21 1.67 
WH     2251 2.4% 3.3% 6.1% 7.5% 2.54 2.27 
WH     2101 1.5% 1.3% 2.8% 1.6% 1.87 1.23 
WH     2330 0.4% 0.2% 1.9% 0.4% 4.75 2.00 
WH     9814 0.9% 1.1% 13.8% 2.7% 15.33 2.45 
WHA  9810 0.2% 0.2% 3.0% 0.5% 15.00 2.50 
WH     2128 0.6% 0.8% 4.8% 2.0% 8.00 2.50 
WH     2293 0.5% 1.0% 3.1% 1.9% 6.20 1.90 
WH     2305 0.1% 0.7% 4.9% 2.4% 49.00 3.43 
U         9704 1.6% 2.3% 10.9% 6.7% 6.81 2.91 
WH     2288 0.6% 1.6% 0.8% 2.2% 1.33 1.38 
WH     2253 0.5% 0.5% 2.3% 2.1% 4.60 4.20 
WH     2285 0.2% 0.3% 6.8% 2.5% 34.00 8.33 
U         2047 0.7% 0.5% 5.0% 1.9% 7.14 3.80 
WH     2844 0.4% 0.4% 10.1% 4.6% 24.59 11.55 
WH     9717 0.3% 0.4% 6.4% 2.7% 19.91 6.38 
WH     2268 0.5% 1.3% 2.3% 1.1% 4.60 0.85 
WHA  9718 0.5% 0.9% 3.2% 2.9% 6.4 3.22 
WH     2285 0.5% 0.4% 4.5% 1.2% 9 3 
Median 0.6% 1.0% 4.9% 2.5% 6.6% 2.7% 
Maximum 2.9% 3.3% 13.8% 7.5% 49.0% 11.6% 
Minimum 0.1% 0.2% 0.8% 0.4% 1.3% 0.8% 
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There was no negative impact on the ability of the T cell CD8+subset to produce the immune regulator 
cytokines. Both groups displayed similar measurable cytokine production post activation. (Tables 40, 40a) 
 
TABLE 40 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS ACCORDING TO 
CONDITIONING REGIMEN (CHEMOTHERAPY) 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 IFNy IL-4 IFNy IL-4 
C
H
E
M
O
T
H
E
R
A
P
Y
 
WH      2125 1.6% 3.2% 23.5% 16.6% 14.69 5.19 
WH      2363 0.8% 0.7% 26.0% 12.4% 32.50 17.71 
WH      2343 2.0% 1.0% 26.7% 9.8% 13.35 9.80 
WHA   9908 2.1% 0.5% 45.4% 24.9% 21.62 49.80 
WHA   9720 0.8% 0.4% 4.8% 0.8% 6.00 2.00 
WH      2342 0.1% 0.4% 12.3% 2.0% 123.00 5.00 
WH       9821 0.8% 1.0% 14.8% 6.1% 18.50 6.10 
WH      2258 0.7% 0.6% 18.0% 8.1% 25.71 13.50 
U          2056 0.6% 0.6% 16.4% 4.5% 27.33 7.50 
U          2044 1.9% 2.7% 9.0% 4.9% 4.74 1.81 
WH      2350 1.3% 1.0% 12.4% 3.3% 9.54 3.30 
WHA   9809 0.5% 0.8% 9.5% 5.1% 19.00 6.38 
U          2065 6.9% 10.5% 12.0% 20.4% 1.74 1.94 
WH       2259 1.1% 1.0% 16.3% 8.0% 14.82 8.00 
WHA    2061 2.9% 1.8% 19.8% 16.8% 6.83 9.33 
WHA   9716 0.6% 0.5% 11.4% 4.8% 19.00 9.60 
WHA   9909 1.5% 1.9% 20.4% 8.7% 13.60 4.58 
U          2046 0.1% 0.9% 9.3% 9.1% 93.00 10.11 
WHA   9823 0.2% 0.1% 9.9% 1.6% 49.50 16.00 
U          2037 0.5% 0.6% 13.8% 3.2% 27.60 5.33 
WHA   9822 0.2% 0.3% 11.0% 4.4% 55.00 14.67 
WHA   9828 0.3% 0.4% 15.0% 4.7% 50.00 11.75 
WH      2347 0.3% 0.5% 13.3% 4.4% 44.33 8.80 
U          2032 1.0% 2.1% 4.8% 1.7% 4.80 0.81 
U          2062 0.2% 0.8% 6.1% 3.2% 30.50 4.00 
WH      2359 0.6% 0.5% 16.9% 8.6% 28.17 17.20 
U          2054 0.5% 0.4% 9.0% 2.6% 18.00 6.50 
WH      2361 1.5% 0.2% 2.5% 1.3% 1.67 6.50 
U          2067 0.5% 0.5% 3.4% 1.8% 6.80 3.60 
Median 0.7% 0.6% 12.4% 4.8% 19.0% 6.5% 
Maximum 6.9% 10.55 45.4% 24.9% 123.0% 49.8% 
Minimum 0.1% 0.1% 2.5% 0.8% 1.7% 0.8% 
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TABLE 40a 
IN VITRO PRODUCTION OF IFN- AND IL4 WITHIN THE CD8+ T CELLS ACCORDING TO 
CONDITIONING REGIMEN (CHEMOTHERAPY AND RADIOTHERAPY) 
 
CD8+ CELLS 
 Unstimulated Stimulated Ratio 
Type Subjects INFy IL-4 INFy IL-4 INFy IL-4 
C
H
E
M
O
T
H
E
R
A
P
Y
 A
N
D
 R
A
D
IO
T
H
E
R
A
P
Y
 
WHA   9715 0.9% 0.9% 18.9% 10.1% 21.00 11.22 
WH      2246 0.4% 0.6% 9.1% 4.8% 22.75 8.00 
WH      2138 0.2% 0.2% 2.0% 0.9% 10.00 4.50 
WH      2309 0.5% 0.8% 3.0% 1.9% 6.00 2.38 
WH      2321 0.4% 0.7% 9.6% 3.3% 24.00 4.71 
WH      2280 0.4% 0.5% 14.8% 7.4% 37.00 14.80 
WH      2277 0.3% 0.4% 8.3% 4.7% 27.67 11.75 
WH      9704 1.6% 0.9% 11.3% 2.2% 7.06 2.44 
WH      2256 1.0% 1.5% 7.1% 4.4% 7.10 2.93 
WH      2101 1.7% 1.6% 12.9% 5.6% 7.59 3.50 
WH      2330 0.3% 0.2% 8.4% 1.6% 28.00 8.00 
WH      9814 0.9% 0.8% 22.4% 2.7% 24.89 5.20 
WHA   9810 0.1% 0.2% 6.1% 0.7% 61.00 3.50 
WH      2128 0.3% 0.4% 11.8% 3.6% 39.33 9.00 
WH      2293 0.2% 0.3% 3.1% 3.3% 15.50 11.00 
WH      2305 0.3% 1.5% 14.6% 4.1% 48.67 2.73 
U          9704 0.9% 1.3% 16.5% 6.5% 18.33 5.00 
WH      2288 0.3% 0.9% 1.5% 2.4% 5.00 2.67 
WH      2253 0.1% 0.2% 3.0% 2.5% 30.00 12.50 
WH      2285 0.2% 0.3% 11.2% 2.0% 56.00 6.67 
U          2047 0.4% 0.3% 13.9% 4.1% 34.75 13.67 
WH      2284 0.1% 0.3% 22.0% 8.3% 219.50 27.77 
WH      9717 0.3% 0.5% 15.8% 5.4% 52.80 9.96 
WH      2268 0.4% 1.0% 7.9% 2.3% 19.75 2.30 
WHA   9718 0.3% 0.7% 4.6% 3.6% 15.33 5.14 
WH      2285 0.4% 0.3% 5.8% 1.3% 14.50 4.33 
Median 0.4% 0.6% 9.4% 3.4% 23.4% 5.1% 
Maximum 1.7% 1.6% 22.4% 10.1% 219.5% 27.8% 
Minimum 0.1% 0.2% 1.55 0.7% 5.0% 2.3% 
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7.5.2.5 DISCUSSION 
The in vitro functional data generated during this study provided some unique findings: to date, most studies 
following transplant patients have focused on the basic hematology parameters in the blood and such data has 
only implied that patients have regenerated their peripheral components post transplant.  As far as we know, 
no studies have actually investigated the functionality of such elements.  It is apparent from our data that 
although the subjects showed normal levels of blood elements, the functions of these cells are severely 
hampered in vitro, especially the innate immune cells’ responses.  
 
Analysis of the data  showed that all three subgroups display a reduced neutrophil activity (innate response) in 
vitro: it is also evident that those who had received autografts had the best, most intact profile when compared 
to the other patients although these are still considered as impaired when compared to healthy controls. The 
age of the transplantation had a significant difference between subgroups: the most recently transplanted 
patients had the best and most “intact” responses (albeit abnormal when compared to healthy controls) 
 
The lymphoid group had better responses to E.Coli stimulation (a physiological stimulus used for the in vitro 
evaluation) in comparison to those who had myeloid diseases. Reduction in the myeloid group could be due to 
the cells being affected originally, causing them not to recover their function. In the different conditioning 
regimens both had reduced innate functions in vitro. The patients who received combination chemotherapy 
and radiotherapy seemed more intact than those who had chemotherapy only perhaps implying that the 
combination of several chemotherapeutic agents has more detrimental effects on the functional potential of 
neutrophils post transplantation.  
 
When the adaptive responses were evaluated in vitro (cytokine production in response to a non-specific 
stimulus and evaluation of the type of cytokine produced), the subjects who had had autografts showed the 
best CD4+ cell cytokine production when compared to their counterparts.  When regrouped according to age 
of transplant normal cytokine responses were seen in both CD4+ and CD8+ subsets. No major differences 
were noted amongst these three groups. Both the myeloid and lymphoid group displayed normal cytokine 
responses of the T-cell subset CD4+and CD8+ cells. The myeloid category showed marginally better reactivity 
post activation. There were normal cytokine responses in both CD4+ and CD8+ subsets when various 
conditioning regimens were used. No differences between the two therapies could be shown. 
 
7.5.2.6 CONCLUDING SUMMARY 
Studies investigating immune reconstitution post-transplantation are limited and generally relate to episodes 
of bacteremias including overt neutropaenias in the post-transplantation period. Castagnola and Faraci 
(2009)131,132 proposed that irrespective of the magnitude of myeloid suppression, patients should be covered 
by prophylactic antibacterials to prevent pulmonary complications.  To date, there have been no studies 
undertaken to determine the functionality of the peripheral blood elements in post-transplant patients.  Hence 
we believe that our data contributes new and unique data to the literature: it is the first to analyse both innate 
and adaptive responses of blood cells from subjects post-transplantation, in a relatively large cohort of 55 
subjects who received their transplants more than 10 years ago enrolled in South Africa. Various reports 
investigating cellular immune deficiency can be found in the literature.133,134 
 
Stellenbosch University  https://scholar.sun.ac.za
 196 
The data clearly indicates that irrespective of the type of transplant, age of the graft, disease category and pre-
conditioning regimen, this cohort displayed reduced granulocytic functions in vitro.  Contrastingly, all 
subjects showed normal cytokine production by CD4+ and CD8+ T cells when these were  activated in vitro to 
produce immune regulatory cytokines implying that their lymphoid component is intact post-transplantation.  
In other words, it appears that the innate response of granulocytic cells never recovers irrespective of time or 
type of transplant or conditioning regimen.  However, the adaptive response seems to be more robust and able 
to recover fully.  It appears that the proposal by Castagnola and Faraci (2009) to prophylactically treat 
subjects with antimicrobials is supported by our data: patients remain prone to developing bacterial infections 
(implying that the innate response is hampered) and yet are spared of viral or fungal infections (where the 
adaptive response is the most important).  
 
There have been individual reports investigating the cellular immune deficiencies following stem cell 
transplantation: it was reported by Seggewiss and Einsele (2010)117,135 that cytotoxic activity exhibited by NK 
cells or CD8+ T cells were severely reduced quantitatively and qualitatively up to 100 days post-
transplantation. In this cohort of patients studied, it was evident that such deficiencies were not apparent but 
this could be due to the fact that these subjects had passed the 100 day period post-transplantation.  It is also 
not clear from this data whether the cytotoxic activity of these cells was reduced: this was not determined.  
However, the assays conducted, namely the cytokine production post-activation in vitro, would imply that 
cytotoxic activity would be intact compared to healthy subjects. 
 
The granulocyte deficiency deserves some discussion:  this assay is extremely sensitive to delay in the 
processing of samples from blood drawn.  All samples were processed within four hours of phlebotomy and 
the results cannot therefore be explained by loss of functional cells in the sample or the toxic effects of the 
anti-coagulant used in the tubes.  Healthy subjects whose bloods are assayed up to six hours following 
collection draw display normal responses (data not shown).  The results imply that even up to ten years or 
more post-transplantation, the granulocytes never recover their full functional potential.  This would explain 
the incidence of bacterial episodes affecting predominantly the pulmonary system.  Although the subjects 
display normal haematological parameters on routine analysis, it appears that the granulocytes are defective 
in their functions 
 
 
7.5.3 BONE DISEASE  
7.5.3.1 INTRODUCTION 
At initiation of bone marrow transplantation in South Africa, there was already a worldwide appreciation that, 
among non-haematopoietic target organs, bone was particularly susceptible to demineralization injury.136,137 
Additionally, the skeleton is not only a very large structural and functional organ that interfaces with 
haematopoiesis but has distinctive metabolic and hormonal differences existing on a regional basis varying 
between trabecular and cortical  areas that are respectively – also variable - rich in these two components.138 
The impact of solid organ transplantation on rapid bone loss and fracture is impressive but data for bone 
marrow is scarce139 although mechanisms have been defined to explain accelerating hazard of osteoporosis 
secondary to demineralisation associated with underlying illness, chemotherapy, gender and graft-versus-host 
disease.140 With other predisposition, including allogeneic as opposed to autologous transplantation, and 
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often more prominent in the older age group leading to osteoporosis. Longer term follow up suggested 
benefits from calcium, with addition of vitamin D and bisphosphonate therapy. 
 
It was against this international experience that the opportunity was taken to document corresponding 
changes in a relatively homogenous population of patients transplanted in an accredited unit and on 
standardised protocols. Differences present in a wide range of physical activity, calcium and dietary intake, a 
number of skeletal damaging practices, such as culturally high intake of beer and other alcohol containing 
toxins described to give rise to alterations in bone mineral density.141,142 Additionally using 
immunosuppressive preparation employing monoclonal antibodies in contrast to known damage from 
conventional chemotherapy and particularly corticosteroids.143 This is known to influence skeletal integrity. 
Assessment was thus necessary to establish whether the present regimens also had adverse effects. The study 
aim was to measure bone mineral density (BMD) employing the gold standard of dual energy x-ray 
absorptiometry (DXA) and quantitative computer tomography (QCT). 
 
This was linked to obtaining a clinical fracture history and performance of vertebral fracture assessment (VFA) 
to detect the presence of vertebral fractures. Additionally, by the determination of bone turnover as an 
independent risk factor for fracture and by measuring serum osteocalcin as a parameter of formation and 
urine deoxypyridinoline reflecting resorption one hoped to find a correlation with imaging studies. This 
information was to challenge the clinical impression, coupled with early results, that bone mineral density 
measured with DXA differed from the same endpoint expressed in quantitative computed tomography (QCT) 
by directly comparing these two differing technologies.144 
 
7.5.3.2 PATIENTS 
A cohort (n=54) was available for DXA scanning of which 23 were female. Forty three individuals from the 
same group were evaluated for QCT analysis of which 16 were female. In a separate group derived from the 
previous study for the DXA scoring, 36 patients were initially available. For the QCT there were 
correspondingly data on 36 subjects, with results available for 25 pre-procedure, 30 at six months and 20 at 
one year. For the biochemical studies the starting number was 55 of which 23 (42%) were female. 
 
7.5.3.3 METHODS 
DXA based bone mineral density and vertebral fracture assessment145, 146 was carried out on the lumbar spine 
(L1 - L 4), the total hip and femora, employing a Hologic Discovery DXA machine.  The left hip shows normal 
bone density with a t-score of 1.6. (Figure 42) The measurements were subjected to strict quality control, 
involving the daily scanning of a manufacturer phantom. Values are expressed as t-scores (using the 
normative NHANES III data for young caucasians)147 in postmenopausal woman, in men over the age of 50 
years and the Z scores in premenopausal woman and men under 50 years. The WHO (1994)148 classification 
was employed using t-scores to categorise post-menopausal and subjects over the age of 50 as normal, 
osteopenic or osteoporotic. In younger individuals, a Z score if decreased or increased by more than 2.0 
standard deviations (SD) was regarded as abnormal. Vertebral fracture assessment was performed by 
manually spiking lumbar and thoracic vertebrae (T 12 - T 6) and having a DXA programme determine the 
anterior, mid and posterior vertebral heights. This procedure was performed by only one experienced   
technologist allowing for uniformity. 
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FIGURE 42 
EXAMPLE OF DXA RESULT USING HOLOGIC DISCOVERY DXA MACHINE 
 
 
Courtesy Dr Derek Solomon  
 
 
The comment that QCT is not as precise as DXA may stem from earlier studies that preceded the introduction 
of newer software. To this end the precision of the system in a group of volunteers was tested and found to be 
in the order of 1 to 2% which is on par with DXA.138 A CT-Siemens sensation 64 scanner with osteo- package 
was used. Scanners were calibrated against a stable phantom for each image. The radiation dose was 
extremely low, less than for a standard posterior anterior chest radiograph. Considering that the studies were 
performed at intervals of 1 to 2 years this risk was perceived of as minimal and of limited or no clinical 
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concern.  Measurements for trabecular and cortical densities through L2, with a graph showing the trabecular 
bone densities for L1-4 and the average density indicating a t-score of -2.47 which is just above the 
osteoporotic threshold. (Figure 43) 
 
Quantitative computed tomography (QCT)149, 150 gives a volumetric measurement of both trabecular and 
cortical bone with the t-score being calculated from the volume of the trabecular bone density. By analysing 
the high-resolution axial images of the vertebrae it is possible to visualise directly abnormalities that may 
account for discrepant readings.138   This method was chosen to compare with DXA as we had previous results, 
from an audit, on a group which was studied at six monthly intervals.   
 
FIGURE 43 
EXAMPLE OF QCT SCAN – MEASUREMENTS FOR TRABECULAR AND CORTICAL DENSITIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Courtesy Dr Derek Solomon 
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Figure 44 shows a QCT slice through individual vertebral body with an osteoma in the right half trabecular 
volume which would give an artificially high density for this reason.138 
 
FIGURE 44 
QCT SCAN – ABNORMALITY POSSIBLY CAUSING DISCREPANT READING 
 
Courtesy Dr Derek Solomon 
 
 
Biomarkers were measured to define formation and resorption as an index of bone health151 employing serum 
osteocalcin152 using the liason diasorin assay and deoxypyridinolene153 in urine respectively – the latter 
performed on the Immulite 1000 method using chemiluminescence.153 These findings were correlated with 
radiological studies. Both platforms were automated and the procedure done by a dedicated technologist. 
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7.5.3.4 RESULTS 
A cohort of patients was available for DXA (n=54) and QCT (n=43).  Where bone loss occurred, comparing the 
same individuals (43), there was a BMD decrease in 9 (21%) for DXA and 30 (70%) with QCT. (Table 41) 
 
TABLE 41 
 BMD RESULTS OF SUBJECTS COMPARING DXA AND QCT  
 
FEMALES  < 50 YEARS 
PATIENT DXA QCT 
WH2359 NORMAL OSTEOPENIA 
WH2256 NORMAL OSTEOPENIA 
WH2309 OSTEOPENIA OSTEOPENIA 
WH9908 OSTEOPENIA OSTEOPENIA 
WHA2061 NORMAL NOT DONE 
WH2321 NORMAL NOT DONE 
U2044 NORMAL NOT DONE 
WH2246 NORMAL NOT DONE 
WH2311 INCREASED OSTEOPENIA 
U2056 NORMAL NOT DONE 
WH2293 NORMAL NORMAL 
WH2253 NORMAL NORMAL 
WH2263 NORMAL NORMAL 
U2062 NORMAL NORMAL 
  
  
  
FEMALES  ≥ 50 YEARS  
WH9704 OSTOPENIA OSTEOPOROTIC 
WH2342 OSTOPENIA OSTEOPENIA 
WHA9828 OSTOPENIA OSTEOPENIA 
WHA9809 OSTOPENIA OSTEOPENIA 
WH9720 NORMAL OSTEOPENIA 
WH2101 NORMAL OSTEOPENIA 
WHA9823 INCREASED NOT DONE 
WH2125 INCREASED NOT DONE 
WH2330 NORMAL NORMAL 
 
 
 
 
 
 
MEN < 50 YEARS 
PATIENT DXA QCT 
U9704 NORMAL NOT DONE 
WH2028 OSTEOPENIA NOT DONE 
WH2277 NORMAL NORMAL 
WH2259 NORMAL NORMAL 
WH2285 NORMAL NORMAL 
WH2138 NORMAL OSTEOPOROTIC  
WH2343 NORMAL OSTEOPENIA 
WHA9829 INCREASED NOT DONE 
WH9814 NORMAL NORMAL 
U2054 NORMAL OSTEOPENIA 
U2037 INCREASED NORMAL 
WHA2067 NORMAL OSTEOPENIA 
WHA9909 INCREASED OSTEOPENIA 
  
  
 
  
  MEN ≥ 50 YEARS  
WH2268 NORMAL OSTEOPOROTIC 
WH2288 NORMAL OSTEOPOROTIC 
WH2280 NORMAL OSTEOPOROTIC 
WHA9718 NORMAL OSTEOPENIA 
WHA9810 NORMAL OSTEOPENIA 
WHA9716 NORMAL NORMAL 
WH2258 NORMAL NORMAL 
U2047 NORMAL NORMAL 
WHA9715 INCREASED OSTEOPENIA 
WH2305 OSTEOPENIA NOT DONE 
WH2347 NORMAL OSTEOPENIA 
WH9821 INCREASED OSTEOPENIA 
U2046 OSTEOPENIA OSTEOPOROTIC 
WH9717 OSTEOPENIA OSTEOPOROTIC 
WH2361 OSTEOPENIA OSTEOPOROTIC 
WH2284 NORMAL OSTEOPOROTIC 
U2032 NORMAL OSTEOPENIA 
WH2350 NORMAL OSTEOPOROTIC 
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In a subgroup of 36 individuals on which both DXA and QCT scans could be compared over time, the median 
shows there was statistical significance (p= 0.0062) in the DXA t-score scan where there was an improvement 
over time (the reason could not be explained) and in the QCT-t-score there was no significant difference 
(p=0.2564). (Table 42) 
 
TABLE 42 
DIFFERENCES IN DXA AND QCT T-SCORES OVER TIME – SIX MONTHLY PROCEDURES 
 
        QCT t-score 
 Observations Median (mg/cm3) IQR Range 
Pre t-score 25 -1.6 -2.4 to -0.8 -2.9 to 0.66 
6 month t-score 30 -1.95 -2.57 to -1.2 -3.7 to 1.83 
1 year t-score 20 -1.77 -2.7 to -1.275 -4.6 to 2.8 
 
 
        DXA t-score 
 Observation Median (g/cm2) IQR Range 
Pre t-score 36 -0.65 -1.55 to 0.25 -3.5 to 1.5 
6 month t-score 36 -0.55 -1.7 to 0.2 -3.0 to 1.5 
1 year t-score 19 -0.3 -1.3 to 0.7 -2.4 to 1.6 
 
 
In men under the age of 50 years (n=13), DXA showed one decrease at the spine and hip but some had 
significant increases in BMD. The QCT scan (n= 10) recorded normal BMD in five subjects only, osteopenia in 
four and frank osteoporosis in one. The DXA recorded one subject with osteopenia and no osteoporosis. There 
was 40% accordance between the scans. The average age, serum osteocalcin - or urine deoxypiridinoline 
(DPD/creatinine) - did not differ in this group.  
 
In older men above 50 years (n=18) the DXA was normal in 12 and only modestly decreased in the rest. The 
cut off value, t-score -2.5, was not reached in any individual. With the QCT (n=7) a normal BMD was  found in 
three; osteopenia in another six and osteoporosis in eight (47%) here only 18% showed similarity. The 
biomarkers between those with normal BMD and those with decreased values did not differ significantly.  
 
Amongst young women less than 50 years (n=14) BMD was normal in 11 and significantly increased in one 
subject. Two women were osteopenic. In comparison, the QCT (n=9) showed normal BMD in four subjects 
and osteopenia in five. Here a discrepancy between the scans was 33%. 
 
In women 50 years and above DXA (n=9) was normal in three subjects, significantly increased in two and 
osteopenic in four. With the QCT (n=7) one had a normal BMD, five had osteopenia and one had osteoporosis. 
The difference between the scans was 43%.  
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When diagnosis, type of transplant and conditioning were analysed in those who had DXA showing 
osteopenia, no significant differences were seen.  
 
With QCT demonstrating osteopenia, diagnosis did not have an impact but in type of transplant, autografts 
were predominant at 11/20 (55%) and in conditioning, the chemotherapy alone was 13/20 (65%). 
 
No patients had osteoporosis on DXA but 10 (23%) on QCT.  Here the myeloid group was 8 (80%), the 
allografts 6 (60%) and chemotherapy with radiotherapy 7 (70%). 
 
The median age for females was 46 years and for males 55.5 years. DPD and serum osteocalcin values did not 
differ significantly between age groups or sexes, nor did they differ significantly between those with a normal 
or abnormal BMD.  Biomarkers showed normal results with median levels in all tests being similar between 
males and females. (Table 43) 
 
TABLE 43 
BIOMARKERS – RESULTS IN FIFTY-FIVE POST-TRANSPLANT PATIENTS 
 
DPD Creatinine Ratio 
(nM/mM) 
Median IQR Min Max Normal 
Range 
(nM/mM) 
 
Female 4.9 1.75 – 6.1 0.41 8.0 3.0 to 7.4 
Male 4.3 3.15 – 5.45 0.24 12.2 2.3 to 5.4 
 
Osteocalcin 
(ng/ml) 
Median IQR Min Max Normal 
Range 
(ng/ml) 
 
Female 13.3 10.8 – 15.6 9.1 21.4 5.4 to 59.1 
Male 14.15 11.75 – 16.85 8.1 31.8 4.6 to 65.4 
 
Age (years) Obs Median IQR Range 
 
All 55 52 37 - 62 26 to 73 
Female 23 46 33 - 58 26 to 71 
Male 32 55.5 40.5 – 62.5 27 to 73 
 
 
This population was devoid of any fracture history. With the exception of two vertebral 
abnormalities/deformities, no clear evidence of a vertebral fracture could be documented. 
 
7.5.3.5 DISCUSSION 
The study included 17% elderly women, few over 50 years and hardly any over 70 years. As osteoporosis is a 
disease affecting the very elderly, this group was not particularly prone to develop this although they were 
most probably menopausal (not tested) because of myeloablative conditioning. History on the use of bone 
protective agents e.g. bisphosphonates, calcium and vitamin D was not accurate but it was never used 
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prophylactically except in the patients with myeloma(n= 3). It is well known that many bone toxic agents (eg. 
glucocorticosteroids, pre-transplant conditioning therapy) 154 affect patients of all ages and gender. It did not 
appear to be the case in this study where DXA scan did not have any patient reaching the so called 
osteoporosis range However QCT scans documented osteoporosis in a number of subjects. 
 
7.5.3.6 CONCLUDING SUMMARY 
Unlike conventional post-transplantation chemotherapeutic regimens, the immunotherapy used in the present 
study of long term survivors, employing a monoclonal antibody against CD52, appeared to be remarkably bone 
friendly. No fracture history of note and no objective evidence of vertebral fractures assessed quantitatively 
employing DXA and vertebral fracture assessment (VFA), could be ascertained in this cohort of 54 patients. 
Moreover, the current gold standard surrogate marker of skeletal strength, DXA-measured bone mineral 
density (BMD), was quite unremarkable. Very surprising is the fact that not a single subject having DXA had a 
BMD value in the so-called osteoporosis range (i.e. t-score ≤ 2.5 SD in older subjects or a Z-score ≤ -2.0 SD in 
those < 50 years). Of particular interest also is the finding of an apparent increase in BMD in no less than 15% 
(8/54) of the study population. The reason for this remains unclear.  The literature shows  bone loss after stem 
cell transplantation to occur frequently due to the conditioning drugs and gonodal dysfunction following 
radiotherapy.154 
 
Biomarkers of bone turnover did not improve insight into the skeletal health of our study population, but this 
may merely reflect small study numbers. 
 
A poor correlation appeared to exist between the DXA and QCT BMD results, 155 with only 39% concordance. 
These were available in the vast majority of individuals (80%). However, analysed separately, it is clear that a 
much better correlation is present in the female population with similar results being reported in more than 
63% (10/16) of subjects. The poor correlation therefore appears to exist largely in the male population, where 
more than 73% of results were discrepant.  
 
No consensus has been reached in establishing which modality (DXA vs QCT) is the more superior.  
Advantages and disadvantages exist for both methods. 146, 151 
 
DXA is still the International Gold Standard for measuring BMD.  QCT is still a research instrument and it has 
not yet been validated for predicting fracture risk thus it is not recommended for screening. It seems to be 
more sensitive and can provide an alternative method as a supplement to DXA.  However there is at present 
no evidence that one is better than the other and more studies are required.  To detect and manage 
osteoporosis, DXA remains the recommended technique for diagnosing and monitoring BMD in South Africa. 
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7.6 SUMMARISING COMMENT 
 
 
This chapter included an audit of acute associations that occurred within the first three 
months and a study for the late effects after one year. It was shown that in nephrology 
nearly all kidney injuries returned to normal after the first 12 weeks. In dermatology 
there was a marked reduction in GVHD following the addition of anti-CD52 antibody to 
the graft ex vivo. This was also reported by other centres. Cardiac complications were 
negligible, emphasising the need to function within a multidisciplinary team. 
Gastroenterology immediately post-transplant presented with many side-effects. The 
nausea, vomiting, anorexia and diarrhoea were mostly related to the high doses of 
chemotherapy used for the conditioning regimen and worsened with the subsequent 
neutropenia. The symptoms usually disappeared when there was marrow 
regeneration. In the few patients where this persisted it was necessary to refer them to 
a gastroenterologist. In the study using post transplant survivors, no abnormalities 
were seen in the respiratory group. The chest x-rays and lung function studies were 
normal. In our cohort, GVHD was not a problem thus reducing respiratory side-effects.  
Most of these non-infectious complications reported in the literature occur due to 
GVHD. Immunology indicated that the innate response of granulocytic cells never 
recovers but the adaptive immune response seems to recover fully. It is unsure whether 
these results are due to the antibody that was administered ex vivo, as world literature 
reports reversal of immune status by one year. The bone disease indicated that there 
were only slight BMD decreases and even increases in some individuals. It is unclear if 
this could be attributable to the CD52 antibody as unmanipulated transplants have a 
different outcome. There was a discrepancy between the techniques used to measure 
BMD with QCT detecting more abnormalities than DXA. This study provided data on 
complications that can be used as a reference for new research projects on the African 
continent. 
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8. FINAL SUMMARY 
 
It was a challenge to how most lucidly present an evolving series of biological phenomena in which goalposts 
shifted from the traditional endpoint of haematologic recovery to include events taking place now in non-
haematopoietic tissues and encapsulating the concept of survivorship. 
 
In starting a new department with no infrastructure, many obstacles had to be conquered. Negotiations with 
hospital and university authorities achieved available space and equipment. This culminated in the building of 
a prototype physical plant in which achievements from international groups could be duplicated. Another 
impediment was the lack of skills to nurse these patients. This was overcome by arranging international 
training programmes in established units.  Financial constraints were often solved by obtaining sponsorship 
for special equipment such as cell separators. This unit became the prototype on which all other South African 
units were built and provided all the training.  
 
During the developmental phase, the source for the transplant procedure changed from bone marrow to 
peripheral blood stem cells and then cord blood. Initially only allografts were performed, moving to autografts 
and this was followed by matched unrelated donors that required the establishment of a local Bone Marrow 
Registry. 
 
For our unit, the most important achievement was when there was the opportunity to collaborate with 
Professor Herman Waldman and Professor Geoff Hale regarding the use of a monoclonal antibody as a unique 
immunosuppressant regimen. The anti CD52 antibody was added to the bag and infused - the ex vivo 
approach - leading to diminishing of GVHD and significantly changing quality of life.  Thereafter, 
unmanipulated stem cells were no longer used in our unit. 
 
Data was reported to registries to attain accreditation. 
 
Data collected for the registries stimulated the study on acute associations and late effects in non-
haematopoietic tissue.  The goal was to establish the influences of the major change in conditioning using 
monoclonal antibodies of the Campath® series of immunoglobulins.  The early complications were analysed by 
performing an audit extracting data from the patient records. It had advantages as it took less time and the 
information was readily available but as a negative, this relied on others for the accuracy of the record keeping.  
It also had fewer financial implications. Biases may have occured at various levels and in this study there was 
selection bias as only patients with sufficient data for analysis were used. It did not have a control group which 
would have provided a comparison between unmanipulated and manipulated stem cells, as the question 
required insight into the difference Campath® made to the outcome.  
 
 
In the late effects, a volunteer group of post transplant survivors was selected. Specialised tests were done at 
one point in time. It provided some outcome information but could only be evaluated against published 
literature. A limitation here could have been a “healthy survivor” effect in that those with major dysfunction 
could have succumbed and only the healthier subjects who were still alive could be studied. This was 
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particularly relevant to the respiratory function testing. Again, the main disadvantage was that there was no 
control group in whom a comparison between the use of unmanipulated grafts and those using Campath® ex 
vivo could be made. An attempt was made to compare outcome in different types of transplants, diseases and 
conditioning regimens.  Most of the results were normal but as there was no control group, no definite 
conclusion could be made that adding the monoclonal antibody to the graft resulted in these positive 
outcomes. 
 
The solution would be for all the units in South Africa to create a research study and collaborate with one 
another, which would then allow comparison, as all the centres do not use Campath® ex vivo. The numbers 
would be increased, diseases could then be categorized and serial studies conducted over a time period. 
Numerous attempts to achieve such cooperation have unfortunately failed. There would also be financial 
constraints as State hospitals have fixed budgets and in private facilities, the medical insurance will not pay for 
research studies. A solution could be sponsorship or research grant requests. Even if no prospective study can 
be done there would be sufficient data available to do an audit with a control group. 
 
This study showed that our early complications occurred with a similar frequency to published data.  In the 
late effects, most of the results were normal except the immunology where the functional study indicated that 
the patients had reduced granulocyte function. The immunological evaluation could have been done 
sequentially to evaluate how long dysfunction persists and thus, when recovery occurs. It would also have been 
useful to correlate immune function with actual infective episodes and aetiological agents. This would attest to 
the functional relevance of the specialised immunological tests and delineate the frequency of long-term 
surveillance.  A prospective study with a control group would also be able to prove if the monoclonal antibody 
could be implicated.  Previous studies focusing on haematological parameters implied that immune 
reconstitution takes place up to one year post transplant. Even if these were healthy individuals, late 
complications could have occurred as many of them had radiotherapy, known to cause respiratory injury as 
well as bone loss. 
 
In conclusion, although it was difficult to confirm outcome as related to the Campath® ex vivo, it still provided 
information on the impact of acute and late injury to organ systems. These are judged to solidly underpin 
accumulation of data supporting a contribution with matching groups from other centres.  This could assist in 
promoting future collaboration in South Africa between transplant teams. 
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ANNEXURE 1 
DEMOGRAPHIC DATA ON ALL PATIENTS TRANSPLANTED AND REPORTED TO REGISTRIES 
 
INITIALS SEX AGE 
(A/C) 
DOT DLS TYPE SOURCE DISEASE AGE 
CC M A 12.04.95 28.12.10 ALLO BM CML 42 
JH F A 24.05.95 05.12.98 ALLO BM AML 54 
BH F A 14.06.95 11.01.99 ALLO BM NHL 36 
YS F A 05.07.95 28.12.10 ALLO BM AML 35 
GP M A 16.08.95 15.12.97 ALLO BM CML 49 
AC M C 06.09.95 28.12.10 ALLO BM AA 18 
JT M A 08.11.95 01.06.07 ALLO BM CML 24 
ME F A 06.12.95 28.12.10 ALLO BM CML 38 
JK M A 06.03.96 30.11.96 ALLO BM CML 27 
GP F C 03.04.96 28.12.10 ALLO BM FANCONI 10 
MS F C 15.05.96 28.12.10 ALLO BM THALASSAEMIA 7 
ET  M C 31.07.96 24.04.00 ALLO BM AML 3 
WK M A 07.08.96 11.04.01 ALLO BM CML 45 
RC M A 14.08.96 21.08.96 ALLO BM CML 48 
JS M C 28.08.96 13.01.97 ALLO BM AML 4 
GB F A 11.09.96 26.05.05 ALLO BM MM 53 
RN F C 09.10.96 28.12.10 ALLO PBSC FANCONI 12 
CM F C 30.10.96 28.12.10 ALLO PBSC FANCONI 6 
CB M A 04.12.96 18.05.97 ALLO PBSC CLL 50 
KF F C 08.01.97 28.12.10 ALLO PBSC FANCONI 11 
JD F C 15.01.97 28.12.10 ALLO PBSC CML 13 
BS M C 21.01.97 04.04.97 ALLO PBSC FANCONI 7 
WS F A 05.02.97 28.12.10 ALLO PBSC NHL 56 
VE M A 12.02.97 28.12.10 ALLO PBSC AA 24 
BS M C 27.02.97 04.04.97 ALLO PBSC FANCONI 7 
JK F A 12.03.97 15.04.98 ALLO PBSC ALL 42 
JR M C 03.04.97 28.12.10 ALLO PBSC AA 11 
CW F A 23.04.97 05.07.97 ALLO PBSC MM 43 
KN M A 05.05.97 28.12.10 ALLO PBSC NHL 37 
CT F A 25.06.97 01.08.97 ALLO PBSC AML 41 
PP M A 02.07.97 28.12.10 ALLO PBSC CML 30 
SW M C 09.07.97 28.12.10 ALLO PBSC HL 12 
JN M C 10.07.97 14.07.98 ALLO PBSC AA 13 
BJ M A 16.07.97 28.12.10 ALLO PBSC CML 49 
LK F A 23.07.97 28.12.10 ALLO PBSC ALL 31 
JM M C 13.08.97 28.12.10 ALLO PBSC ALL 19 
TE M A 20.08.97 28.12.10 ALLO PBSC CML 40 
FL M A 17.09.97 28.12.10 ALLO PBSC NHL 49 
PC M A 01.10.97 28.12.10 ALLO PBSC ALL 34 
SN F C 23.10.97 28.12.10 ALLO PBSC AML 15 
AB M A 04.11.97 20.07.98 ALLO PBSC AML 39 
SK M A 12.11.97 26.06.99 ALLO PBSC AA 34 
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IS F A 26.11.97 28.12.10 ALLO PBSC NHL 41 
LB F C 04.12.97 20.02.98 ALLO PBSC GERM CELL 2 
DH M A 10.12.97 18.11.00 ALLO PBSC CML 45 
BH M A 24.12.97 04.01.98 ALLO PBSC MM 59 
LW F A 31.12.97 28.12.10 ALLO PBSC NHL 49 
NS F C 14.01.98 28.12.10 ALLO PBSC MDS-CMML 2 
KW F A 04.02.98 18.07.98 ALLO PBSC HL 32 
JN M C 10.02.98 14.07.98 ALLO PBSC AA 13 
KO M A 12.02.98 27.06.03 ALLO PBSC ALL 33 
JP M A 12.03.98 28.12.10 ALLO PBSC CML 46 
LN F C 18.03.98 28.12.10 ALLO PBSC AML 14 
MN F A 25.03.98 28.12.10 ALLO PBSC AML 34 
AR M A 08.04.98 28.12.98 ALLO PBSC NHL 41 
ER F A 06.05.98 28.12.10 ALLO PBSC CML 40 
GW F A 20.05.98 09.06.98 ALLO PBSC PRA 29 
IS F A 28.05.98 24.04.99 ALLO PBSC AA 50 
SL F A 10.06.98 23.05.99 ALLO PBSC CML 57 
PN M A 24.06.98 19.07.99 ALLO PBSC CML 30 
CE M A 22.07.98 21.04.99 ALLO PBSC ALL 27 
GM M A 13.08.98 28.12.10 ALLO PBSC AML 32 
EB M A 19.08.98 28.12.10 ALLO PBSC CML 55 
JC M C 21.08.98 28.12.10 ALLO MUD HURLERS SYNDROME 2 
BK M A 16.09.98 12.03.99 ALLO PBSC AA 28 
JP M A 18.11.98 08.07.00 ALLO PBSC AML 51 
SN F C 15.12.98 06.01.99 ALLO PBSC AML 12 
JB M A 17.12.98 03.07.99 ALLO PBSC ALL 32 
AK M A 30.12.98 28.12.10 ALLO PBSC NHL 58 
DE M A 31.12.98 28.12.10 ALLO PBSC NHL 28 
SN F A 06.01.99 02.01.00 ALLO PBSC MASTOCYTOSIS 52 
NT M A 20.01.99 28.09.99 ALLO PBSC NHL 42 
BO M A 03.02.99 28.10.99 ALLO PBSC NHL 45 
OG F A 10.02.99 30.04.99 ALLO PBSC AA 94 
LS F A 17.02.99 27.07.99 ALLO PBSC NHL 44 
BW M A 24.02.99 09.10.99 ALLO PBSC NHL 58 
DN M A 03.03.99 09.09.03 ALLO PBSC NHL 29 
LB F C 17.03.99 28.12.10 MUD PBSC FANCONI 9 
AB F A 10.03.99 26.09.99 ALLO PBSC HL 40 
IP M A 25.03.99 31.08.99 ALLO PBSC AA 94 
MH M C 25.03.99 28.12.10 ALLO PBSC CML 19 
NS F A 31.03.99 11.06.99 ALLO PBSC NHL 37 
AA M A 14.04.99 28.12.10 ALLO PBSC MM 42 
MZ M A 29.04.99 15.12.99 ALLO PBSC MM 42 
GM F A 29.04.99 30.10.99 ALLO PBSC NHL 57 
AS F A 05.05.99 28.12.10 ALLO PBSC NHL 53 
BJ M A 12.05.99 28.12.10 ALLO PBSC ALL 44 
SC F C 19.05.99 28.12.10 MUD BM ET 17 
PK M A 03.06.99 23.11.99 MUD PBSC CLL 58 
WC M C 23.06.99 21.07.99 MUD PBSC ALL 16 
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RR F A 07.07.99 28.12.10 ALLO PBSC CML 40 
JT M C 04.08.99 28.12.10 ALLO PBSC SICKLE CELL ANAEMIA 10 
RS M A 25.08.99 10.12.99 ALLO PBSC MM 46 
AP F A 01.09.99 21.03.02 ALLO PBSC CML 56 
DM M C 08.09.99 28.12.10 ALLO PBSC SICKLE CELL ANAEMIA 2 
CT F A 15.09.99 28.12.10 ALLO PBSC CML 40 
CC M C 21.09.99 10.09.00 MUD PBSC ALL 17 
JS M C 22.09.99 28.06.99 ALLO PBSC FANCONI 16 
JW M A 29.09.99 28.12.10 ALLO PBSC CML 30 
TZ F A 06.10.99 28.12.10 ALLO PBSC CML 33 
NO M C 15.10.99 28.12.10 MUD PBSC CML 18 
OO M A 03.11.99 09.11.99 ALLO PBSC FANCONI 29 
SB F A 03.11.99 10.10.00 ALLO PBSC AA 25 
JM M A 10.11.99 13.02.02 ALLO PBSC CML 25 
RH M A 10.11.99 15.08.07 ALLO PBSC NHL 50 
NY F C 08.12.99 28.12.10 ALLO PBSC ALL 16 
JH F A 08.12.99 02.04.02 ALLO PBSC CML 44 
PF M C 23.12.99 17.08.02 ALLO PBSC AML 11 
SE F A 12.01.00 19.12.03 ALLO PBSC NHL 25 
AH M A 26.01.00 06.05.01 ALLO PBSC AML 52 
EB F A 02.02.00 10.12.00 ALLO PBSC NHL 37 
PD M A 02.02.00 24.05.00 ALLO PBSC NHL 50 
KB F A 09.02.00 28.08.10 ALLO PBSC AML 31 
CR F A 16.02.00 26.01.03 ALLO PBSC ET 51 
BS F A 01.03.00 29.04.00 ALLO PBSC CML 46 
CB F A 01.03.00 23.04.00 ALLO PBSC NHL 25 
NS F A 23.03.00 19.11.01 ALLO PBSC AML 34 
ND F C 29.03.00 25.04.00 ALLO PBSC FANCONI 6 
TC F A 17.05.00 29.06.00 MUD PBSC MYELOPROLIF 23 
ML F A 14.06.00 15.12.00 MUD PBSC CML 24 
DS M C 26.07.00 28.12.10 ALLO PBSC SCID 11 
AM M A 02.08.00 16.06.01 ALLO PBSC MM 57 
CC M C 09.08.00 10.09.00 MUD PBSC ALL 19 
WP M A 06.09.00 13.06.03 ALLO PBSC ALL 21 
MO F A 13.09.00 26.01.01 ALLO PBSC MM 51 
DV F C 20.09.00 20.10.00 ALLO PBSC FANCONI 4 
ND M A 20.09.00 24.09.00 MUD PBSC NHL 47 
LL M C 13.10.00 28.12.10 MUD PBSC ALL 20 
LL M C 08.11.00 28.12.10 MUD PBSC ALL 20 
AB F A 29.11.00 09.12.00 MUD BM CML 42 
SF M A 07.12.00 28.12.10 MUD PBSC CML 52 
CF F A 05.01.01 28.12.10 MUD BM CML 41 
MG M A 10.01.01 28.12.10 MUD PBSC CML 40 
NC F C 24.01.01 01.03.02 MUD PBSC ALL 17 
SF F C 25.01.01 11.02.01 MUD PBSC AA 8 
DH M A 07.02.01 06.01.08 ALLO PBSC MM 32 
KL M C 07.02.01 28.12.10 ALLO PBSC SICKLE CELL ANAEMIA 16 
KD M A 17.01.01 23.12.01 ALLO PBSC MYELOPROLIF 64 
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GF M A 14.03.01 28.12.10 ALLO PBSC ALL 34 
ZV F C 28.03.01 28.12.10 ALLO PBSC FANCONI 7 
CM F C 04.04.01 28.12.10 ALLO PBSC SICKLE CELL ANAEMIA 6 
TL M C 11.04.01 27.05.01 MUD PBSC CML 14 
MG F A 26.04.01 28.12.10 MUD BM AML 44 
CW F A 16.05.01 28.12.10 ALLO PBSC CML 32 
CD M A 17.05.01 23.05.01 MUD BM MDS 56 
MM F A 23.05.01 28.12.10 ALLO PBSC CML 56 
JF M A 30.05.01 18.09.03 ALLO PBSC NHL 39 
BR F A 04.07.01 28.12.10 MUD BM MM 48 
WB M A 11.07.01 28.12.10 MUD BM PNH 29 
IZ M A 18.07.01 28.12.10 ALLO PBSC NHL 44 
EG M A 08.08.01 29.12.01 ALLO PBSC AA 47 
NR F A 15.08.01 02.09.01 MUD PBSC AML 47 
PO M A 15.08.01 19.03.02 ALLO PBSC CML 47 
JC M A 29.08.01 28.12.10 ALLO PBSC ALL 46 
JM M A 19.09.01 28.12.10 ALLO PBSC CML 27 
FK M A 12.09.01 28.12.10 ALLO PBSC MM 54 
GG M A 19.09.01 13.02.02 MUD PBSC MM 38 
HW M C 24.10.01 16.12.01 ALLO PBSC NHL 19 
RA M A 24.10.01 28.12.10 ALLO PBSC CML 37 
MT M A 07.03.01 14.02.04 ALLO PBSC MM 31 
PF M C 31.10.01 17.08.02 ALLO PBSC AML 13 
VS M A 07.11.01 28.12.10 ALLO PBSC AA 53 
AP M A 07.11.01 15.07.02 ALLO PBSC NHL 54 
HP M A 28.11.01 17.01.05 ALLO PBSC MM 59 
GC M C 12.12.01 28.12.10 MUD BM AA 19 
KB M C 12.12.01 28.12.10 ALLO PBSC AML 17 
MK F C 19.12.01 28.12.10 ALLO PBSC SICKLE CELL ANAEMIA 11 
PF F C 27.12.01 28.12.10 ALLO PBSC AA 18 
CB F C 09.01.02 28.12.10 ALLO PBSC AML 19 
CS F C 23.01.02 19.04.02 ALLO PBSC CML 13 
AB M A 06.02.02 28.12.10 ALLO PBSC AML 45 
MB M C 14.02.02. 28.12.10 MUD PBSC AA 14 
LC M A 27.02.02 03.03.02 ALLO PBSC NHL 57 
MA M A 06.03.02 28.12.10 MUD PBSC CML 62 
LF F A 17.04.02 28.12.10 ALLO PBSC MM 51 
TS F A 24.04.02 28.12.10 MUD BM AML 24 
JS M C 30.04.02 02.11.03 ALLO PBSC NHL 11 
BM F A 30.04.02 13.02.06 ALLO PBSC NHL 60 
DS F A 09.05.02 28.12.10 MUD BM AML 36 
MN F A 19.06.02 28.06.02 ALLO PBSC MM 57 
DM M A 26.06.02 28.12.10 ALLO PBSC NHL 48 
JK M C 17.07.02 28.12.10 ALLO PBSC CML 18 
JM M A 28.08.02 23.03.04 ALLO PBSC AMYLOID 50 
PB M A 11.09.02 06.10.04 ALLO PBSC MYELOFIBROSIS 55 
CM M A 18.09.02 15.01.09 MUD PBSC MDS-RARS 61 
JK M A 20.11.02 17.10.03 MUD PBSC HL 35 
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MC F A 04.12.02 20.04.03 MUD PBSC CML 47 
AN M A 04.12.02 15.05.03 MUD PBSC AA 28 
JI M A 11.12.02 29.05.03 MUD PBSC MM 42 
SK M A 28.03.01 28.12.10 ALLO PBSC ALL 28 
MC M A 18.12.02 28.12.10 MUD PBSC CML 53 
JS M A 19.12.02 28.12.02 MUD PBSC AML 30 
WS M A 16.01.03 05.08.03 MUD PBSC NHL 45 
MH F A 29.01.03 13.05.03 ALLO PBSC NHL 56 
CD F A 12.02.03 02.04.03 ALLO PBSC MM 47 
AF M A 05.03.03 11.10.04 ALLO PBSC CML 32 
JB F A 23.04.03 28.12.10 ALLO PBSC AML 45 
ZR M A 24.04.03 31.10.03 ALLO PBSC ALL 30 
MJ M A 30.04.03 16.05.03 ALLO PBSC MM 51 
PM M A 07.05.03 28.12.10 MUD PBSC NHL 38 
RC M A 02.07.03 17.11.03 ALLO PBSC NHL 52 
AC M C 02.07.03 25.09.03 ALLO PBSC MDS-RAEB 11 
CM M A 06.08.03 28.12.10 MUD PBSC AML 47 
NB M C 03.09.03 28.12.10 MUD PBSC AA 17 
BV M A 10.09.03 28.12.10 ALLO PBSC NHL 37 
AM M A 10.09.03 28.12.10 ALLO PBSC CML 54 
FB M A 08.10.03 28.12.10 MUD PBSC ALL 31 
JK M A 15.10.03 17.10.03 MUD PBSC NHL 35 
JE M C 16.11.03 20.01.04 MUD PBSC MDS-CMML 1 
MP F A 10.12.03 19.12.03 MUD PBSC MM 52 
JE M C 18.12.03 20.01.04 MUD PBSC MDS-CMML 1 
BB M A 14.01.04 28.12.10 MUD PBSC CML 57 
MM F C 21.01.04 18.03.04 MUD PBSC AML 4 
ZR F A 18.02.04 03.03.04 MUD PBSC CML 32 
TN M A 18.02.04 23.02.04 ALLO PBSC AA 32 
LO F A 25.02.04 26.07.04 MUD PBSC CML 57 
GT M A 03.03.04 15.11.07 MUD PBSC AML 55 
LC F A 10.03.04 28.12.10 MUD PBSC FANCONI 31 
AE F A 24.03.04 01.04.04 MUD PBSC MDS 36 
DL M A 24.03.04 28.12.10 ALLO PBSC HL 22 
MT M C 05.05.04 11.05.04 MUD PBSC ALL 4 
MT M A 19.05.04 28.12.10 ALLO PBSC CML 48 
JJ M C 27.05.04 30.05.04 MUD BM FANCONI 17 
NB F A 20.08.04 19.10.04 MUD BM MDS 60 
HW F C 15.09.04 08.01.06 ALLO PBSC AML 10 
DT M A 03.11.04 16.08.05 MUD PBSC AML 32 
DA M C 10.11.04 12.05.09 ALLO PBSC AA 8 
AN M A 10.12.04 25.01.05 MUD BM CML 38 
SG M A 15.12.04 28.12.10 MUD BM P VERA 37 
PJ M A 12.01.05 12.01.05 MUD PBSC NHL 33 
SF M A 26.01.05 28.12.10 MUD PBSC MDS 60 
AN M A 25.01.05 25.01.05 MUD PBSC CML 38 
EB F A 13.04.05 26.10.05 ALLO PBSC AML 54 
LT F C 20.04.05 28.12.10 MUD PBSC FANCONI 10 
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CA F A 10.05.05 12.06.05 MUD BM AML 52 
SN F A 28.07.05 28.12.10 MUD BM ALL 40 
NM F A 28.09.05 28.12.10 ALLO BM AA 23 
MH F A 12.10.05 28.12.10 MUD PBSC CML 28 
LT F A 09.11.05 28.12.10 MUD PBSC AML 27 
MS F A 30.11.05 05.07.07 ALLO PBSC AML 48 
BW M A 30.12.05 28.12.10 MUD PBSC CML 21 
GC F A 25.01.06 25.03.06 MUD PBSC CML 21 
MD M A 22.02.06 28.12.10 ALLO PBSC CML 31 
JL M A 08.03.06 03.09.06 ALLO PBSC NHL 49 
PM M A 04.05.06 15.10.06 ALLO PBSC AML 44 
JS M A 10.05.06 11.06.09 ALLO PBSC MM 48 
GN M A 31.05.06 30.11.06 ALLO PBSC CML 35 
ED F A 21.06.06 28.12.10 ALLO PBSC AML 34 
LL M C 29.06.06 28.12.10 MUD PBSC AA 16 
AS M C 19.07.06 13.06.07 ALLO PBSC AML 9 
HM F A 16.08.06 05.03.07 MUD PBSC AML 43 
CB M A 13.09.06 05.01.07 ALLO PBSC AML 51 
LM F A 25.10.06 28.12.10 ALLO PBSC NHL 44 
LC F C 01.11.06 28.12.10 ALLO PBSC AA 11 
FM M A 29.11.06 03.06.07 MUD PBSC MYELOFIBROSIS 51 
DH M C 23.03.07 03.02.08 MUD CORD WISKOTT-ALDICH 7 
SA F A 28.03.07 28.12.10 ALLO PBSC AML 48 
MH F A 04.04.07 07.04.07 MUD CORD FANCONI 39 
CR F A 18.04.07 28.12.10 MUD PBSC AML 34 
SG M A 27.07.07 28.12.10 MUD PBSC AML 41 
JK F C 29.08.07 05.07.08 ALLO PBSC ALL 6 
MK F C 10.10.07 28.12.10 ALLO PBSC SICKLE CELL ANAEMIA 17 
CK F A 17.10.07 23.10.07 MUD PBSC AML 28 
CH M A 30.11.07 15.08.08 ALLO PBSC CML 50 
BB F C 05.12.07 07.01.10 MUD PBSC AA 14 
KS F A 24.01.08 28.12.10 ALLO PBSC AML 52 
AB F A 30.01.08 08.03.08 ALLO PBSC AML 56 
RW M A 27.02.08 17.07.08 MUD PBSC CLL 63 
JK F C 19.03.08 05.07.08 ALLO PBSC ALL 7 
EC F A 07.05.08 28.12.10 ALLO PBSC CML 54 
GB M A 23.10.08 28.12.10 MUD BM HL 35 
JN M A 09.07.08 07.04.09 MUD PBSC CML 51 
JJ M A 01.04.09 22.07.09 ALLO PBSC AML 43 
EB M C 21.04.09 28.12.10 ALLO PBSC AA 20 
CM M A 19.06.09 28.12.10 MUD PBSC AML 49 
JK M C 01.07.09 28.12.10 MUD PBSC NHL 13 
RM M A 29.07.09 30.08.09 MUD CORD CML 46 
KJ M A 28.07.09 28.12.10 ALLO PBSC MDS 53 
WH M A 04.08.09 11.10.09 ALLO PBSC MDS 59 
EE F A 18.08.09 28.12.10 ALLO PBSC AML 50 
JT M A 26.08.09 09.05.10 MUD PBSC MDS 62 
RM M A 12.11.09 23.11.09 MUD PBSC NHL 55 
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CG F A 28.01.10 16.04.10 MUD PBSC AML 35 
HL M A 09.03.10 26.08.10 MUD PBSC AML 59 
CG F A 20.05.10 31.05.10 MUD PBSC AML 25 
AJ M C 30.06.10 03.08.10 MUD BM AML 11 
LV M A 05.08.10 28.12.10 MUD BM NHL 22 
MB F A 08.09.10 28.12.10 ALLO PBSC AML 40 
AL F C 04.11.10 28.12.10 MUD PBSC AA 19 
JE M A 24.11.10 28.12.10 ALLO PBSC AML 58 
SK F A 1.12.10 28.12.10 MUD PBSC MDS 21 
ET F A 26.07.95 28.12.10 AUTO PBSC AML 30 
GY M A 06.09.95 15.03.97 AUTO PBSC MM 48 
GS M A 27.09.95 13.04.97 AUTO PBSC MM 55 
JH M A 18.10.95 19.11.95 AUTO PBSC MM 52 
DB F A 22.11.95 19.05.99 AUTO PBSC NHL 63 
SC F A 29.11.95 21.08.97 AUTO PBSC AML 28 
DP M C 05.01.96 17.05.04 AUTO PBSC ALL 5 
HR M A 17.01.96 25.01.97 AUTO PBSC MM 62 
MC F A 24.01.96 28.12.10 AUTO PBSC NHL 49 
GB M A 13.03.96 28.12.10 AUTO PBSC AML 44 
MR M A 27.03.96 28.12.10 AUTO PBSC AML 28 
CD F A 11.04.96 03.04.01 AUTO PBSC AML 45 
RG F C 02.05.96 28.09.99 AUTO PBSC ALL 6 
CT M A 12.06.96 26.05.01 AUTO PBSC CML 54 
HR F A 20.06.96 28.12.10 AUTO PBSC NHL 30 
LP F A 26.06.96 28.12.10 AUTO PBSC NHL 48 
VA F A 16.07.96 23.10.99 AUTO PBSC CML 40 
CM M A 01.08.96 04.11.00 AUTO PBSC CML 39 
AK F A 18.09.96 02.05.01 AUTO PBSC HL 26 
AL M A 26.09.96 29.01.97 AUTO PBSC AML 41 
JN F A 02.10.96 08.02.00 AUTO PBSC AML 22 
KD F A 16.10.96 05.12.02 AUTO PBSC NHL 53 
NW M A 11.12.96 28.12.10 AUTO PBSC MM 58 
PP M A 16.01.97 28.12.10 AUTO PBSC AML 34 
RW M A 29.01.97 28.12.10 AUTO PBSC ALL 32 
SN F C 11.02.97 07.05.02 AUTO PBSC NEUROBLASTOMA 4 
NO M C 19.02.97 28.12.10 AUTO PBSC CML 16 
RS F A 26.02.97 05.09.04 AUTO PBSC CML 29 
IP F C 19.03.97 04.05.98 AUTO PBSC ALL 5 
FM M A 20.03.97 28.12.10 AUTO PBSC NHL 36 
MD F A 02.05.97 12.07.99 AUTO PBSC NHL 42 
JM F A 21.05.97 17.09.97 AUTO PBSC AML 37 
PL M A 28.05.97 08.07.99 AUTO PBSC CML 23 
GJ F A 04.06.97 28.12.10 AUTO PBSC NHL 38 
LW F A 12.06.97 17.06.98 AUTO PBSC NHL 53 
FW M A 19.06.97 28.12.10 AUTO PBSC AML 47 
BE M A 03.07.97 28.12.10 AUTO PBSC AML 39 
SW M C 30.07.97 28.12.10 AUTO PBSC CML 27 
NK M A 31.07.97 28.12.10 AUTO PBSC AML 58 
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CB M A 06.08.97 28.12.10 AUTO PBSC AML 28 
CS M A 08.10.67 28.12.10 AUTO PBSC ALL 40 
GD F A 15.10.97 14.06.98 AUTO PBSC AML 24 
VC F A 29.10.97 28.12.10 AUTO PBSC NHL 54 
ST M A 21.11.97 28.09.99 AUTO PBSC AML 56 
DT F C 03.12.97 18.04.98 AUTO PBSC NHL 9 
JM F A 18.12.97 09.11.09 AUTO PBSC NHL 50 
NJ F A 07.01.98 11.02.02 AUTO PBSC MDS 33 
CD F C 08.01.98 29.06.99 AUTO PBSC ALL 13 
SG M A 21.01.98 28.12.10 AUTO PBSC NHL 28 
CC M C 05.02.98 23.03.99 AUTO PBSC ALL 16 
WR M C 11.02.98 23.09.98 AUTO PBSC ALL 17 
AS F A 11.03.98 21.03.98 AUTO PBSC NHL 59 
DV M A 18.03.98 14.11.02 AUTO PBSC NHL 51 
JR F A 25.03.98 19.04.98 AUTO PBSC CML 44 
JU F A 01.04.98 28.12.10 AUTO PBSC NHL 43 
MP M A 17.04.98 28.12.10 AUTO PBSC AML 55 
JK M A 22.04.98 02.12.98 AUTO PBSC NHL 50 
SW F A 29.04.98 20.08.98 AUTO PBSC AML 64 
JM F A 03.06.98 28.12.10 AUTO PBSC NHL 57 
JG M A 11.06.98 16.06.98 AUTO PBSC AMYLOID 58 
DK M C 19.06.98 15.11.99 AUTO PBSC NEUROBLASTOMA 2 
PR M A 18.06.98 28.12.10 AUTO PBSC NHL 26 
WS M A 01.07.98 29.06.01 AUTO PBSC ALL 22 
CT M A 16.09.98 28.12.10 AUTO PBSC NHL 31 
DI F A 23.09.98 15.05.08 AUTO PBSC MDS 52 
PM F A 23.09.98 28.12.10 AUTO PBSC AML 54 
MK F A 14.10.98 28.05.00 AUTO PBSC HL 21 
HO M A 21.10.98 28.12.10 AUTO PBSC AML 22 
IM F A 28.10.98 28.12.10 AUTO PBSC MM 49 
CH M C 28.10.98 07.02.99 AUTO PBSC HL 19 
ES F A 04.11.98 28.12.10 AUTO PBSC AML 49 
MN M A 11.11.98 21.12.99 AUTO PBSC HL 43 
GC M A 18.11.98 18.01.06 AUTO PBSC NHL 22 
DB F A 25.11.98 28.12.10 AUTO PBSC NHL 35 
CW F A 09.12.98 23.12.98 AUTO PBSC CML 36 
KM M A 23.12.98 09.02.05 AUTO PBSC NHL 42 
SB M A 13.01.99 03.02.01 AUTO PBSC AML 35 
NT M A 27.01.99 12.03.04 AUTO PBSC NHL 39 
HM F A 03.02.99 28.12.10 AUTO PBSC NHL 53 
SR F C 16.02.99 28.12.10 AUTO PBSC ALL 6 
AT M A 17.02.99 28.11.01 AUTO PBSC NHL 62 
BR M A 24.02.99 19.07.05 AUTO PBSC NHL 46 
EV F A 14.04.99 26.06.03 AUTO PBSC AML 42 
HS F C 21.04.99 28.12.10 AUTO PBSC NHL 20 
RR M A 21.04.99 28.12.10 AUTO PBSC AML 39 
VM M A 26.05.99 15.01.10 AUTO PBSC CML 42 
FS M A 09.06.99 20.06.00 AUTO PBSC AML 38 
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SM F A 17.06.99 15.09.99 AUTO PBSC CML 41 
AB F A 30.06.99 29.11.00 AUTO PBSC CML 41 
MA F A 07.07.99 29.04.00 AUTO PBSC ALL 37 
PF M A 14.07.99 28.12.10 AUTO PBSC CLL 58 
ER F A 14.07.99 24.07.99 AUTO PBSC EWINGS SARCOMA 22 
JB F A 21.07.99 18.01.02 AUTO PBSC NHL 37 
LC M C 06.08.99 01.07.00 AUTO PBSC ALL 12 
JD M C 12.08.99 30.08.04 AUTO PBSC HL 14 
DK F A 18.08.99 28.12.10 AUTO PBSC NHL 38 
AM M A 25.08.99 29.11.06 AUTO PBSC NHL 39 
MR F A 01.09.99 10.07.03 AUTO PBSC AML 37 
HA M C 08.09.99 18.06.02 AUTO PBSC NHL 20 
MN M A 18.10.99 16.06.08 AUTO PBSC AMYLOID 55 
WW F C 27.10.99 28.12.10 AUTO PBSC AML 14 
JK M A 17.11.99 21.09.01 AUTO PBSC HL 31 
BS M A 24.11.99 14.12.99 AUTO PBSC NHL 48 
AX F C 09.02.00 28.12.10 AUTO PBSC AML 15 
LD M A 23.02.00 18.07.01 AUTO PBSC NHL 95 
MR M A 23.02.00 22.11.00 AUTO PBSC NHL 29 
CZ F A 31.05.00 28.12.10 AUTO PBSC NHL 57 
NL M A 14.06.00 28.12.10 AUTO PBSC NHL 56 
GS M A 10.08.00 11.09.07 AUTO PBSC ALL 43 
GW M A 16.08.00 06.08.04 AUTO PBSC ALL 29 
NJ M C 07.12.00 28.12.10 AUTO PBSC NHL 16 
JK M A 20.12.00 14.02.03 AUTO PBSC AML 61 
RL M A 14.03.01 28.12.10 AUTO PBSC NHL 31 
SC M A 30.05.01 28.12.10 AUTO PBSC NHL 33 
AP F A 14.06.01 28.12.10 AUTO PBSC HL 32 
CK M A 29.08.01 03.04.03 AUTO PBSC MYELOPROLIF 52 
SR M C 07.11.01 28.12.10 AUTO PBSC NEUROBLASTOMA 2 
ST F A 05.12.01 28.12.10 AUTO PBSC NHL 42 
DC M A 27.02.02 10.09.03 AUTO PBSC NHL 51 
JS M A 15.05.02 14.06.02 AUTO PBSC NHL 57 
JV M A 15.05.02 28.12.10 AUTO PBSC AMYLOID 47 
PB M A 24.07.02 12.09.07 AUTO PBSC AML 41 
FB M A 10.07.02 01.06.04 AUTO PBSC HL 24 
MM F C 07.08.02 29.10.02 AUTO PBSC AML 4 
 DB F C 07.08.02 05.09.03 AUTO PBSC NEUROBLASTOMA 4 
HR F A 28.08.02 28.12.10 AUTO PBSC HL 22 
DE M A 09.10.02 20.05.03 AUTO PBSC NHL 58 
YC F A 11.12.02 28.12.10 AUTO PBSC NHL 51 
NI F A 13.01.03 28.12.10 AUTO PBSC MM 57 
JL M C 05.02.03 15.11.03 AUTO PBSC NEUROBLASTOMA 3 
CJ M A 17.03.03 15.09.05 AUTO PBSC MM 41 
MH M A 14.05.03 17.06.06 AUTO PBSC NHL 49 
AT F A 28.05.03 27.12.05 AUTO PBSC MM 58 
JL M A 03.09.03 26.10.03 AUTO PBSC AML 51 
MB M A 20.10.03 28.12.10 AUTO PBSC MM 63 
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AC M A 17.12.03 28.12.10 AUTO PBSC AML 45 
PS M A 20.02.04 15.10.05 AUTO PBSC MM 44 
PJ M A 05.05.04 24.01.05 AUTO PBSC NHL 42 
ML F A 14.05.04 02.06.06 AUTO PBSC MM 56 
LM M A 16.02.05 28.12.10 AUTO PBSC NHL 28 
HF F A 23.02.05 05.03.05 AUTO PBSC HL 50 
CB M A 13.04.05 28.12.10 AUTO PBSC HL 28 
DS M A 13.06.05 18.04.06 AUTO PBSC MM 40 
GO M A 14.06.05 28.12.10 AUTO PBSC NHL 58 
CS F A 10.08.05 16.02.06 AUTO PBSC NHL 22 
RS M A 17.08.05 28.12.10 AUTO PBSC NHL 60 
AD F A 07.09.05 28.12.10 AUTO PBSC NHL 37 
JH M A 13.12.05 22.03.06 AUTO PBSC MM 48 
EF M A 22.12.05 28.12.10 AUTO PBSC MM 57 
IS M A 11.01.06 28.12.10 AUTO PBSC NHL 50 
SW F A 04.07.06 28.12.10 AUTO PBSC MM 54 
MS M C 01.11.06 28.12.10 AUTO PBSC HL 9 
JW M A 11.12.06 15.08.07 AUTO PBSC NHL 36 
DG F A 13.12.06 16.12.07 AUTO PBSC MM 44 
CK M C 24.01.07 28.12.10 AUTO PBSC HL 16 
DH M A 20.06.07 28.12.10 AUTO PBSC HL 42 
AB M A 27.06.07 28.12.10 AUTO PBSC NHL 39 
LA F A 19.07.07 25.08.07 AUTO PBSC NHL 60 
CA F A 19.09.07 28.12.10 AUTO PBSC AML 40 
CE M A 19.10.07 13.05.08 AUTO PBSC AML 39 
MG M C 12.12.07 28.12.10 AUTO PBSC NHL 14 
PS M A 09.04.08 18.11.08 AUTO PBSC AML 27 
IH F A 16.04.08 24.04.08 AUTO PBSC MM 58 
IP F A 03.09.08 28.12.10 AUTO PBSC NHL 22 
NJ F A 19.11.08 28.12.10 AUTO PBSC AML 27 
SG F A 18.02.09 20.08.09 AUTO PBSC ALL 32 
CB M A 02.03.09 15.03.09 AUTO PBSC NHL 60 
KS M C 19.05.09 28.12.10 AUTO PBSC NHL 19 
LS F A 27.08.09 28.12.10 AUTO PBSC HL 25 
NA M A 16.09.09 16.10.09 AUTO PBSC NHL 44 
AS M A 23.09.09 28.12.10 AUTO PBSC NHL 37 
KL F C 07.12.09 28.12.10 AUTO PBSC HL 13 
MB M A 11.02.10 28.12.10 AUTO PBSC NHL 39 
GC M A 21.04.10 28.12.10 AUTO PBSC MM 54 
MK F A 18.08.10 28.12.10 AUTO PBSC NHL 63 
TW M A 02.09.10 28.12.10 AUTO PBSC MM 55 
PB F A 08.11.10 28.12.10 AUTO PBSC AML 46 
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ANNEXURE 2 
DEMOGRAPHIC DATA ON TRANSPLANTED VOLUNTEERS FOR THE LATE 
COMPLICATIONS STUDY 
 
NUMBER DLS SEX RACE DOB DOT DISEASE TYPE 
WH2125 20.8.12 F w 13.2.45 23.5.01 CML ALLO 
WHA9715 27.8.12 M W 26.3.60 30.7.97 CML AUTO 
WH2263 28.8.12 F W 16.2.85 13.1.11 PNH ALLO 
WH2246 28.8.12 F W 26.4.83 9.1.02 AML ALLO 
WH2343 3.9.12 M W 12.10.76 23.10.08 HD ALLO 
WH2138 3.9.12 M w 12.5.64 24.10.01 CML ALLO 
WH9908 4.9.12 F W 2.4.79 21.4.99 NHL AUTO 
WH2309 10.9.12 F W 1.7.64 28.7.05 ALL ALLO 
WHA2309 10.9.12 F W 9.6.43 29.10.97 NHL ALLO 
WH2321 11.9.12 F W 25.3.72 21.6.06 AML ALLO 
WH2342 11.9.12 F W 21.9.54 7.5.08 CML ALLO 
WH2280 17.9.12 M W 19.8.56 6.8.03 AML ALLO 
WH2277 17.9.12 M W 9.3.65 5.7.03 NHL ALLO 
WH9821 18.9.12 M W 22.12.40 30.12.98 NHL ALLO 
WH2258 18.9.12 M W 22.8.54 26.6.02 NHL ALLO 
U2044 25.9.12 F C 11.1.58 7.9.05 NHL AUTO 
U2056 25.9.12 F W 17.5.67 19.9.07 AML AUTO 
WH9704 1.10.12 F W 15.6.41 5.2.97 NHL ALLO 
WH2350 1.10.12 M W 11.10.56 28.7.09 MDS ALLO 
U2065 2.10.12 F C 7.12.83 27.8.09 HD AUTO 
WHA9809 8.10.12 F C 22.8.55 1.4.98 NHL AUTO 
WH2259 8.10.12 M W 29.12.83 17.7.02 CML ALLO 
WHA2061 8.10.12 F C 30.7.86 3.9.08 NHD AUTO 
WH2256 9.10.12 F W 1.7.66 9.5.02 AML ALLO 
WH2101 15.10.12 F W 31.7.60 5.1.01 CML ALLO 
WHA9716 15.10.12 M W 19.5.39 31.7.97 APL AUTO 
WH9814 16.10.12 M W 30.5.66 13.8.98 APL ALLO 
WHA9909 16.10.12 M W 22.1.60 21.4.99 AML AUTO 
WH2128 23.10.12 M W 24.1.75 11.7.01 PNH ALLO 
WH2293 23.10.12 M W 13.4.73 10.3.04 FA ALLO 
WH2330 29.10.12 F W 16.3.62 28.3.07 AML ALLO 
WHA9810 29.10.12 M W 29.3.43 17.4.98 AML AUTO 
U2037 30.10.12 M W 11.6.77 16.2.05 NHL AUTO 
WHA9823 30.10.12 F W 27.6.49 28.10.98 MM AUTO 
WHA9529 5.11.12 M W 16.1.76 21.10.98 APL AUTO 
WHA9828 5.11.12 F W 13.2.53 25.11.98 NHL ALLO 
WH2347 5.11.12 M W 20.1.50 19.6.09 AML ALLO 
WH2305 6.11.12 M W 20.10.44 26.1.05 MDS ALLO 
U2032 6.11.12 M W 9.9.40 20.10.03 MM AUTO 
U9704 6.11.12 M W 16.8.81 20.5.03 CML ALLO 
U2046 12.11.12 M W 25.8.48 22.12.05 MM AUTO 
WH2288 12.11.12 M W 21.7.47 14.1.04 CML ALLO 
WH2253 13.11.12 F W 16.4.78 24.4.02 AML ALLO 
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WH2268 19.11.12 M W 2.3.50 18.12.02 CML ALLO 
WHA9718 19.11.12 M W 26.3.57 8.10.97 ALL AUTO 
WH2285 21.11.12 M W 20.2.72 8.10.03 ALL ALLO 
WH2311 23.11.12 F W 23.2.77 13.10.05 CML ALLO 
U2047 4.2.13 M W 16.3.55 11.1.06 NHL AUTO 
U2062 4.2.13 F C 12.9.81 19.11.08 AML AUTO 
WH2361 12.2.13 M W 2.12.51 24.11.10 AML ALLO 
WH9717 18.2.13 M W 10.11.47 20.8.97 CML ALLO 
WH2284 18.2.13 M W 7.1.50 10.9.03 CML ALLO 
U2067 25.2.13 M W 10.12.71 23.9.09 NHL AUTO 
U2054 5.2.13 M W 16.7.86 27.6.07 NHL AUTO 
WH2359 4.2.2013 F W 19.2.70 8.9.2010 AML ALLO 
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ANNEXURE 3 
KEY TO CAPTURE DEMOGRAPHIC DATA ON ALL TRANSPLANT PATIENTS (n=468) 
 
# - IDENTIFIER 
Number Initials Age DOB Gender 
(Depicted by M or F) 
Race 
(Depicted by B, C, A or W) 
 
Δ - DIAGNOSIS 
 a b c d e f g 
1. Fanconi        
2. Aplasia        
3. MDS RA RARS RAEB CMML Blastic   
4. AML Secondary FAB 1 FAB 2 FAB 3 FAB 4 FAB 5  
5. ALL B lineage T lineage Low risk Intermediate High risk Refractory Relapse 
6. CML        
7. CLL B lineage T lineage RAI 1 RAI 2 RAI 3 RAI 4  
8. HL NLP NS MC LD CL   
9. NHL HCL LL Follicular DLBC Burkitt T-lineage Other 
10. Myeloma 
Durie/Salmo
n 1 
Durie/Salmo
n 2 
Durie/Salmo
n 3 
Durie/Salmo
n 4 
   
11. Miscellaneous        
 
R – TREATMENT 
 a b c d e f 
1. Fanconi Androgen Steroids NIL    
2. AA Androgen Steroids NIL ALG Cyclosporin  
3. MDS HLL Flag CTR IV CTR V Erythropoietin GCSF 
4. AML CTR IV CTR V ETI RA Other  
5. ALL Low risk Intermediate High    
6. CML Imatinib Mini-ICE Other Hydrea®   
7. CLL Chlorambucil RFC MFC Other   
8. HL ABVD Cologne Salvage Other   
9. NHL Rituximab COP CHOP/CNOP DHAC R ICE Other 
10. Myeloma Melphalan Medrol Thalidomide Bortezomib VECD Other  
11. Miscellaneous       
 
T – TRANSPLANT 
 a b C d e f 
1. Date Auto Allo MUD Cord BM Blood 
 
O - OUTCOME 
 a b c d e 
1. Date LTFU Death CR PR Relapse 
 
C - COMPLICATIONS 
 a b c d e f g h i 
1. Date Lung Skeleton Kidney Heart GIT Skin Rejection GVHD CNS 
 
I – INFECTIONS 
 a b c d e 
1. Date Bacterial Viral Fungal HIV Other 
 
EXAMPLE OF SYMBOLS USED TO GENERATE THE DATABASE FOR ANALYSIS 
 
 
 
 
 # Δ R T O C I 
001  GB 53   1.3.43 fw  10  a  b c  b c    a 
        11.9.98 26.5.05    1.9.96 
002 RN 12    13.11.84  1  9b  bf  c    a 16.10.96 
        9.10.96 28.10.10    26.10.96    14.11.96 
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